WO2012055587A1 - Active ingredient combination and anti-dandruff hair treatment products iii - Google Patents

Active ingredient combination and anti-dandruff hair treatment products iii Download PDF

Info

Publication number
WO2012055587A1
WO2012055587A1 PCT/EP2011/059039 EP2011059039W WO2012055587A1 WO 2012055587 A1 WO2012055587 A1 WO 2012055587A1 EP 2011059039 W EP2011059039 W EP 2011059039W WO 2012055587 A1 WO2012055587 A1 WO 2012055587A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
preferred
acid
hair treatment
contain
Prior art date
Application number
PCT/EP2011/059039
Other languages
German (de)
French (fr)
Inventor
Volker Scheunemann
Erik Schulze Zur Wiesche
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Priority to EP11722461.8A priority Critical patent/EP2632422A1/en
Publication of WO2012055587A1 publication Critical patent/WO2012055587A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/004Preparations used to protect coloured hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/12Preparations containing hair conditioners

Definitions

  • the invention relates to a cosmetic hair treatment agent based on a specific combination of active ingredients, a method using the means and the use of the means for the prophylaxis, reduction, elimination and alleviation of dandruff on hairy body surfaces.
  • Skin and hair cleansers such as those commercially available as liquid soaps, shampoos, shower baths, bubble baths, shower gels, and wash gels, not only must have good detergency, but should also be well tolerated by the skin and hair if used frequently, do not cause excessive defatting or dryness.
  • dandruff An important aspect of hair cleansing and care is the fight against dandruff, because even the slight appearance of dandruff on the scalp or other hairy body regions is considered a sign of lack of care.
  • dandruff is usually accompanied by itching, which is perceived as disturbing. Itching, on the other hand, causes scratching reactions, which can lead to injuries of the affected skin, which in turn can form the basis for infections and pathogenic agents.
  • the requirements for a cosmetic remedy for dandruff are therefore high, because on the one hand the scalp should be thoroughly and permanently freed of dandruff, and on the other hand, the remedy for hair and scalp should be well tolerated.
  • Another important requirement is to have the fastest possible effect, so that the above-mentioned chain of disadvantages does not occur at all.
  • EP-A-348 015 discloses the use of zinc salts as anti-dandruff agents.
  • This object has been achieved by using the antidandruff active ingredient climbazole in combination with a special epsilon-poly-L-amino acid in a composition suitable for use on hairy body surfaces.
  • the invention therefore hair treatment compositions containing - based on their weight - a) 0.0001 to 5 wt .-% E silane poly-L-lysine of the general formula (I)
  • n stands for integers between 5 and 100
  • the compositions according to the invention contain epsilon-poly-L-lysine, an oligomer or polymer of the natural amino acid lysine, which is also referred to as epsilon-polylysine due to its linkage in epsilon position.
  • This compound leads to an increase in the activity and acceleration of the antidandruff active ingredient, which goes beyond the own antidandruff effect of epsilon-poly-L-lysine.
  • compositions of the invention epsilon-poly-L-lysine is used within narrower ranges.
  • Hair treatment agents preferred according to the invention are characterized in that they contain from 0.0005 to 4, preferably from 0.001 to 3, more preferably from 0.005 to 2 and in particular from 0.01 to 1% by weight of epsilon-poly-L-lysine of the general formula (I) ,
  • the degree of polymerization of the epsilon-poly-L-lysines used according to the invention is between 5 and 100. Depending on the hair treatment agent and use concentration, it was possible to observe an optimum effect for polymers within narrower degrees of polymerization. Accordingly, hair treatment agents according to the present invention containing epsilon-poly-L-lysine of the general formula (I) in which n is an integer of 10 to 70, preferably from 15 to 60, more preferably from 20 to 50 and in particular for the numbers 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35.
  • n is an integer of 10 to 70, preferably from 15 to 60, more preferably from 20 to 50 and in particular for the numbers 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35.
  • the agents according to the invention contain from 0.01 to 10% by weight of climbazole.
  • Climbazole is a chemical compound that is antifungal and fungistatic. It comes in the form of a racemate in the trade
  • Climbazole is also used in preferred compositions according to the invention within narrower ranges.
  • Hair treatment agents preferred according to the invention are characterized in that they contain 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole.
  • Very particularly preferred hair treatment compositions according to the invention contain
  • Hair treatment compositions according to the invention comprise a total amount of epsilon-poly-L-lysine of the general formula (I) (ingredient a)) and climbazole (ingredient b)) of 0.01 to 2% by weight, preferably of 0, 1 to 1, 75 wt .-%, more preferably from 0.25 to 1, 5 wt .-% and in particular from 0.5 to 1, 25 wt .-%.
  • moisturizing agents are used in the compositions of the invention.
  • certain active ingredients have been found so that preferred hair treatment compositions of the invention contain at least one moisturizing active ingredient from the group pantolactone, glycerol, allantoin, panthenol, isopentyl.
  • hair treatment compositions according to the invention are preferred, the or the moisturizing active substance (s) in amounts of 0, 1 to 10 Wt .-%, preferably from 0, 15 to 7.5 wt .-%, more preferably from 0.2 to 5 wt .-% and in particular from 0.25 to 4 wt .-%.
  • Very particularly preferred hair treatment compositions according to the invention with various moisturizing active substances and the respective quantities are disclosed on pages 6 to 17 of the priority document.
  • the cosmetic compositions preferably further contain at least one member selected from the group consisting of anionic, amphoteric, zwitterionic, nonionic, cationic surfactants or mixtures thereof, water-insoluble oil components, vitamins, provitamins, protein hydrolysates, plant extracts, UV filter, Amino acids, water-insoluble silicones, water-soluble silicones and / or amodimethicones
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight and in particular from 5 to 25% by weight of anionic and / or nonionic (s) and / or cationic and / or amphoteric surfactant (s).
  • Suitable anionic surfactants and emulsifiers for the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic Group such as As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms.
  • anionic Group such as As a carboxylate, sulfate, sulfonate or phosphate group
  • a lipophilic alkyl group having about 8 to 30 carbon atoms.
  • glycol or polyglycol ether groups, ester, ether and amide groups as well as hydroxyl groups may be present in the molecule.
  • anionic surfactants and emulsifiers are, in each case in the form of the sodium, potassium and ammonium as well as the mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group,
  • Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 carbon atoms are alpha-sulfofatty acids having 8 to 30 carbon atoms.
  • R CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, which from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C 12 / 14- or Ci 2 / i8-coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, particularly sodium N-cocoyl and sodium N-stearoyl-L-glutamate,
  • esters of a hydroxy-substituted di- or tricarboxylic acid of the general formula (T2)
  • Y is CHCOOR 2 wherein X is H or a -CH 2 COOR group, Y is H or -OH is under the condition that Y is H when X is -CH 2 COOR, R, R and R 2 independently of one another denote a hydrogen atom, an alkali metal or alkaline earth metal cation, an ammonium group which is a cation of an ammonium organic base or a Z radical derived from a polyhydroxylated organic compound selected from the group of etherified (C 6 -C 18 ) Alkyl polysaccharides with 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C 6 -C 6 ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R, R or R 2 is a radical Z,
  • R and R 2 are independently a hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C 6 -C 8) -Alkylpolysaccharide having 1 to 6 monomeric saccharide units and / or etherified aliphatic (C 6 -C 6) -hydroxyalkylpolyols is selected having 2 to 16 hydroxyl radicals, among the proviso that at least one of the groups R or R 2 Rest Z is,
  • Sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 24 C atoms in the alkyl group and 1 to 6 oxyethyl groups,
  • Alkyl sulfates and alkyl polyglycol ether sulfates of the formula R- (O-CH 2 -CH 2 ) x -OSO 3 H, in which R is a preferably linear alkyl group having 8 to 30 C atoms and x 0 or 1 - 12,
  • Esters of tartaric acid and citric acid with alcohols the addition products of about 2-15 molecules of ethylene oxide and / or propylene oxide to C 8 . 2 represent 2-fatty alcohols
  • Monoglyceride sulfates and monoglyceride ether sulfates Monoglyceride sulfates and monoglyceride ether sulfates.
  • Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which in particularly preferred embodiments of an octanoyl, decanoyl, lauroyl , Myristoyl, palmitoyl and stearoyl radical, esters of tartaric acid, citric acid or succinic acid or of the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium Coco-glucosides sulfosuccinates, alkyl polyglycol ether sulfates and ether carboxylic acids having 8 to 18 C atoms in the alkyl group and up to 12 ethoxy groups in the
  • Zwitterionic surfactants and emulsifiers are surface-active compounds which contain at least one quaternary ammonium group and at least one in the molecule - carry or -S0 3 ⁇ _) group - COO ⁇ _).
  • Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3 carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acid salts having 10 to 18 C atoms in the alkyl group and up to 12 glycol ether groups in the molecule and sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethylester with 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups.
  • Particularly preferred anionic surfactants are the alkali metal or ammonium salts of lauryl ether sulfate having a degree of ethoxylation of 2 to 4 EO.
  • Particularly preferred hair treatment compositions according to the invention are characterized in that they contain - based on their weight - 0.1 to 20 wt .-%, preferably 0.25 to 17.5 wt .-% and in particular 5 to 15 wt .-% of anionic (s ) Surfactant (s), more preferably fatty alcohol ether sulfates of the formula
  • n represents values of from 5 to 21, preferably from 7 to 19, particularly preferably from 9 to 17 and in particular from 1 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1, 2 or 3 and especially 2
  • M is a cation from the group Na + , K + NH 4 + , Mg 2+ , Zn 2+ , preferably Na + ,
  • Zwitterionic surfactants and emulsifiers are surface-active compounds which contain at least one quaternary ammonium group and at least one in the molecule - carry or -S0 3 ⁇ _) group - COO ⁇ _).
  • Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3 carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • a preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
  • Ampholytic surfactants and emulsifiers are understood to mean those surface-active compounds which, apart from a C 8 -C 24 -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SO 3 H group and are capable of forming internal salts .
  • suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group.
  • Particularly preferred hair treatment compositions according to the invention are characterized in that they contain amphoteric surfactant (s) from the groups of N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids containing around 8 to 24 carbon atoms in the alkyl group, alkyl aminoacetic acids containing around 8 to 24 carbon atoms in the alkyl group, N-cocoalkylaminopropionate, cocoacylaminoethyl aminopropionate C 12 - C 8 - acyl sarcosine, N-alkyl - ⁇ , ⁇ -dimethylammonium glycinates, for example, cocoalkyl dimethylammonium
  • Particularly preferred hair treatment agents contain as amphoteric surfactants betaines of the formula (T4)
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.
  • surfactants are referred to the INCI nomenclature as Amidopropylbetaine, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamidopropylbetaine.
  • surfactants of the formula (T4) which are a mixture of the following representatives:
  • agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T4).
  • the hair-treatment compositions according to the invention can be used with particular preference as amphoteric surfactants betaines of the formula (T5)
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.
  • surfactants are referred to according to the INCI nomenclature as amphoacetates, wherein the representatives derived from coconut fatty acids are preferred and are referred to as cocoamphoactetates.
  • surfactants of this type often also contain betaines of the formula (T5a)
  • R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms and M is a cation.
  • surfactants are referred to according to the INCI nomenclature as Amphodiacetate, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamphodiactetate.
  • surfactants of the formula (T5) which are a mixture of the following representatives:
  • H 3 C- (CH 2 ) 7 -C (O) -NH- (CH 2 ) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO " , H 3 C- (CH 2 ) 9 -C ( 0) -NH- (CH 2 ) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO ⁇ , HaC-iCHzJu-CiOJ-NH-iCHz NH ⁇ CHzCHzOHJCHzCHzCOO " , H 3 C- (CH 2 ) 13 - C (O) -NH- (CH 2 ) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO " , H 3 C- (CH 2 ) 15 -C (O) -NH- (CH 2) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO ⁇ , H 3 C- (CH 2) 7 -CH CH- (CH 2) 7 -C (0) -NH- (CH 2) 2 NH +
  • agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T5).
  • nonionic surfactants are alkyl polyglycosides. Accordingly, hair treatment compositions according to the invention are preferred which contain as nonionic surfactants - based on their weight - 0, 1 to 20 wt .-% alkylpolyglycosides of the general formula RO- (Z) x , where R is alkyl, Z for sugar and x for the number the sugar units stands.
  • Alkylpolyglycosides are nonionic surfactants made entirely from renewable resources (sugar building blocks, predominantly glucose, for example from corn starch and fatty alcohol, for example from coconut oil). Alkyl polyglycosides are accessible by acid-catalyzed reaction (Fischer reaction) of sugars, especially glucose (or starch) or butyl glycosides with fatty alcohols.
  • alkyl monoglucoside alkyl- ⁇ -D- and ⁇ -D-glucopyranoside and small amounts of glucofuranoside
  • alkyldiglucosides -isomaltosides, maltosides, etc.
  • alkyl oligoglucosides maltotriosides, tetraosides, etc.
  • the average degree of polymerization of commercial products whose alkyl radicals are in the range C8-C16 is 1, 2-1, 5.
  • alkylpolyglycosides corresponding to the general formula RO - (Z) x , where R is alkyl, Z is sugar and x is the number of sugar units.
  • R is alkyl
  • Z is sugar
  • x is the number of sugar units.
  • Ci 2 - to Ci6-alkyl groups consisting essentially of Ci 2 - to Ci6-alkyl groups or
  • sugar building block Z it is possible to use any desired mono- or oligosaccharides.
  • sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used.
  • Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.
  • Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.
  • the alkylpolyglycosides which can be used according to the invention contain on average 1, 1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 8.
  • compositions according to the invention which can be used particularly advantageously in the compositions according to the invention, especially in admixture with alkylpolyglycosides, are glutamates, asparaginates and sulfoacetates.
  • hair treatment compositions according to the invention are preferred which contain, based on their weight, from 0.1 to 20% by weight of fatty acid glutamates (acylglutamates) and / or fatty acid asparaginates (acylasparaginates) and / or alkylsulfoacetates (sulfoacetic acid alkyl esters).
  • R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alka nolammonium or glucammonium stands.
  • blends of alkyl glucosides with acyl glutamates have a very good dermatological compatibility and an improved foamability both with regard to the base foam and the foam stability in the presence of water hardness.
  • Acylglutamates are known anionic surfactants which can be obtained, for example, by Schotten-Baumann acylation of glutamic acid with fatty acids, fatty acid esters or chlorides. Products for sale are available, for example, from Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP.
  • acylglutamates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C 12/14 and C 12/18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-glutamate
  • the compositions according to the invention may contain the alkyl and / or alkenyl oligoglucosides and the acyl glutamates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.
  • R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium ,
  • Acylasparaginates are known anionic surfactants which can be obtained, for example, by Schotten-Baumann acylation of aspartic acid with fatty acids, fatty acid esters or chlorides. Products for sale are available, for example, from Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP.
  • acylasparaginates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C12 / 14 or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-aspartate
  • the agents according to the invention may also contain the alkyl and / or alkenyl oligoglucosides and the acylasparaginates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.
  • Sulfoacetates are usually salts of esters of sulfoacetic acid and can be represented by the general formula
  • R is a linear or branched alkyl or alkenyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium stands.
  • X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium stands.
  • Particularly preferred is the use of the sodium salt of sulfoacetic acid with the INCI name: sodium lauryl sulfoacetate):
  • Sodium lauryl sulphoacetate is a white, free-flowing powder which reacts neutrally, with good foaming power, wetting power and dispersibility.
  • Cationic surfactants of the quaternary ammonium compound type, the esterquats and the amidoamines can be used according to the invention.
  • Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides.
  • the long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as.
  • cetyl trimethyl ammonium chloride stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, lauryl dimethyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride and tricetylmethyl ammonium chloride.
  • Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.
  • Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as cationic care substance - based on their weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0.2 to 3, 5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) surfactant (s) from the group of quaternary ammonium compounds and / or the esterquats and / or the amidoamines containing preferred cationic (s) Surfactant (s) is / are selected
  • Alkyltrimethylammoniumchloriden having preferably 10 to 18 carbon atoms in the alkyl radical and / or
  • Dialkyldimethylammoniumchloride having preferably 10 to 18 carbon atoms in the alkyl radical and / or
  • Trialkylmethylammoniumchloride preferably having 10 to 18 carbon atoms in the alkyl radical and / or
  • compositions according to the invention can be further enhanced by using certain care substances.
  • these are selected from certain groups of known care substances, since these care substances harmonize perfectly with the formulation and the care effect with the combination used according to the invention against dandruff.
  • Hair treatment compositions which are preferred according to the invention are characterized in that they additionally have care substance (s), based on their weight, in amounts of from 0.001 to 10% by weight, preferably from 0.005 to 7.5% by weight, particularly preferably from 0.01 to 5 Wt .-% and in particular 0.05 to 2.5 wt .-%, with preferred care substance (s) are selected from the group i. L-carnitine and / or its salts;
  • Preferred hair treatment compositions according to the invention are characterized in that they contain from -0.001 to 10% by weight, preferably 0.005 to 7.5% by weight, particularly preferably 0.01 to 5% by weight and in particular 0.05% by weight contain up to 2.5 wt .-% L-carnitine or L-carnitine derivatives, preferred L-carnitine derivatives are selected from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.
  • preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).
  • vitamins, provitamins or vitamin precursors are vitamins, provitamins or vitamin precursors. These are described below:
  • vitamin A The group of substances referred to as vitamin A include retinol (vitamin A-1) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ß-carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • the agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
  • the vitamin B group or the vitamin B complex include, among others
  • Vitamin B 2 (riboflavin)
  • Vitamin B 3 Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B 5 pantothenic acid, panthenol and pantolactone. Panthenol and / or pantolactone are preferably used in the context of this group (see below).
  • the said compounds of the vitamin B 5 type are preferably contained in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
  • Vitamin B 6 pyridoxine and pyridoxamine and pyridoxal.
  • Vitamin C (ascorbic acid). Vitamin C is used in the inventive compositions preferably in amounts of 0, 1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-cf] - imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • hair-treatment compositions according to the invention are preferred which, based on their weight, are 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.25 to 3.5% by weight, more preferably Contain 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors, preferably the groups A, B, C, E, F and H.
  • compositions according to the invention can therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)
  • X, Y, Z are independently -O- or -NH- or NR 4 - or a chemical bond
  • R, R 2 , R 3 independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C 1 -C 6) -alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (d-Ce) -alkylene group, or a ( C 1 -C 6) -acyl radical, preferred radicals being selected independently of one another from -H, CH 3, -CH 2 CH 3, - (CH 2) 2 CH 2, -CH (CH 3) 2, - (CH 2) 3 CH 3, -CH (CH 3) CH 2 CH 3, CH 2 CH (CH 3 ) 2 , -C (CH 3 ) 3
  • R 4 is -CH 3 , -CH 2 CH 3 , - (CH 2 ) 2 CH 2 , -CH (CH 3 ) 2 ,
  • n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.
  • Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0, 1 wt .-% containing at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, preferred agents containing a ubiquinone of the formula (Ubi)
  • the agents according to the invention may also contain plastoquinones.
  • preferred agents according to the invention are characterized in that they are 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-b)
  • n stands for values of 1 to 20, preferably of 2 to 15 and in particular for 5, 6, 7, 8, 9, 10, whereby particularly preferred means Plastochinon PQ-9 of the formula
  • the agents according to the invention may contain ectoin.
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0 , 1 to 1% by weight of (S) -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (ectoine) and the physiologically tolerated salts of this compound and / or (S, S) -5- Hydroxy-2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (hydroxyectoine) and the physiologically acceptable salts of this compound.
  • compositions according to the invention may contain purine and / or purine derivatives as a care substance.
  • purine and / or purine derivatives with ubiquinones and / or plastoquinones as a care substance means that the hairs treated with appropriate agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.
  • Purine (7H-imidazo [4,5-d] pyrimidine) does not occur freely in nature, but forms the main body of the purines.
  • Purines are a group of important compounds of widespread nature involved in human, animal, plant and microbial metabolic processes, which differ from the parent by substitution with OH, NH 2 , SH in the 2-, 6-, and 8-positions and / or with CH 3 in 1-, 3-, 7-position derived.
  • purine can be made out Aminoacetonitrile and formamide are produced.
  • Purines and purine derivatives are often isolated from natural products, but are also synthetically accessible in many ways.
  • Preferred agents according to the invention contain purine and / or purine derivatives in narrower quantitative ranges.
  • inventively preferred cosmetic agents characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% purine (s) and / or purine derivative (s).
  • Hair treatment compositions which are preferred according to the invention are characterized in that they contain as care substance - based on their weight - from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s), preferred agents containing purine and / or purine derivative (s) of formula (Pur-I)
  • radicals R, R 2 and R 3 are independently selected from -H, - OH, NH 2 , -SH and the radicals R 4 , R 5 and R 6 are independently selected from -H, -CH 3 and -CH 2 - CH 3 , the following compounds being preferred:
  • agents according to the invention are preferred in which the weight ratio of purine (derivative (s)) and biochinone (s) is 10: 1 to 1: 100, preferably 5: 1 to 1:50, particularly preferably 2: 1 to 1:20 and in particular 1: 1 to 1:10.
  • caffeine is a particularly preferred purine derivative
  • coenzyme Q10 is a particularly preferred biochinone.
  • Particularly preferred agents according to the invention are therefore characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular 0.01 to 0.1 wt .-% caffeine and 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% coenzyme Q10 included.
  • the compositions of the invention may also contain flavonoids.
  • the flavonoids are a group of water-soluble plant dyes and play an important role in the metabolism of many plants. They belong together with the phenolic acids to the polyphenols. There are well over 6500 different flavonoids known, which can be divided into flavonols, flavones, flavanones, isoflavonoids and anthocyanins.
  • flavonoids from all six groups can be used, with certain representatives from the individual groups are preferred as a care substance because of their particularly intense action.
  • Preferred flavonols are quercetin, rutin, kaempferol, myricetin, isorhamnetin, preferred flavanols are catechin, gallocatechin, epicatechin, epigallocatechin gallate, theaflavin, thearubigin, preferred flavones are luteolin, apigenin, morin, preferred flavanones are hesperetin, naringenin, eriodictyol, preferred isoflavonoids are genistein , Daidzein, and preferred anthocyanidins (anthocyanins) are cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin.
  • particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% flavonoids, especially flavonols, more preferably 3,3 ', 4', 5,7-Pentahydroxyflavon (quercetin) and / or 3,3 ', 4', 5,7-Pentahydroxyflavon -3-0-rutinoside (rutin), included.
  • hair treatment compositions according to the invention which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1, 5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol.
  • Creatine is also suitable as a care substance according to the invention.
  • Creatine (3-methylguanidinoacetic acid) is an organic acid that helps to supply muscles with energy in vertebrates. Creatine is synthesized in the kidney, liver and pancreas. It is formally derived from the amino acids glycine and arginine and is 95% present in skeletal muscle.
  • compositions according to the invention contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 bis 7.5 wt .-% and in particular 0.5 to 5 wt .-% / V-methyl guanidino-acetic acid (creatine).
  • the compositions according to the invention may contain, in addition to the ingredients mentioned above and optional further ingredients, other substances which prevent, alleviate or cure hair loss.
  • a content of hair root stabilizing agents is advantageous. These substances are described below:
  • Propecia (Finasteride) is currently the only preparation that is approved worldwide and has been proven in many studies to be effective and tolerable. Propecia causes less DHT to form from testosterone.
  • Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. For the treatment of hair loss, it may only be used for external application. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil. The effectiveness increases with the dosage, in hair waters Minoxidil is only up to 5% share soluble. In many countries, hair tonic with up to 2% minoxidil content is available without prescription.
  • spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application.
  • Spironolactone acts as an androgen receptor blocker, ie. the binding of DHT to the hair follicles is prevented.
  • hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.
  • the agents according to the invention may contain further care substances. Their presence is not absolutely necessary for achieving the effects according to the invention, but further effects, such as a pleasant touch or a pleasant application feel, can result from the use of these care substances.
  • the agents according to the invention may with particular preference contain one or more amino acids.
  • Particularly preferred amino acids which can be used according to the invention are from the group of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, ⁇ Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cy
  • Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges.
  • hair treatment agent characterized in that it as a care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1, 5 wt .-%, further preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or Threonine included.
  • the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides.
  • preferred hair treatment compositions according to the invention characterized in that they are used as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt. -%, more preferably 0.5 to 3.5 wt .-% and in particular 0.75 to 2.5 wt .-% carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides containing preferred carbohydrates are selected out
  • Monosaccharides in particular D-ribose and / or D-xylose and / or L-arabinose and / or D-glucose and / or D-mannose and / or D-galactose and / or D-fructose and / or sorbose and / or L. Fucose and / or L-rhamnose
  • Disaccharides in particular sucrose and / or maltose and / or lactose and / or trehalose and / or cellobiose and / or gentiobiose and / or isomaltose.
  • Particularly preferred agents according to the invention contain based on their weight
  • preferred agents according to the invention contain (a) amino acid (s).
  • Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges.
  • preferred cosmetic compositions according to the invention are characterized in that they additionally contain from 0.05 to 5% by weight, preferably from 0.1 to 2.5% by weight, more preferably from 0 to 15% by weight and in particular from 0 to 15% by weight , 2 to 0.5 wt .-% amino acid (s), preferably (one) amino acid (s) from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.
  • Particularly preferred agents according to the invention contain based on their weight
  • a particularly preferred group of ingredients are the silicones.
  • Preferred agents according to the invention are characterized in that they contain at least one silicone.
  • compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.
  • x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.
  • silicones are called DIMETHICONE according to the INCI nomenclature.
  • the following compounds are preferably those compounds of the formula Si-I: (CH 3 ) 3 Si-O-Si (CH 3 ) 3, (CH 3 ) 3 Si-O- (CH 3 ) 2 Si 0-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 2 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 3 -0-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 4 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 5 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 6 -O-Si (CH 3 ) 3, ( CH
  • compositions of the invention may be included in the compositions of the invention.
  • Preferred silicones which can be used according to the invention have viscosities of 0.2 to 2 mm 2 s -1 at 20 ° C., silicones having viscosities of 0.5 to 1 mm 2 s -1 being particularly preferred.
  • Particularly preferred agents according to the invention contain one or more amino-functional silicones.
  • Such silicones may e.g. through the formula
  • R in the above formula is a hydrocarbon or a hydrocarbon radical having 1 to about 6 carbon atoms
  • Q is a polar radical of the general formula -R HZ, wherein R is a divalent linking group attached to hydrogen and the radical Z.
  • Z is an organic, amino-functional radical containing at least one amino-functional group; "a” assumes values in the range of about 0 to about 2, “b” assumes values in the range of about 1 to about 3, “a” + “b” is less than or equal to 3, and “c” is a number in the range from about 1 to about 3, and x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25, and y is a number ranging from about 20 to about 10,000 , preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000, and M is a suitable silicone end group as known in the art, preferably trimethylsiloxy.
  • Non-limiting examples of the groups represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals such as cyclobutyl, cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, 4-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur containing radicals such as mercaptoethyl, mercaptopropyl,
  • R examples include methylene, ethylene, propylene, hexamethylene, decamethylene, - CH 2 CH (CH 3 ) CH 2 -, phenylene, naphthylene, -CH 2 CH 2 SCH 2 CH 2 -, -CH 2 CH 2 OCH 2 -, -OCH 2 CH 2 -, - OCH 2 CH 2 CH 2 -, -CH 2 CH (CH 3 ) C (O) 2 -, - (CH 2 ) 3 CC (O) 2 CH 2 -, -C 6 H 4 C 6 H 4 -, -C 6 H 4 CH 2 C 6 H 4 -; and - (CH 2 ) 3 C (O) SCH 2 CH 2 -.
  • Z is an organic, amino-functional radical containing at least one functional amino group.
  • a possible formula for Z is NH (CH 2 ) Z NH 2 , wherein z is 1 or more.
  • Another possible formula for Z is -NH (CH 2 ) Z (CH 2 ) ZZ NH, wherein both z and zz are independently 1 or more, which structure includes diamino ring structures, such as piperazinyl.
  • Z is most preferably a -NHCH 2 CH 2 NH 2 radical.
  • Z is - N (CH 2 ) z (CH 2 ) zzNX 2 or -NX 2 , wherein each X of X 2 is independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0.
  • Q is most preferably a polar, amine functional group of the formula -CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 .
  • "a” assumes values in the range of about 0 to about 2
  • "b” assumes values in the range of about 2 to about 3
  • "a” + “b” is less than or equal to 3
  • the molar ratio of the R a Q b SiO ( 4. a - b ) / 2 units to the R c SiO ( 4 -c) / 2 units is in the range from about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1:15 to about 1:20.
  • Preferred agents according to the invention are characterized in that they contain an amino-functional silicone of the formula (Si-II)
  • G is -H, a phenyl group, -OH, -O-CH 3 , -CH 3 , -O-CH 2 CH 3 , -CH 2 CH 3 , -O-
  • a is a number between 0 and 3, in particular 0;
  • b is a number between 0 and 1, in particular 1,
  • n and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n is preferably values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10,
  • R - R ' is a monovalent radical selected from
  • each Q is a chemical bond, -CH 2 -, -CH 2 -CH 2 -, -CH2CH2CH2-, -C (CH 3) 2 -, -CH2CH2CH2CH2-, -CH 2 C (CH 3) 2 -, - CH (CH 3 ) CH 2 CH 2 -,
  • R " is identical or different radicals from the group -H, -phenyl, -benzyl, -CH 2 - CH (CH 3 ) Ph, the Ci. 20 -alkyl radicals, preferably -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 Cl-I 3 , - CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 H 3 , -CH 2 CH (CH 3 ) 2 , -CH (CH 3 ) CH 2 CH 3 , -C ( CH 3 ) 3 , and A represents an anion, which is preferably selected from chloride, bromide, iodide or methosulfate.
  • Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)
  • n and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.
  • compositions according to the invention which are an amino-functional silicone of the formula (Si-IIb)
  • n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.
  • silicones are referred to as amodimethicones according to the INCI declaration.
  • agents according to the invention which contain an amino-functional silicone whose amine number is above 0.25 meq / g, preferably above 0.3 meq / g and in particular above 0.4 meq / g, are preferred ,
  • the amine number stands for the milliequivalents of amine per gram of the amino-functional silicone. It can be determined by titration and also expressed in mg KOH / g.
  • Agents preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.1 to 8% by weight, particularly preferably 0.25 to 7.5% by weight and in particular 0, 5 to 5 wt.% Amino-functional silicone (s) included.
  • agents according to the invention which contain at least one silicone of the formula Si-III
  • x is a number from 3 to 200, preferably from 3 to 10, more preferably from 30 to 7 and especially 3, 4, 5 or 6, stands.
  • the silicones described above have a backbone composed of -Si-O-Si units. Of course, these Si-O-Si units may also be interrupted by carbon chains. Appropriate molecules are accessible by chain extension reactions and are preferably used in the form of silicone-in-water emulsions. Agents which are likewise preferred according to the invention are characterized in that they contain at least one silicone of the formula Si-IV
  • R stands for identical or different radicals from the group -H, - phenyl, -benzyl, -CH 2 -CH (CH 3) Ph
  • the CI_ 20 -alkyl preferably -CH 3, -CH 2 CH 3, -CH 2 CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 H 3 , -CH 2 CH (CH 3 ) 2 , -CH (CH 3 ) CH 2 CH 3 , -C ( CH 3 ) 3
  • x and y are a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and in particular 0, 1, 2, 3, 4, 5 or 6, and n is a number from 0 to 10, preferably from 1 to 8 and in particular from 2, 3, 4, 5, 6.
  • the silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone.
  • hair treatment agents which are preferred according to the invention are therefore characterized by being transparent or translucent.
  • NTU Nephelometrie Turbidity Unit
  • an agent according to the invention may also contain UV filters (I).
  • the UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC ( ⁇ 280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.
  • the UV filters (I) are contained in the compositions according to the invention usually in amounts of 0.1-5 wt .-%, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.
  • compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J).
  • a 2-pyrrolidinone-5-carboxylic acid and its derivatives Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C 1 to C 4 alkyl groups.
  • the sodium salt is most preferred.
  • the amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total agent, more preferably 0, 1 to 5, and in particular 0, 1 to 3 wt.%.
  • compositions according to the invention contain penetration aids and / or swelling agents (M).
  • M penetration aids and / or swelling agents
  • M include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol, for example Propylene glycol monoethyl ether, carbonates, bicarbonates, diols and triols, and in particular 1, 2-diols and 1, 3-diols such as 1, 2-propanediol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-dodecanediol, 1 , 3-propanediol, 1, 6-hexanediol, 1, 5-pentanediol, 1, 4-butane
  • short-chain carboxylic acids may additionally support the active substance complex (A).
  • Short-chain carboxylic acids and their derivatives in the context of the invention are understood to mean carboxylic acids which may be saturated or unsaturated and / or straight-chain or branched or cyclic and / or aromatic and / or heterocyclic and have a molecular weight of less than 750.
  • preference may be given to saturated or unsaturated straight-chain or branched carboxylic acids having a chain length of from 1 to 16 C atoms in the chain, very particular preference being given to those having a chain length of from 1 to 12 C atoms in the chain.
  • the short-chain carboxylic acids according to the invention may have one, two, three or more carboxy groups.
  • Preferred within the meaning of the invention are carboxylic acids having a plurality of carboxy groups, in particular di- and tricarboxylic acids.
  • the carboxy groups may be wholly or partly present as esters, acid anhydride, lactone, amide, imidic acid, lactam, lactim, dicarboximide, carbohydrazide, hydrazone, hydroxam, hydroxime, amidine, amidoxime, nitrile, phosphonic or phosphate ester.
  • the carboxylic acids used according to the invention may of course be substituted along the carbon chain or the ring skeleton.
  • the substituents of the carboxylic acids used according to the invention include, for example, C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, aryl, aralkyl and aralkenyl, hydroxymethyl, C 2 -C 8 -hydroxyalkyl, C 2 -C 8 -hydroxyalkenyl , Aminomethyl, C 2 -C 8 -aminoalkyl, cyano, formyl, oxo, thioxo, hydroxy, mercapto, amino, carboxy or imino groups.
  • Preferred substituents are C 1 -C 8 alkyl, hydroxymethyl, hydroxy, amino and carboxy groups. Particularly preferred are substituents in position.
  • substituents are hydroxyl, alkoxy and amino groups, where the amino function may optionally be further substituted by alkyl, aryl, aralkyl and / or alkenyl radicals.
  • preferred carboxylic acid derivatives are the phosphonic and phosphate esters.
  • the agents according to the invention may contain emulsifiers (F).
  • Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion.
  • Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions.
  • An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants.
  • the selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion.
  • Emulsifiers which can be used according to the invention are, for example Addition products of 4 to 30 moles of ethylene oxide and / or 0 to 5 moles of propylene oxide to linear fatty alcohols having 8 to 22 carbon atoms, to fatty acids having 12 to 22 carbon atoms and to alkylphenols having 8 to 15 carbon atoms in the alkyl group,
  • Glucosides mixtures of alkyl (oligo) and fatty alcohols for example, the commercially available product ® Montanov 68,
  • Sterols are understood to mean a group of steroids which carry a hydroxyl group on C-atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterines) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are ergosterol, stigmasterol and sitosterol. Mushrooms and yeasts are also used to isolate sterols, the so-called mycosterols.
  • glucose phospholipids e.g. as lecithins or phosphatidylcholines from e.g. Egg yolk or plant seeds (e.g., soybeans) are understood.
  • Fatty acid esters of sugars and sugar alcohols such as sorbitol
  • Polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate (commercial product Dehymuls ® PGPH),
  • Linear and branched fatty acids with 8 to 30 C atoms and their Na, K, ammonium, Ca, Mg and Zn salts.
  • the agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.
  • compositions according to the invention may preferably contain at least one nonionic emulsifier having an HLB value of 8 to 18.
  • Nonionic emulsifiers having an HLB value of 10 to 15 may be particularly preferred according to the invention.
  • the anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups.
  • anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for all or some of the sulfonic acid group to be present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,
  • the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid which is commercially available, for example under the name Rheothik ® 1 1-80 is.
  • copolymers of at least one anionic monomer and at least one nonionic monomer are preferable to use copolymers of at least one anionic monomer and at least one nonionic monomer.
  • anionic monomers reference is made to the substances listed above.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers.
  • a particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group is wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt is present.
  • This copolymer may also be crosslinked, with crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used.
  • crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used.
  • crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used.
  • Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • This compound which in addition to the polymer component contains a hydrocarbon mixture (Ci 3 -Ci 4 -lsopar
  • anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ® commercially. Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers. A 1, 9-decadiene crosslinked maleic acid methyl vinyl ether copolymer is available under the name ® Stabileze QM.
  • the agents according to the invention may contain nonionic polymers (G4).
  • Suitable nonionic polymers are, for example:
  • Vinylpyrrolidone / vinyl ester copolymers as sold, for example, under the trademark Luviskol ® (BASF).
  • Luviskol ® VA 64 and Luviskol ® VA 73, each vinylpyrrolidone / vinyl acetate copolymers are also preferred nonionic polymers.
  • Cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropylcellulose Methylhy-, as sold for example under the trademark Culminal® ® and Benecel ® (AQUALON) and Natrosol ® grades (Hercules).
  • Starch and its derivatives in particular starch, such as Structure XL ® (National Starch), a multifunctional, salt-tolerant starch;
  • Siloxanes These siloxanes can be both water-soluble and water-insoluble. Both volatile and nonvolatile siloxanes are suitable, nonvolatile siloxanes being understood as meaning those compounds whose boiling point is above 200 ° C. under normal pressure.
  • Preferred siloxanes are polydialkylsiloxanes, such as, for example, polydimethylsiloxane, polyalkylarylsiloxanes, such as, for example, polyphenylmethylsiloxane, ethoxylated polydialkylsiloxanes and polydialkylsiloxanes which contain amine and / or hydroxyl groups.
  • the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.
  • the other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0, 1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.
  • Another object of the present invention is a method for the treatment of keratinic fibers, in particular human hair, in which a hair treatment agent according to the invention applied to keratinic fibers and leave there either until the next hair wash (so-called “leave-on” product) or after Exposure time of 30 to 300 seconds rinsed out (so-called rinse-off product) is.
  • n stands for integers between 5 and 100
  • epsilon-poly-L-lysines enhances and accelerates the antidandruff effect of climbazole.
  • a further subject of the present invention is the use of epsilon-poly-L-lysine of the general formula (I)
  • n stands for integers between 5 and 100
  • Another object of the present invention is the use of mixtures
  • n stands for integers between 5 and 100

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Rapidly effective high-performance anti-dandruff products which are gentle on the scalp and hair and which do not negatively influence the hair with respect to its combability, shine and suppleness contain, based on their weight, 0.0001 to 5% by weight of epsilon poly-L-lysine of the general formula (I), wherein n represents integer numbers between 5 and 100 and 0.01 to 10% by weight of climbazole.

Description

"Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen IM"  "Active substance combination and hair treatment agent for dandruff IM"
Die Erfindung betrifft ein kosmetisches Haarbehandlungsmittel auf der Basis einer speziellen Wirkstoffkombination, ein Verfahren unter Verwendung der Mittel sowie die Verwendung der Mittel zur Prophylaxe, Verminderung, Beseitigung und Linderung von Schuppen auf behaarten Körperoberflächen. The invention relates to a cosmetic hair treatment agent based on a specific combination of active ingredients, a method using the means and the use of the means for the prophylaxis, reduction, elimination and alleviation of dandruff on hairy body surfaces.
Reinigungsmittel für Haut und Haar, wie sie beispielsweise als flüssige Seifen, Shampoos, Duschbäder, Schaumbäder, Dusch- und Waschgele im Handel erhältlich sind, müssen nicht nur ein gutes Reinigungsvermögen aufweisen, sondern sollen weiterhin für die Haut und das Haar gut verträglich sein und auch bei häufiger Anwendung nicht zu starker Entfettung oder Trockenheit führen.  Skin and hair cleansers, such as those commercially available as liquid soaps, shampoos, shower baths, bubble baths, shower gels, and wash gels, not only must have good detergency, but should also be well tolerated by the skin and hair if used frequently, do not cause excessive defatting or dryness.
Einen wichtigen Aspekt bei der Haarreinigung und -pflege stellt die Bekämpfung von Schuppen dar, denn schon das leichte Auftreten von Schuppen auf der Kopfhaut oder anderen behaarten Körperregionen wird als Zeichen mangelnder Pflege angesehen. Darüber hinaus geht mit der Schuppenbildung meist ein Juckreiz einher, der als störend empfunden wird. Ein Juckreiz hingegen ruft Kratzreaktionen hervor, so dass es zu Verletzungen der betroffenen Hautpartien kommen kann, die wiederum die Basis für Infektionen und pathogene Erreger bilden können. Die Anforderungen an ein kosmetisches Mittel zur Schuppenbekämpfung sind daher hoch, denn zum einen soll die Kopfhaut gründlich und nachhaltig von Schuppen befreit werden, und zum anderen soll das Mittel für Haar und Kopfhaut gut verträglich sein.  An important aspect of hair cleansing and care is the fight against dandruff, because even the slight appearance of dandruff on the scalp or other hairy body regions is considered a sign of lack of care. In addition, dandruff is usually accompanied by itching, which is perceived as disturbing. Itching, on the other hand, causes scratching reactions, which can lead to injuries of the affected skin, which in turn can form the basis for infections and pathogenic agents. The requirements for a cosmetic remedy for dandruff are therefore high, because on the one hand the scalp should be thoroughly and permanently freed of dandruff, and on the other hand, the remedy for hair and scalp should be well tolerated.
Eine weitere, wichtige Anforderung ist eine möglichst schnelle Wirkung, so dass die oben genannte Kette von Nachteilen gar nicht erst auftreten.  Another important requirement is to have the fastest possible effect, so that the above-mentioned chain of disadvantages does not occur at all.
Aus der Literatur sind eine Vielzahl von haarkosmetischen Mitteln bekannt, die die Schuppenbildung verhindern oder reduzieren sollen. Zur Auswahl stehen üblicherweise Mittel in der Form von Shampoos, Lotionen oder Haarwässern.  From the literature, a variety of hair cosmetics are known to prevent or reduce dandruff. The choice is usually made in the form of shampoos, lotions or hair lotions.
Aus der EP-A-348 015 ist die Verwendung von Zinksalzen als Antischuppenmittel bekannt.  EP-A-348 015 discloses the use of zinc salts as anti-dandruff agents.
Die Kombination dreier herkömmlicher und wirksamer Antischuppenmittel ist Gegenstand der EP 1 238 645 B1. Darin werden 1 -(4-Chlorophenoxy)-1-(1 H-imidazolyl)-3,3-dimethyl-2-butanon (INCI- Bezeichnung: Climbazole), Bis(1-Hydroxy-2-(1 H)-Pyridinethionato)Zinc (INCI-Bezeichnung: Zinc Pyrithione) und 1-Hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-(1 H)pyridinone, 2-Aminoethanol Salz (INCI-Bezeichnung: Piroctone Olamine) bereits in niedrigen Einsatzkonzentrationen miteinander kombiniert, um ein Antischuppenmittel herzustellen, das die Bildung von Schuppen verhütet oder vermindert. Nachteilig an den Mitteln des Standes der Technik war bislang, dass sie zwar wirksam gegen Schuppen waren, diese Wirkung aber erst nach häufiger Anwendung eintrat. The combination of three conventional and effective antidandruff agents is the subject of EP 1 238 645 B1. Therein are 1 - (4-chlorophenoxy) -1- (1H-imidazolyl) -3,3-dimethyl-2-butanone (INCI name: climbazole), bis (1-hydroxy-2- (1H) -pyridineethionato ) Zinc (INCI name: Zinc Pyrithione) and 1-hydroxy-4-methyl-6- (2,4,4-trimethylpentyl) -2- (1H) pyridinone, 2-aminoethanol salt (INCI name: Piroctone Olamine ) are already combined at low levels of use to produce an antidandruff agent that prevents or reduces the formation of dandruff. A disadvantage of the means of the prior art has been that they were effective against dandruff, but this effect only after frequent use occurred.
Deshalb war es zusätzlich Aufgabe der vorliegenden Erfindung, ein schnell gegen Schuppen wirksames Mittel zu finden, das schonend zur Kopfhaut und dem Haar ist und das Haar im Hinblick auf seine Kämmbarkeit, seinen Glanz und seine Geschmeidigkeit nicht negativ beeinflusst. Darüber hinaus sollte die Antischuppenwirkung bekannter Wirkstoffe nach Möglichkeit nach Möglichkeit nicht nur beschleunigt, sondern auch gesteigert werden. Therefore, it was an additional object of the present invention to find a fast dandruff agent that is gentle on the scalp and the hair and does not adversely affect the hair in terms of its combability, its shine and suppleness. In addition, the anti-dandruff effect of known drugs should, if possible, not only be accelerated, but also increased as far as possible.
Diese Aufgabe wurde gelöst, indem der Antischuppenwirkstoff Climbazol im Kombination mit einer speziellen Epsilon-Poly-L-Aminosäure in einem für die Anwendung auf behaarten Körperoberflächen geeigneten Mittel eingesetzt wurde.  This object has been achieved by using the antidandruff active ingredient climbazole in combination with a special epsilon-poly-L-amino acid in a composition suitable for use on hairy body surfaces.
Überraschenderweise konnte festgestellt werden, dass durch die Haarbehandlung mit kosmetischen Mitteln auf der Basis dieser Kombination eine deutlich schnellere und intensivere Wirkung eintrat als bei herkömmlichen Mitteln.  Surprisingly, it was found that hair treatment with cosmetic products based on this combination resulted in a significantly faster and more intensive action than conventional compositions.
Gegenstand der Erfindung sind daher Haarbehandlungsmittel, enthaltend - bezogen auf ihr Gewicht - a) 0,0001 bis 5 Gew.-% E silon-Poly-L-Lysin der allgemeinen Formel (I)  The invention therefore hair treatment compositions containing - based on their weight - a) 0.0001 to 5 wt .-% E silane poly-L-lysine of the general formula (I)
Figure imgf000003_0001
Figure imgf000003_0001
in der n für ganze Zahlen zwischen 5 und 100 steht,  where n stands for integers between 5 and 100,
b) 0,01 bis 10 Gew.-% Climbazol.  b) from 0.01 to 10% by weight of climbazole.
Als ersten wesentlichen Inhaltsstoff enthalten die erfindungsgemäßen Mittel Epsilon-Poly-L-Lysin, ein Oligo- bzw. Polymeres der natürlichen Aminosäure Lysin, das aufgrund seiner Verknüpfung in Epsilon-Position auch als Epsilon-Polylysin bezeichnet wird. Diese Verbindung führt zu einer Wirkungssteigerung und -beschleunigung des Antischuppenwirkstoffes, die über die eigene Antischuppenwirkung des Epsilon-Poly-L-lysins hinausgeht. As the first essential ingredient, the compositions according to the invention contain epsilon-poly-L-lysine, an oligomer or polymer of the natural amino acid lysine, which is also referred to as epsilon-polylysine due to its linkage in epsilon position. This compound leads to an increase in the activity and acceleration of the antidandruff active ingredient, which goes beyond the own antidandruff effect of epsilon-poly-L-lysine.
In bevorzugten erfindungsgemäßen Mitteln wird Epsilon-Poly-L-Lysin innerhalb engerer Mengenbereiche eingesetzt. Erfindungsgemäß bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie 0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) enthalten.  In preferred compositions of the invention epsilon-poly-L-lysine is used within narrower ranges. Hair treatment agents preferred according to the invention are characterized in that they contain from 0.0005 to 4, preferably from 0.001 to 3, more preferably from 0.005 to 2 and in particular from 0.01 to 1% by weight of epsilon-poly-L-lysine of the general formula (I) ,
Der Polymerisationsgrad der erfindungsgemäß eingesetzten Epsilon-Poly-L-Lysine liegt zwischen 5 und 100. Es konnte - je nach Haarbehandlungsmittel und Einsatzkonzentration - ein Wirkungsoptimum für Polymere innerhalb engerer Polymerisationsgrade beobachtet werden. Dementsprechend sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die Epsilon-Poly-L- Lysin der allgemeinen Formel (I) enthalten, in der n für ganze Zahlen von 10 bis 70, vorzugsweise von 15 bis 60, weiter bevorzugt von 20 bis 50 und insbesondere für die Zahlen 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35 steht. The degree of polymerization of the epsilon-poly-L-lysines used according to the invention is between 5 and 100. Depending on the hair treatment agent and use concentration, it was possible to observe an optimum effect for polymers within narrower degrees of polymerization. Accordingly, hair treatment agents according to the present invention containing epsilon-poly-L-lysine of the general formula (I) in which n is an integer of 10 to 70, preferably from 15 to 60, more preferably from 20 to 50 and in particular for the numbers 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35.
Ganz besonders bevorzugte erfindungsgemäße Haarbehandlungsmittel enthalten 0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 23 und/oder n = 24 und/oder n = 25 und/oder n = 26 und/oder n = 27 und/oder n = 28 und/oder n = 29 und/oder n = 30 und/oder n = 31 und/oder n = 32 und/oder n = 33 und/oder n = 34, wobei die Gesamtmenge an Epsilon-Poly-L- Lysinen der allgemeinen Formel (I) erfindungsgemäß 0,0001 bis 5 Gew.-% beträgt.  Very particularly preferred hair treatment compositions according to the invention contain 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 23 and / or n = 24 and / or n = 25 and / or n = 26 and / or n = 27 and / or n = 28 and / or n = 29 and / or n = 30 and / or n = 31 and / or n = 32 and / or n = 33 and / or n = 34, wherein the total amount of epsilon-poly-L-Lysinen of the general formula (I) according to the invention is 0.0001 to 5 wt .-%.
Als zweiten wesentlichen Inhaltsstoff enthalten die erfindungsgemäßen Mittel 0,01 bis 10 Gew.-% Climbazol. Climbazol ist eine chemische Verbindung, die antimykotisch und fungistatisch wirkt. Es kommt in Form eines Racemats in den Handel As a second essential ingredient, the agents according to the invention contain from 0.01 to 10% by weight of climbazole. Climbazole is a chemical compound that is antifungal and fungistatic. It comes in the form of a racemate in the trade
Figure imgf000004_0001
Figure imgf000004_0001
Die exakte Bezeichnung der Verbindung ist (RS)-1-(4-Chlorphenoxy)- 1-(1 /-/-imidazol-1-yl)- 3,3- dimethylbutan-2-οη, der INCI-Name ist Climbazole. The exact name of the compound is (RS) -1- (4-chlorophenoxy) - 1- (1 / - / - imidazol-1-yl) - 3,3-dimethylbutan-2-one, the INCI name is Climbazole.
Auch Climbazol wird in bevorzugten erfindungsgemäßen Mitteln innerhalb engerer Mengenbereiche eingesetzt. Erfindungsgemäß bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol enthalten. Climbazole is also used in preferred compositions according to the invention within narrower ranges. Hair treatment agents preferred according to the invention are characterized in that they contain 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole.
Ganz besonders bevorzugte erfindungsgemäße Haarbehandlungsmittel enthalten  Very particularly preferred hair treatment compositions according to the invention contain
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 23 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 23 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 24 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 24 and 0.02 bis 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 25 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 25 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 26 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 26 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 27 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 27 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 28 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 28 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 29 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 29 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 30 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 30 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 31 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 31 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 32 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder  0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 32 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or
0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 33 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol und/oder 0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) mit n = 34 und 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol, 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 33 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 34 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole,
wobei die Gesamtmenge an Epsilon-Poly-L-Lysinen der allgemeinen Formel (I) erfindungsgemäß 0,0001 bis 5 Gew.-% beträgt. wherein the total amount of epsilon-poly-L-lysines of the general formula (I) according to the invention is 0.0001 to 5 wt .-%.
Ganz besonders bevorzugt werden die Mengen von Epsilon-Poly-L-Lysin(en) und Climbazol aufeinander abgestimmt, um eine möglichst große Wirkungssteigerung und Effektivität zu bewirken. Hier sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die eine Gesamtmenge von Epsilon-Poly-L-Lysin der allgemeinen Formel (I) (Inhaltsstoff a)) und Climbazol (Inhaltsstoff b)) von 0,01 bis 2 Gew.-%, vorzugsweise von 0, 1 bis 1 ,75 Gew.-%, weiter bevorzugt von 0,25 bis 1 ,5 Gew.-% und insbesondere von 0,5 bis 1 ,25 Gew.-% enthalten.  Most preferably, the amounts of epsilon-poly-L-lysine (s) and climbazole are coordinated to achieve the greatest possible increase in effectiveness and effectiveness. Hair treatment compositions according to the invention are preferred here which comprise a total amount of epsilon-poly-L-lysine of the general formula (I) (ingredient a)) and climbazole (ingredient b)) of 0.01 to 2% by weight, preferably of 0, 1 to 1, 75 wt .-%, more preferably from 0.25 to 1, 5 wt .-% and in particular from 0.5 to 1, 25 wt .-%.
Da insbesondere Kopfhautschuppen oft mit einer sehr trockenen Haut einhergehen, ist es bevorzugt, feuchtigkeitsspendende Wirkstoffe in die erfindungsgemäßen Mittel einzuarbeiten. Als besonders verträglich mit der erfindungsgemäßen Kombination haben sich dabei bestimmte Wirkstoffe erwiesen, so daß bevorzugte erfindungsgemäße Haarbehandlungsmittel mindestens einen feuchtigkeitspendenden Aktivstoff aus der Gruppe Pantolacton, Glycerin, Allantoin, Panthenol, Isopentyldiol enthalten.  Since scalp dandruff is often associated with a very dry skin, it is preferred to incorporate moisturizing agents in the compositions of the invention. As a particularly compatible with the combination of the invention, certain active ingredients have been found so that preferred hair treatment compositions of the invention contain at least one moisturizing active ingredient from the group pantolactone, glycerol, allantoin, panthenol, isopentyl.
Unabhängig von der Art des bevorzugten feuchtigkeitsspendenden Wirkstoffs und unabhängig davon, ob lediglich ein solcher Wirkstoff eingesetzt wird oder Mischungen dieser Wirkstoffe zum Einsatz kommen, sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die den bzw. die feuchtigkeitspendenden Aktivstoff(e) in Mengen von 0, 1 bis 10 Gew.-%, vorzugsweise von 0, 15 bis 7,5 Gew.-%, weiter bevorzugt von 0,2 bis 5 Gew.-% und insbesondere von 0,25 bis 4 Gew.-% enthalten.  Irrespective of the nature of the preferred moisturizing active ingredient and whether only such an active ingredient is used or mixtures of these active ingredients are used, hair treatment compositions according to the invention are preferred, the or the moisturizing active substance (s) in amounts of 0, 1 to 10 Wt .-%, preferably from 0, 15 to 7.5 wt .-%, more preferably from 0.2 to 5 wt .-% and in particular from 0.25 to 4 wt .-%.
Ganz besonders bevorzugte erfindungsgemäße Haarbehandlungsmittel mit verschiedenen feuchtigkeitspendenden Aktivstoffen und den jeweiligen Mengenangaben sind auf den Seiten 6 bis 17 des Prioritätsdokuments offenbart.  Very particularly preferred hair treatment compositions according to the invention with various moisturizing active substances and the respective quantities are disclosed on pages 6 to 17 of the priority document.
Die kosmetischen Mittel enthalten vorzugsweise weiterhin mindestens einen Vertreter aus der Gruppe der anionischen, amphoteren, zwitterionischen, nichtionischen, kationischen Tenside oder aus Gemischen davon, der wasserunlöslichen Olkomponenten, der Vitamine, der Provitamine, der Proteinhydrolysate, der Pflanzenextrakte, der UV-Filter, der Aminosäuren, der wasserunlöslichen Silikone, der wasserlöslichen Silikone und/oder der Amodimethicone  The cosmetic compositions preferably further contain at least one member selected from the group consisting of anionic, amphoteric, zwitterionic, nonionic, cationic surfactants or mixtures thereof, water-insoluble oil components, vitamins, provitamins, protein hydrolysates, plant extracts, UV filter, Amino acids, water-insoluble silicones, water-soluble silicones and / or amodimethicones
Erfindungsgemäß bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie - bezogen auf ihr Gewicht - 0,5 bis 70 Gew.-%, vorzugsweise 1 bis 60 Gew.-% und insbesondere 5 bis 25 Gew.-% anionische(s) und/oder nichtionische(s) und/oder kationische(s) und/oder amphotere(s) Tensid(e), enthalten.  Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight and in particular from 5 to 25% by weight of anionic and / or nonionic (s) and / or cationic and / or amphoteric surfactant (s).
Als anionische Tenside und Emulgatoren eignen sich für die erfindungsgemäßen Zusammensetzungen alle für die Verwendung am menschlichen Körper geeigneten anionischen oberflächenaktiven Stoffe. Diese sind gekennzeichnet durch eine wasserlöslich machende, anionische Gruppe wie z. B. eine Carboxylat-, Sulfat-, Sulfonat- oder Phosphat-Gruppe und eine lipophile Alkylgruppe mit etwa 8 bis 30 C-Atomen. Zusätzlich können im Molekül Glycol- oder Polyglycol- ether-Gruppen, Ester-, Ether- und Amidgruppen sowie Hydroxylgruppen enthalten sein. Beispiele für geeignete anionische Tenside und Emulgatoren sind, jeweils in Form der Natrium-, Kalium- und Ammonium- sowie der Mono-, Di- und Trialkanolammoniumsalze mit 2 bis 4 C-Atomen in der Alkanolgruppe, Suitable anionic surfactants and emulsifiers for the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic Group such as As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups as well as hydroxyl groups may be present in the molecule. Examples of suitable anionic surfactants and emulsifiers are, in each case in the form of the sodium, potassium and ammonium as well as the mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group,
lineare und verzweigte Fettsäuren mit 8 bis 30 C-Atomen (Seifen),  linear and branched fatty acids with 8 to 30 carbon atoms (soaps),
Ethercarbonsäuren der Formel R-0-(CH2-CH20)x-CH2-COOH, in der R eine lineare Alkylgruppe mit 8 bis 30 C-Atomen und x = 0 oder 1 bis 16 ist, Ethercarbonsäuren the formula R-0- (CH 2 -CH 2 0) x -CH 2 -COOH, in which R is a linear alkyl group having 8 to 30 carbon atoms and x = 0 or 1 to 16,
Acylsarcoside mit 8 bis 24 C-Atomen in der Acylgruppe,  Acylsarcosides having 8 to 24 carbon atoms in the acyl group,
Acyltauride mit 8 bis 24 C-Atomen in der Acylgruppe,  Acyltaurides having 8 to 24 carbon atoms in the acyl group,
Acylisethionate mit 8 bis 24 C-Atomen in der Acylgruppe,  Acyl isethionates having 8 to 24 carbon atoms in the acyl group,
lineare Alkansulfonate mit 8 bis 24 C-Atomen,  linear alkanesulfonates having 8 to 24 C atoms,
lineare Alpha-Olefinsulfonate mit 8 bis 24 C-Atomen,  linear alpha-olefin sulfonates having 8 to 24 C atoms,
Alpha-Sulfofettsäuremethylester von Fettsäuren mit 8 bis 30 C-Atomen,  Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 carbon atoms,
Acylglutamate der Formel (T1 ),  Acylglutamates of the formula (T1),
XOOC-CH2CH2CH-COOX (T1 ) XOOC-CH 2 CH 2 CH-COOX (T1)
I I
HN-COR HN-COR
in der R CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0, 1 , 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alkanolammonium oder Glucammonium steht, beispielsweise Acylglutamate, die sich von Fettsäuren mit 6 bis 22, vorzugsweise 12 bis 18 Kohlenstoffatomen ableiten, wie beispielsweise C12/14- bzw. Ci2/i8-Kokosfettsäure, Laurinsäure, Myristinsäure, Palmitinsäure und/oder Stearinsäure, insbesondere Natrium-N-cocoyl- und Natrium-N-stearoyl- L-glutamat, in which R CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, which from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C 12 / 14- or Ci 2 / i8-coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, particularly sodium N-cocoyl and sodium N-stearoyl-L-glutamate,
Ester einer hydroxysubstituierten Di- oder Tricarbonsäure der allgemeinen Formel (T2),  Esters of a hydroxy-substituted di- or tricarboxylic acid of the general formula (T2),
XX
II
HO— C— COOR (T2) HOCCOOR (T2)
I  I
Y— CH— COOR2 in der X=H oder eine -CH2COOR-Gruppe ist, Y=H oder -OH ist unter der Bedingung, dass Y=H ist, wenn X=-CH2COOR ist, R, R und R2 unabhängig voneinander ein Wasserstoffatom, ein Alkali- oder Erdalkalimetallkation, eine Ammoniumgruppe, das Kation einer ammoniumorganischen Base oder einen Rest Z bedeuten, der von einer polyhydroxylierten organischen Verbindung stammt, die aus der Gruppe der veretherten (C6-C18)-Alkylpolysaccharide mit 1 bis 6 monomeren Saccharideinheiten und/oder der veretherten aliphatischen (C6-Ci6)- Hydroxyalkylpolyole mit 2 bis 16 Hydroxylresten ausgewählt sind, unter der Maßgabe, dass wenigstens eine der Gruppen R, R oder R2 ein Rest Z ist, Y is CHCOOR 2 wherein X is H or a -CH 2 COOR group, Y is H or -OH is under the condition that Y is H when X is -CH 2 COOR, R, R and R 2 independently of one another denote a hydrogen atom, an alkali metal or alkaline earth metal cation, an ammonium group which is a cation of an ammonium organic base or a Z radical derived from a polyhydroxylated organic compound selected from the group of etherified (C 6 -C 18 ) Alkyl polysaccharides with 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C 6 -C 6 ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R, R or R 2 is a radical Z,
Ester der Sulfobernsteinsäure oder der Sulfosuccinate der allgemeinen Formel (T3I),  Esters of sulfosuccinic acid or sulfosuccinates of the general formula (T3I),
H2C— COOR (T3) H 2 COOR (T3)
I  I
M(n+/n) -Q3S _ QH _ COOR2 in der M(n+/n) für n = 1 ein Wasserstoffatom, ein Alkalimetallkation, eine Ammoniumgruppe oder das Kation einer ammonium-organischen Base und für n = 2 ein Erdalkalimetallkation darstellt und R und R2 unabhängig voneinander ein Wasserstoffatom, ein Alkali- oder Erdalkalimetallkation, eine Ammoniumgruppe, das Kation einer ammonium-organischen Base oder einen Rest Z bedeuten, der von einer polyhydroxylierten organischen Verbindung stammt, die aus der Gruppe der veretherten (C6-Ci8)-Alkylpolysaccharide mit 1 bis 6 monomeren Saccharideinheiten und/oder der veretherten aliphatischen (C6-Ci6)-Hydroxyalkylpolyole mit 2 bis 16 Hydroxylresten ausgewählt ist, unter der Maßgabe, dass wenigstens eine der Gruppen R oder R2 ein Rest Z ist, M (n + / n) -Q 3S _ Q H _COOR 2 in the M (n + / n) for n = 1, a hydrogen atom, an alkali metal cation, an ammonium group or the cation of an ammonium organic base and for n = 2 Represents alkaline earth metal cation and R and R 2 are independently a hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C 6 -C 8) -Alkylpolysaccharide having 1 to 6 monomeric saccharide units and / or etherified aliphatic (C 6 -C 6) -hydroxyalkylpolyols is selected having 2 to 16 hydroxyl radicals, among the proviso that at least one of the groups R or R 2 Rest Z is,
Sulfobernsteinsäuremono- und -dialkylester mit 8 bis 24 C-Atomen in der Alkylgruppe und Sulfobernsteinsäuremonoalkylpolyoxyethylester mit 8 bis 24 C-Atomen in der Alkylgruppe und 1 bis 6 Oxyethylgruppen,  Sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 24 C atoms in the alkyl group and 1 to 6 oxyethyl groups,
Alkylsulfate und Alkylpolyglycolethersulfate der Formel R-(0-CH2-CH2)x-OS03H, in der R eine bevorzugt lineare Alkylgruppe mit 8 bis 30 C-Atomen und x = 0 oder 1 - 12 ist, Alkyl sulfates and alkyl polyglycol ether sulfates of the formula R- (O-CH 2 -CH 2 ) x -OSO 3 H, in which R is a preferably linear alkyl group having 8 to 30 C atoms and x = 0 or 1 - 12,
gemischte oberflächenaktive Hydroxysulfonate gemäß DE-A-37 25 030,  mixed surface-active hydroxysulfonates according to DE-A-37 25 030,
Ester der Weinsäure und Zitronensäure mit Alkoholen, die Anlagerungsprodukte von etwa 2-15 Molekülen Ethylenoxid und/oder Propylenoxid an C8.22-Fettalkohole darstellen, Esters of tartaric acid and citric acid with alcohols, the addition products of about 2-15 molecules of ethylene oxide and / or propylene oxide to C 8 . 2 represent 2-fatty alcohols,
Alkyl- und/oder Alkenyletherphosphate,  Alkyl and / or alkenyl ether phosphates,
sulfatierte Fettsäurealkylenglycolester,  sulfated fatty acid alkylene glycol esters,
Monoglyceridsulfate und Monoglyceridethersulfate.  Monoglyceride sulfates and monoglyceride ether sulfates.
Bevorzugte anionische Tenside und Emulgatoren sind Acylglutamate, Acylisethionate, Acylsarcosinate und Acyltaurate, jeweils mit einem linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0, 1 , 2 oder 3 Doppelbindungen, der in besonders bevorzugten Ausführungsformen aus einem Octanoyl-, Decanoyl-, Lauroyl-, Myristoyl-, Palmitoyl- und Stearoylrest ausgewählt ist, Ester der Weinsäure, Zitronensäure oder Bernsteinsäure bzw. der Salze dieser Säuren mit alkylierter Glucose, insbesondere die Produkte mit der INCI-Bezeichnung Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate und Disodium Coco-Glucoside Sulfosuccinate, Alkylpolyglycolethersulfate und Ethercarbonsäuren mit 8 bis 18 C-Atomen in der Alkylgruppe und bis zu 12 Ethoxygruppen im Molekül, Sulfobernsteinsäuremono- und -dialkylester mit 8 bis 18 C-Atomen in der Alkylgruppe und Sulfobernsteinsäuremonoalkylpolyoxyethylester mit 8 bis 18 C-Atomen in der Alkylgruppe und 1 bis 6 Ethoxygruppen. Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which in particularly preferred embodiments of an octanoyl, decanoyl, lauroyl , Myristoyl, palmitoyl and stearoyl radical, esters of tartaric acid, citric acid or succinic acid or of the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium Coco-glucosides sulfosuccinates, alkyl polyglycol ether sulfates and ether carboxylic acids having 8 to 18 C atoms in the alkyl group and up to 12 ethoxy groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 18 C atoms in the alkyl group and 1 to 6 ethoxy groups.
Als zwitterionische Tenside und Emulgatoren werden solche oberflächenaktiven Verbindungen bezeichnet, die im Molekül mindestens eine quartäre Ammoniumgruppe und mindestens eine - COO<_) - oder -S03 <_) -Gruppe tragen. Besonders geeignete zwitterionische Tenside und Emulgatoren sind die sogenannten Betaine wie die N-Alkyl-N,N-dimethylammoniumglycinate, beispielsweise das Kokosalkyldimethylammoniumglycinat, N-Acyl-aminopropyl-N,N-dimethyl- ammoniumglycinate, beispielsweise das Kokosacylaminopropyldimethylammoniumglycinat, und 2- Alkyl-3-carboxymethyl-3-hydroxyethylimidazoline mit jeweils 8 bis 18 C-Atomen in der Alkyl- oder Acylgruppe sowie das Kokosacylaminoethylhydroxyethylcarboxymethylglycinat. Ein bevorzugtes zwitterionisches Tensid ist das unter der INCI-Bezeichnung Cocamidopropyl Betaine bekannte Fettsäureamidderivat. Zwitterionic surfactants and emulsifiers are surface-active compounds which contain at least one quaternary ammonium group and at least one in the molecule - carry or -S0 3 <_) group - COO <_). Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3 carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
Weiter bevorzugte anionische Tenside sind Alkylsulfate, Alkylpolyglykolethersulfate und Ethercarbonsäuresalze mit 10 bis 18 C-Atomen in der Alkylgruppe und bis zu 12 Glykol- ethergruppen im Molekül und Sulfobernsteinsäuremono- und -dialkylester mit 8 bis 18 C-Atomen in der Alkylgruppe und Sulfobernsteinsäuremono-alkylpolyoxyethylester mit 8 bis 18 C-Atomen in der Alkylgruppe und 1 bis 6 Oxyethylgruppen.  Further preferred anionic surfactants are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acid salts having 10 to 18 C atoms in the alkyl group and up to 12 glycol ether groups in the molecule and sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethylester with 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups.
Besonders bevorzugte anionische Tenside sind die Alkali- oder Ammoniumsalze des Laurylethersulfates mit einem Ethoxylierungsgrad von 2 bis 4 EO.  Particularly preferred anionic surfactants are the alkali metal or ammonium salts of lauryl ether sulfate having a degree of ethoxylation of 2 to 4 EO.
Insbesondere bevorzugte erfindungsgemäße Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie - bezogen auf ihr Gewicht - 0, 1 bis 20 Gew.-%, vorzugsweise 0,25 bis 17,5 Gew.-% und insbesondere 5 bis 15 Gew.-% anionische(s) Tensid(e), besonders bevorzugt Fettalkoholethersulfate der Formel  Particularly preferred hair treatment compositions according to the invention are characterized in that they contain - based on their weight - 0.1 to 20 wt .-%, preferably 0.25 to 17.5 wt .-% and in particular 5 to 15 wt .-% of anionic (s ) Surfactant (s), more preferably fatty alcohol ether sulfates of the formula
H3C-(CH2)n-(OCH2CH2)k-OS03" M+ H 3 C- (CH 2) n - (OCH 2 CH 2) k -OSO 3 " M +
enthalten, in der n für Werte von 5 bis 21 , vorzugsweise von 7 bis 19, besonders bevorzugt von 9 bis 17 und insbesondere von 1 1 bis 13 und k für Werte von 1 , 2, 3, 4, 5, 6, 7, 8, 9 oder 10, vorzugsweise für 1 , 2 oder 3 und insbesondere für 2 stehen, und M für ein Kation aus der Gruppe Na+, K+ NH4 +, Mg2+, Zn2+, vorzugsweise für Na+, stehen. in which n represents values of from 5 to 21, preferably from 7 to 19, particularly preferably from 9 to 17 and in particular from 1 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1, 2 or 3 and especially 2, and M is a cation from the group Na + , K + NH 4 + , Mg 2+ , Zn 2+ , preferably Na + ,
Als zwitterionische Tenside und Emulgatoren werden solche oberflächenaktiven Verbindungen bezeichnet, die im Molekül mindestens eine quartäre Ammoniumgruppe und mindestens eine - COO<_) - oder -S03 <_) -Gruppe tragen. Besonders geeignete zwitterionische Tenside und Emulgatoren sind die sogenannten Betaine wie die N-Alkyl-N,N-dimethylammoniumglycinate, beispielsweise das Kokosalkyldimethylammoniumglycinat, N-Acyl-aminopropyl-N,N-dimethyl- ammoniumglycinate, beispielsweise das Kokosacylaminopropyldimethylammoniumglycinat, und 2- Alkyl-3-carboxymethyl-3-hydroxyethylimidazoline mit jeweils 8 bis 18 C-Atomen in der Alkyl- oder Acylgruppe sowie das Kokosacylaminoethylhydroxyethylcarboxymethylglycinat. Ein bevorzugtes zwitterionisches Tensid ist das unter der INCI-Bezeichnung Cocamidopropyl Betaine bekannte Fettsäureamidderivat. Unter ampholytischen Tensiden und Emulgatoren werden solche oberflächenaktiven Verbindungen verstanden, die außer einer C8 - C24 - Alkyl- oder -Acylgruppe mindestens eine freie Aminogruppe und mindestens eine -COOH- oder -S03H-Gruppe enthalten und zur Ausbildung innerer Salze befähigt sind. Beispiele für geeignete ampholytische Tenside sind N-Alkylglycine, N-Alkylaminopropionsäuren, N-Alkylaminobuttersäuren, N-Alkyliminodipropionsäuren, N-Hydroxy- ethyl-N-alkylamidopropylglycine, N-Alkyltaurine, N-Alkylsarcosine, 2-Alkylaminopropionsäuren und Alkylaminoessigsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe. Besonders bevorzugte ampholytische Tenside sind das N-Kokosalkylaminopropionat, das Kokosacylamino- ethylaminopropionat und das d2 - Ci8 - Acylsarcosin. Zwitterionic surfactants and emulsifiers are surface-active compounds which contain at least one quaternary ammonium group and at least one in the molecule - carry or -S0 3 <_) group - COO <_). Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3 carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine. Ampholytic surfactants and emulsifiers are understood to mean those surface-active compounds which, apart from a C 8 -C 24 -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SO 3 H group and are capable of forming internal salts , Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and the d 2 -C 8 -acylsarcosine.
Besonders bevorzugte erfindungsgemäße Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie amphotere(s) Tensid(e) aus den Gruppen der N-Alkylglycine, N-Alkylpropionsäuren, N- Alkylaminobuttersäuren, N-Alkyliminodipropionsäuren, N-Hydroxyethyl-N-alkylamidopropylglycine, N-Alkyltaurine, N-Alkylsarcosine, 2-Alkylaminopropionsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe, Alkylaminoessigsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe, N- Kokosalkylaminopropionat, Kokosacylaminoethylaminopropionat C12 - Ci8 - Acylsarcosin, N-Alkyl- Ν,Ν-dimethylammonium-glycinate, beispielsweise Kokosalkyl-dimethylammoniumglycinat, N-Acyl- aminopropyl-N,N-dimethylammoniumglycinate, beispielsweise Kokosacylaminopropyl- dimethylammoniumglycinat, 2-Alkyl-3-carboxymethyl-3-hydroxyethyl-imidazoline mit jeweils 8 bis 18 C-Atomen in der Alkyl- oder Acylgruppe, Kokosacylaminoethylhydroxyethylcarboxymethyl- glycinat, der unter der INCI-Bezeichnung Cocamidopropyl Betain bekannten Verbindungen, der unter der INCI-Bezeichnung Disodium Cocoamphodiacetate bekannten Verbindungen enthalten, wobei bevorzugte Mittel das bzw. die amphotere(n) Tensid(e) in Mengen von 0,5 bis 9 Gew.-%, vorzugsweise von 0,75 bis 8 Gew.-% und insbesondere von 1 bis 7,5 Gew.-%, jeweils bezogen auf das gesamte Mittel, enthalten. Particularly preferred hair treatment compositions according to the invention are characterized in that they contain amphoteric surfactant (s) from the groups of N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids containing around 8 to 24 carbon atoms in the alkyl group, alkyl aminoacetic acids containing around 8 to 24 carbon atoms in the alkyl group, N-cocoalkylaminopropionate, cocoacylaminoethyl aminopropionate C 12 - C 8 - acyl sarcosine, N-alkyl - Ν, Ν-dimethylammonium glycinates, for example, cocoalkyl dimethylammoniumglycinat, N-acylaminopropyl-N, N-dimethylammoniumglycinate, for example Kokosacylaminopropyl- dimethylammoniumglycinat, 2-alkyl-3-carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 C. -Atomen in the alkyl or acyl group, Kokosacylaminoethylhydroxyethylcarboxymethyl- glycinate, under the INCI name cocamidopropyl betaine bek compounds which contain compounds known by the INCI name Disodium Cocoamphodiacetate, preferred agents comprising the amphoteric surfactant (s) in amounts of from 0.5 to 9% by weight, preferably from 0.75 to 8 Wt .-% and in particular from 1 to 7.5 wt .-%, each based on the total agent included.
Besonders bevorzugte Haarbehandlungsmittel enthalten als amphotere Tenside Betaine der Formel (T4)  Particularly preferred hair treatment agents contain as amphoteric surfactants betaines of the formula (T4)
Figure imgf000010_0001
Figure imgf000010_0001
in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen steht. in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.
Diese Tenside werden nach der INCI-Nomenklatur als Amidopropylbetaine bezeichnet, wobei die Vertreter, die sich von Kokosfettsäuren ableiten, bevorzugt sind und als Cocoamidopropylbetaine bezeichnet werden. Besonders bevorzugt werden erfindungsgemäß Tenside der Formel (T4) eingesetzt, die ein Gemisch der folgenden Vertreter sind:  These surfactants are referred to the INCI nomenclature as Amidopropylbetaine, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamidopropylbetaine. According to the invention, particular preference is given to using surfactants of the formula (T4) which are a mixture of the following representatives:
H3C-(CH2)7-C(0)-NH-(CH2)3N+(CH3)2CH2COO~, H3C-(CH2)9-C(0)-NH-(CH2)3N+(CH3)2CH2COO~, H3C-(CH2)11-C(0)-NH-(CH2)3N+(CH3)2CH2COO", H3C-(CH2)13-C(0)-NH-(CH2)3N+(CH3)2CH2COO", H3C-(CH2)15-C(0)-NH-(CH2)3N+(CH3)2CH2COO~, H3C-(CH2)7-CH=CH-(CH2)7-C(0)-NH- (CH2)3N+(CH3)2CH2COO~ H 3 C- (CH 2) 7 -C (0) -NH- (CH 2) 3 N + (CH 3) 2 CH 2 COO ~, H 3 C- (CH 2) 9 -C (0) -NH - (CH 2) 3 N + (CH 3) 2 CH 2 COO ~, H 3 C- (CH 2) 11 -C (0) -NH- (CH 2) 3 N + (CH 3) 2 CH 2 COO " , H 3 C- (CH 2 ) 13 -C (O) -NH- (CH 2 ) 3 N + (CH 3 ) 2 CH 2 COO " , H 3 C- (CH 2) 15 -C (0) -NH- (CH 2) 3 N + (CH 3) 2 CH 2 COO ~, H 3 C- (CH 2) 7 -CH = CH- (CH 2 ) 7 -C (O) -NH- (CH 2 ) 3 N + (CH 3 ) 2 CH 2 COO ~
Besonders bevorzugt werden Tenside der Formel (T4) innerhalb engerer Mengenbereiche eingesetzt. Hier sind erfindungsgemäße Mittel bevorzugt, die - bezogen auf ihr Gewicht - 0,25 bis 8 Gew.-%, weiter bevorzugt 0,5 bis 7 Gew.-%, weiter bevorzugt 0,75 bis 6,5 Gew.-% und insbesondere 1 bis 5,5 Gew.-% Tensid(e) der Formel (T4) enthalten.  Particular preference is given to using surfactants of the formula (T4) within narrower ranges of amounts. Here, agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T4).
Zusätzlich zu dem bzw. den Amphotensiden der Formel (T4) oder an deren Stelle können die erfindungsgemäßen Haarbehandlungsmittel mit besonderem Vorzug als amphotere Tenside Betaine der Formel (T5)  In addition to the amphoteric surfactant (s) of the formula (T4) or in its place, the hair-treatment compositions according to the invention can be used with particular preference as amphoteric surfactants betaines of the formula (T5)
Figure imgf000011_0001
Figure imgf000011_0001
enthalten, in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen steht. in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.
Diese Tenside werden nach der INCI-Nomenklatur als Amphoacetate bezeichnet, wobei die Vertreter, die sich von Kokosfettsäuren ableiten bevorzugt sind und als Cocoamphoactetate bezeichnet werden.  These surfactants are referred to according to the INCI nomenclature as amphoacetates, wherein the representatives derived from coconut fatty acids are preferred and are referred to as cocoamphoactetates.
Aus herstellungstechnischen Gründen enthalten Tenside dieses Typs oft auch Betaine der Formel (T5a)  For manufacturing reasons surfactants of this type often also contain betaines of the formula (T5a)
Figure imgf000011_0002
Figure imgf000011_0002
in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen und M für ein Kation steht. Diese Tenside werden nach der INCI-Nomenklatur als Amphodiacetate bezeichnet, wobei die Vertreter, die sich von Kokosfettsäuren ableiten, bevorzugt sind und als Cocoamphodiactetate bezeichnet werden. in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms and M is a cation. These surfactants are referred to according to the INCI nomenclature as Amphodiacetate, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamphodiactetate.
Besonders bevorzugt werden erfindungsgemäß Tenside der Formel (T5) eingesetzt, die ein Gemisch der folgenden Vertreter sind:  According to the invention, particular preference is given to using surfactants of the formula (T5) which are a mixture of the following representatives:
H3C-(CH2)7-C(0)-NH-(CH2)2NH+(CH2CH2OH)CH2CH2COO", H3C-(CH2)9-C(0)-NH- (CH2)2NH+(CH2CH2OH)CH2CH2COO~, HaC-iCHzJu-CiOJ-NH-iCHz NH^CHzCHzOHJCHzCHzCOO", H3C-(CH2)13-C(0)-NH-(CH2)2NH+(CH2CH2OH)CH2CH2COO", H3C-(CH2)15-C(0)-NH- (CH2)2NH+(CH2CH2OH)CH2CH2COO~, H3C-(CH2)7-CH=CH-(CH2)7-C(0)-NH- (CH2)2NH+(CH2CH2OH)CH2CH2COO~ H 3 C- (CH 2 ) 7 -C (O) -NH- (CH 2 ) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO " , H 3 C- (CH 2 ) 9 -C ( 0) -NH- (CH 2 ) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO ~ , HaC-iCHzJu-CiOJ-NH-iCHz NH ^ CHzCHzOHJCHzCHzCOO " , H 3 C- (CH 2 ) 13 - C (O) -NH- (CH 2 ) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO " , H 3 C- (CH 2 ) 15 -C (O) -NH- (CH 2) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO ~, H 3 C- (CH 2) 7 -CH = CH- (CH 2) 7 -C (0) -NH- (CH 2) 2 NH + (CH 2 CH 2 OH) CH 2 CH 2 COO ~
Besonders bevorzugt werden Tenside der Formel (T5) innerhalb engerer Mengenbereiche eingesetzt. Hier sind erfindungsgemäße Mittel bevorzugt, die - bezogen auf ihr Gewicht - 0,25 bis 8 Gew.-%, weiter bevorzugt 0,5 bis 7 Gew.-%, weiter bevorzugt 0,75 bis 6,5 Gew.-% und insbesondere 1 bis 5,5 Gew.-% Tensid(e) der Formel (T5) enthalten.  Particular preference is given to using surfactants of the formula (T5) within narrower ranges of amounts. Here, agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T5).
Zusammenfassend sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, bei denen der Rest R in den Formeln (VI) und (VII) ausgewählt ist aus H3C-(CH2)7-, H3C-(CH2)9-, H3C-(CH2)n-, H3C- (CH2)i3-, H3C-(CH2)i5-, H3C-(CH2)7-CH=CH-(CH2)7- oder Mischungen aus diesen. In summary, hair treatment agents according to the invention are preferred in which the radical R in the formulas (VI) and (VII) is selected from H 3 C- (CH 2 ) 7 -, H 3 C- (CH 2 ) 9- , H 3 C- (CH 2 ) n, H 3 C- (CH 2 ) i3-, H 3 C- (CH 2 ) i5-, H 3 C- (CH 2 ) 7 -CH = CH- (CH 2 ) 7 - or Mixtures of these.
Besonders bevorzugte nichtionische Tenside sind Alkylpolyglycoside. Demnach sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die als nichtionische Tenside - bezogen auf ihr Gewicht - 0, 1 bis 20 Gew.-% Alkylpolyglycoside der allgemeinen Formel RO-(Z)x enthalten, wobei R für Alkyl, Z für Zucker sowie x für die Anzahl der Zuckereinheiten steht. Particularly preferred nonionic surfactants are alkyl polyglycosides. Accordingly, hair treatment compositions according to the invention are preferred which contain as nonionic surfactants - based on their weight - 0, 1 to 20 wt .-% alkylpolyglycosides of the general formula RO- (Z) x , where R is alkyl, Z for sugar and x for the number the sugar units stands.
Alkylpolyglycoside (APG) sind nichtionische Tenside, die vollständig aus nachwachsenden Rohstoffen (Zuckerbausteine, vorwiegend Glucose z.B. aus Maisstärke und Fettalkohol z.B. aus Kokosöl) hergestellt werden. Alkylpolyglycoside sind durch sauer katalysierte Reaktion (Fischer- Reaktion) von Zuckern, insbesondere Glucose (oder Stärke) oder von Butylglycosiden mit Fettalkoholen zugänglich. Alkylpolyglycosides (APG) are nonionic surfactants made entirely from renewable resources (sugar building blocks, predominantly glucose, for example from corn starch and fatty alcohol, for example from coconut oil). Alkyl polyglycosides are accessible by acid-catalyzed reaction (Fischer reaction) of sugars, especially glucose (or starch) or butyl glycosides with fatty alcohols.
Dabei entstehen komplexe Gemische aus Alkylmonoglucosid (Alkyl-a-D- und -ß-D-glucopyranosid sowie geringe Anteile -glucofuranosid), Alkyldiglucosiden (-isomaltoside, -maltoside etc.) und Alkyloligoglucosiden (-maltotrioside, -tetraoside etc.). Der durchschnittliche Polymerisationsgrad kommerzieller Produkte, deren Alkyl-Reste im Bereich C8-C16 liegen, beträgt 1 ,2-1 ,5. Complex mixtures of alkyl monoglucoside (alkyl-α-D- and β-D-glucopyranoside and small amounts of glucofuranoside), alkyldiglucosides (-isomaltosides, maltosides, etc.) and alkyl oligoglucosides (maltotriosides, tetraosides, etc.) are formed. The average degree of polymerization of commercial products whose alkyl radicals are in the range C8-C16 is 1, 2-1, 5.
Erfindungsgemäß bevorzugt werden Alkylpolyglycoside entsprechend der allgemeinen Formel RO- (Z)x eingesetzt, wobei R für Alkyl, Z für Zucker sowie x für die Anzahl der Zuckereinheiten steht. Besonders bevorzugt sind solche Alkylpolyglycoside, bei denen R According to the invention, preference is given to using alkylpolyglycosides corresponding to the general formula RO - (Z) x , where R is alkyl, Z is sugar and x is the number of sugar units. Particular preference is given to those alkylpolyglycosides in which R
im wesentlichen aus C8- und Cio-Alkylgruppen, consisting essentially of C 8 and C 10 -alkyl groups,
im wesentlichen aus Ci2- und Ci4-Alkylgruppen, essentially of C 2 - and Ci4 alkyl groups,
im wesentlichen aus C8- bis Ci6-Alkylgruppen oder consisting essentially of C 8 - to C 16 -alkyl groups or
im wesentlichen aus Ci2- bis Ci6-Alkylgruppen oder consisting essentially of Ci 2 - to Ci6-alkyl groups or
im wesentlichen aus d6 bis C-|8-Alkylgruppen essentially from d 6 to C- | 8 alkyl groups
besteht. consists.
Als Zuckerbaustein Z können beliebige Mono- oder Oligosaccharide eingesetzt werden. Üblicherweise werden Zucker mit 5 bzw. 6 Kohlenstoffatomen sowie die entsprechenden Oligosaccharide eingesetzt. Solche Zucker sind beispielsweise Glucose, Fructose, Galactose, Arabinose, Ribose, Xylose, Lyxose, Allose, Altrose, Mannose, Gulose, Idose, Talose und Sucrose. Bevorzugte Zuckerbausteine sind Glucose, Fructose, Galactose, Arabinose und Sucrose; Glucose ist besonders bevorzugt. Die erfindungsgemäß verwendbaren Alkylpolyglycoside enthalten im Schnitt 1 ,1 bis 5 Zuckereinheiten. Alkylpolyglycoside mit x-Werten von 1 , 1 bis 2,0 sind bevorzugt. Ganz besonders bevorzugt sind Alkylglycoside, bei denen x 1 ,1 bis 1 ,8 beträgt. As sugar building block Z it is possible to use any desired mono- or oligosaccharides. Usually, sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used. Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose. Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred. The alkylpolyglycosides which can be used according to the invention contain on average 1, 1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 8.
Weitere Tenside, die - insbesondere in Mischung mit Alkylpolyglycosiden - besonders vorteilhaft in den erfindungsgemäßen Mitteln eingesetzt werden können, sind Glutamate, Asparaginate und Sulfoacetate. Hier sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die - bezogen auf ihr Gewicht - 0, 1 bis 20 Gew.-% Fettsäureglutamate (Acylglutamate) und/oder Fettsäureasparaginate (Acylasparaginate) und/oder Alkylsulfoacetate (Sulfoessigsäure-alkylester) enthalten.  Other surfactants which can be used particularly advantageously in the compositions according to the invention, especially in admixture with alkylpolyglycosides, are glutamates, asparaginates and sulfoacetates. Here, hair treatment compositions according to the invention are preferred which contain, based on their weight, from 0.1 to 20% by weight of fatty acid glutamates (acylglutamates) and / or fatty acid asparaginates (acylasparaginates) and / or alkylsulfoacetates (sulfoacetic acid alkyl esters).
Acylglutamate lassen sich durch die Formel Acylglutamate can be defined by the formula
Figure imgf000013_0001
beschreiben, in der R-CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0 und/ oder 1 , 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alka nolammonium oder Glucammonium steht.
Figure imgf000013_0001
in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alka nolammonium or glucammonium stands.
Überraschenderweise wurde gefunden, daß Abmischungen von Alkylglucosiden mit Acylglutamaten eine sehr gute dermatologische Verträglichkeit und ein verbessertes Schaumvermögen sowohl hinsichtlich des Basisschaums als auch der Schaumstabilität in Gegenwart von Wasserhärte aufweisen. Surprisingly, it has been found that blends of alkyl glucosides with acyl glutamates have a very good dermatological compatibility and an improved foamability both with regard to the base foam and the foam stability in the presence of water hardness.
Acylglutamate stellen bekannte anionische Tenside dar, die beispielsweise durch Schotten- Baumann Acylierung von Glutaminsäure mit Fettsäuren, Fettsäureestern oder -Chloriden erhalten werden können. Verkaufsprodukte sind beispielsweise von der Hoechst AG, Frankfurt/DE oder der Ajinomoto Co. Inc., Tokyo/JP erhältlich. Acylglutamates are known anionic surfactants which can be obtained, for example, by Schotten-Baumann acylation of glutamic acid with fatty acids, fatty acid esters or chlorides. Products for sale are available, for example, from Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP.
Typische Beispiele für geeignete Acylglutamate sind Aniontenside, die sich von Fettsäuren mit 6 bis 22, vorzugsweise 12 bis 18 Kohlenstoffatomen ableiten, wie beispielsweise C 12/14- bzw. C12/18-Kokosfettsäure, Laurinsäure, Myristinsäure, Palmitinsäure und/oder Stearinsäure. Besonders bevorzugt sind Natrium-N-cocoyl- und Natrium-N-stearoyl-L-glutamat Die erfindungsgemäßen Mittel können die Alkyl- und/oder Alkenyloligoglucoside und die Acylglutamate im Gewichtsverhältnis 1 : 99 bis 99 : 1 , vorzugsweise 10 : 90 bis 90 : 10 und insbesondere 80 : 20 bis 50 : 50 enthalten. Typical examples of suitable acylglutamates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C 12/14 and C 12/18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-glutamate The compositions according to the invention may contain the alkyl and / or alkenyl oligoglucosides and the acyl glutamates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.
Acylasparaginate lassen sich durch die Formel Acylasparaginates can be defined by the formula
Figure imgf000014_0001
beschreiben, in der R-CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0 und/ oder 1 , 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alkanolammonium oder Glucammonium steht.
Figure imgf000014_0001
in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium ,
Acylasparaginate stellen bekannte anionische Tenside dar, die beispielsweise durch Schotten- Baumann Acylierung von Asparaginsäure mit Fettsäuren, Fettsäureestern oder -Chloriden erhalten werden können. Verkaufsprodukte sind beispielsweise von der Hoechst AG, Frankfurt/DE oder der Ajinomoto Co. Inc., Tokyo/JP erhältlich. Acylasparaginates are known anionic surfactants which can be obtained, for example, by Schotten-Baumann acylation of aspartic acid with fatty acids, fatty acid esters or chlorides. Products for sale are available, for example, from Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP.
Typische Beispiele für geeignete Acylasparaginate sind Aniontenside, die sich von Fettsäuren mit 6 bis 22, vorzugsweise 12 bis 18 Kohlenstoffatomen ableiten, wie beispielsweise C12/14- bzw. C12/18-Kokosfettsäure, Laurinsäure, Myristinsäure, Palmitinsäure und/oder Stearinsäure. Besonders bevorzugt sind Natrium-N-cocoyl- und Natrium-N-stearoyl-L-asparaginat Typical examples of suitable acylasparaginates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C12 / 14 or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-aspartate
Die erfindungsgemäßen Mittel können die Alkyl- und/oder Alkenyloligoglucoside und die Acylasparaginate ebenfalls im Gewichtsverhältnis 1 : 99 bis 99 : 1 , vorzugsweise 10 : 90 bis 90 : 10 und insbesondere 80 : 20 bis 50 : 50 enthalten. The agents according to the invention may also contain the alkyl and / or alkenyl oligoglucosides and the acylasparaginates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.
Sulfoacetate (Sulfoessigsäure-ester), sind üblicherweise Salze von Estern der Sulfoessigsäure und lassen sich durch die allgemeine Formel Sulfoacetates (sulfoacetic acid esters), are usually salts of esters of sulfoacetic acid and can be represented by the general formula
R-0-C(0)-CH2-S02-OX R-0-C (O) -CH 2 -SO 2 -OX
beschreiben, in der R für einen linearen oder verzweigten Alkyl- oder Alkenylrest mit 6 bis 22 Kohlenstoffatomen und 0 und/ oder 1 , 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alkanolammonium oder Glucammonium steht. Besonders bevorzugt ist der Einsatz vom Natriumsalz der Sulfoessigsäure mit der INCI- Bezeichnung: Sodium Lauryl Sulfoacetate): in which R is a linear or branched alkyl or alkenyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium stands. Particularly preferred is the use of the sodium salt of sulfoacetic acid with the INCI name: sodium lauryl sulfoacetate):
H3C-(CH2)11-0-CO-CH2-S02-ONa H 3 C- (CH 2 ) 11 -O-CO-CH 2 -SO 2 -ONa
Natriumlaurylsulfoacetat ist ein weißes, freifließendes Pulver, das neutral reagiert, mit gutem Schaumvermögen, Netzvermögen und Dispergiervermögen.  Sodium lauryl sulphoacetate is a white, free-flowing powder which reacts neutrally, with good foaming power, wetting power and dispersibility.
Erfindungsgemäß einsetzbar sind kationische Tenside vom Typ der quartären Ammoniumverbindungen, der Esterquats und der Amidoamine. Bevorzugte quaternäre Ammoniumverbindungen sind Ammoniumhalogenide, insbesondere Chloride und Bromide, wie Alkyl- trimethylammoniumchloride, Dialkyldimethylammoniumchloride und Trialkylmethylammonium- chloride. Die langen Alkylketten dieser Tenside weisen bevorzugt 10 bis 18 Kohlenstoffatome auf, wie z. B. in Cetyltrimethylammoniumchlorid, Stearyltrimethylammoniumchlorid, Distearyldimethyl- ammoniumchlorid, Lauryldimethylammoniumchlorid, Lauryldimethylbenzylammoniumchlorid und Tricetylmethylammoniumchlorid. Weitere bevorzugte kationische Tenside sind die unter den INCI- Bezeichnungen Quaternium-27 und Quaternium-83 bekannten Imidazolium-Verbindungen. Cationic surfactants of the quaternary ammonium compound type, the esterquats and the amidoamines can be used according to the invention. Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides. The long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as. In cetyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, lauryl dimethyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride and tricetylmethyl ammonium chloride. Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.
Besonders bevorzugte erfindungsgemäße Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie als kationischen Pflegestoff - bezogen auf ihr Gewicht - 0,05 bis 7,5 Gew.-%, vorzugsweise 0,1 bis 5 Gew.-%, besonders bevorzugt 0,2 bis 3,5 Gew.-% und insbesondere 0,25 bis 2,5 Gew.-% kationische(s) Tensid(e) aus der Gruppe der quartären Ammoniumverbindungen und/oder der Esterquats und/oder der Amidoamine enthalten, wobei bevorzugte kationische(s) Tensid(e) ausgewählt ist/sind aus Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as cationic care substance - based on their weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0.2 to 3, 5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) surfactant (s) from the group of quaternary ammonium compounds and / or the esterquats and / or the amidoamines containing preferred cationic (s) Surfactant (s) is / are selected
- Alkyltrimethylammoniumchloriden mit vorzugsweise 10 bis 18 Kohlenstoffatomen im Alkylrest und/oder  - Alkyltrimethylammoniumchloriden having preferably 10 to 18 carbon atoms in the alkyl radical and / or
Dialkyldimethylammoniumchloride mit vorzugsweise 10 bis 18 Kohlenstoffatomen im Alkylrest und/oder  Dialkyldimethylammoniumchloride having preferably 10 to 18 carbon atoms in the alkyl radical and / or
- Trialkylmethylammoniumchloride mit vorzugsweise 10 bis 18 Kohlenstoffatomen im Alkylrest und/oder  - Trialkylmethylammoniumchloride preferably having 10 to 18 carbon atoms in the alkyl radical and / or
Cetyltrimethylammoniumchlorid und/oder  Cetyltrimethylammonium chloride and / or
Stearyltrimethylammoniumchlorid und/oder  Stearyltrimethylammonium chloride and / or
Distearyldimethylammoniumchlorid und/oder  Distearyldimethylammonium chloride and / or
Lauryldimethylammoniumchlorid und/oder  Lauryldimethylammonium chloride and / or
Lauryldimethylbenzylammoniumchlorid und/oder  Lauryldimethylbenzylammoniumchlorid and / or
- Tricetylmethylammoniumchlorid  - tricetylmethylammonium chloride
Quaternium-27 und/oder  Quaternium-27 and / or
Quaternium-83 und/oder N-Methyl-N(2-hydroxyethyl)-N,N-(ditalgacyloxyethyl)ammonium-methosulfat und/oder Quaternium-83 and / or N-methyl-N (2-hydroxyethyl) -N, N- (ditalgacyloxyethyl) ammonium methosulfate and / or
N-Methyl-N(2-hydroxyethyl)-N,N-(distearoyloxyethyl)ammonium-methosulfat und/oder  N-methyl-N (2-hydroxyethyl) -N, N- (distearoyloxyethyl) ammonium methosulfate and / or
N,N-Dimethyl-N,N-distearoyloxyethyl-ammoniumchlorid und/oder N,N-Di-(2-hydroxyethyl)-N,N-(fettsäureesterethyl)-ammoniumchlorid. Die Pflegeffekte der erfindungsgemäßen Mittel lassen sich noch weiter verstärken, indem bestimmte Pflegestoffe eingesetzt werden. Vorzugsweise werden diese aus bestimmten Gruppen an sich bekannter Pflegestoffe ausgewählt, da diese Pflegestoffe formulierungstechnisch und vom Pflegeffekt hervorragend mit der erfindungsgemäß eingesetzten Kombination gegen Schuppen harmonieren.  N, N-dimethyl-N, N-distearoyloxyethyl ammonium chloride and / or N, N-di- (2-hydroxyethyl) -N, N- (fatty acid ethyl) ammonium chloride. The care effects of the compositions according to the invention can be further enhanced by using certain care substances. Preferably, these are selected from certain groups of known care substances, since these care substances harmonize perfectly with the formulation and the care effect with the combination used according to the invention against dandruff.
Erfindungsgemäß bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie zusätzlich Pfleg estoff(e) - bezogen auf ihr Gewicht - in Mengen von 0,001 bis 10 Gew.-%, vorzugsweise 0,005 bis 7,5 Gew.-%, besonders bevorzugt 0,01 bis 5 Gew.-% und insbesondere 0,05 bis 2,5 Gew.-% enthalten, wobei bevorzugte Pflegstoff(e) ausgewählt sind aus der Gruppe i. L-Carnitin und/oder seiner Salze;  Hair treatment compositions which are preferred according to the invention are characterized in that they additionally have care substance (s), based on their weight, in amounts of from 0.001 to 10% by weight, preferably from 0.005 to 7.5% by weight, particularly preferably from 0.01 to 5 Wt .-% and in particular 0.05 to 2.5 wt .-%, with preferred care substance (s) are selected from the group i. L-carnitine and / or its salts;
ii. Taurin und/oder seiner Salze;  ii. Taurine and / or its salts;
iii. Niacinamid;  iii. niacinamide;
iv. Ubichinon  iv. ubiquinone
v. Ectoin;  v. Ectoin;
Erfindungsgemäße bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie - bezogen auf ihr Gewicht -0,001 bis 10 Gew.-%, vorzugsweise 0,005 bis 7,5 Gew.-%, besonders bevorzugt 0,01 bis 5 Gew.-% und insbesondere 0,05 bis 2,5 Gew.-% L-Carnitin oder L- Carnitinderivate enthalten, wobei bevorzugte L-Carnitinderivate ausgewählt sind aus Acetyl-L- Carnitin, L-Carnitin-Fumarat, L-Carnitin-Citrat, Lauroyl- L-Carnitin und insbesondere L-Carnitin- Tartrat.  Preferred hair treatment compositions according to the invention are characterized in that they contain from -0.001 to 10% by weight, preferably 0.005 to 7.5% by weight, particularly preferably 0.01 to 5% by weight and in particular 0.05% by weight contain up to 2.5 wt .-% L-carnitine or L-carnitine derivatives, preferred L-carnitine derivatives are selected from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.
Ein weiterer, bevorzugter einsetzbarer Pflegestoff, der aktivierende Eigenschaften besitzt, ist das Taurin. Erfindungsgemäß bevorzugte Haarbehandlungsmittel enthalten - bezogen auf ihr Gewicht - 0,01 bis 15 Gew.-%, vorzugsweise 0,025 bis 12,5 Gew.-%, besonders bevorzugt 0,05 bis 10 Gew.-%, weiter bevorzugt 0, 1 bis 7,5 Gew.-% und insbesondere 0,5 bis 5 Gew.-% Taurin (2- Aminoethansulfonsäure).  Another, more preferably usable care substance which has activating properties is taurine. According to the invention preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).
Eine weitere bevorzugte Gruppe von Pflegestoffen in den erfindungsgemäßen Mitteln sind Vitamine, Provitamine oder Vitaminvorstufen. Diese werden nachfolgend beschrieben:  Another preferred group of care agents in the compositions according to the invention are vitamins, provitamins or vitamin precursors. These are described below:
Zur Gruppe der als Vitamin A bezeichneten Substanzen gehören das Retinol (Vitamin A-ι) sowie das 3,4-Didehydroretinol (Vitamin A2). Das ß-Carotin ist das Provitamin des Retinols. Als Vitamin A-Komponente kommen erfindungsgemäß beispielsweise Vitamin A-Säure und deren Ester, Vitamin A-Aldehyd und Vitamin A-Alkohol sowie dessen Ester wie das Palmitat und das Acetat in Betracht. Die erfindungsgemäßen Mittel enthalten die Vitamin A-Komponente bevorzugt in Mengen von 0,05-1 Gew.-%, bezogen auf die gesamte Zubereitung. Zur Vitamin B-Gruppe oder zu dem Vitamin B-Komplex gehören u. a. The group of substances referred to as vitamin A include retinol (vitamin A-1) and 3,4-didehydroretinol (vitamin A 2 ). The ß-carotene is the provitamin of retinol. As vitamin A component according to the invention, for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration. The agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation. The vitamin B group or the vitamin B complex include, among others
Vitamin B-ι (Thiamin)  Vitamin B-ι (thiamine)
Vitamin B2 (Riboflavin) Vitamin B 2 (riboflavin)
Vitamin B3. Erfindungsgemäß bevorzugt ist das Nicotinsäureamid, das in den erfindungsgemäß verwendeten Mitteln bevorzugt in Mengen von 0,05 bis 1 Gew.-%, bezogen auf das gesamte Mittel, enthalten ist. Vitamin B 3 . Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
Vitamin B5 (Pantothensäure, Panthenol und Pantolacton). Im Rahmen dieser Gruppe wird bevorzugt das Panthenol und/oder Pantolacton eingesetzt (siehe weiter unten). Die genannten Verbindungen des Vitamin B5-Typs sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05 - 10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,1 - 5 Gew.-% sind besonders bevorzugt. Vitamin B 5 (pantothenic acid, panthenol and pantolactone). Panthenol and / or pantolactone are preferably used in the context of this group (see below). The said compounds of the vitamin B 5 type are preferably contained in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
Vitamin B6 (Pyridoxin sowie Pyridoxamin und Pyridoxal). Vitamin B 6 (pyridoxine and pyridoxamine and pyridoxal).
Vitamin C (Ascorbinsäure). Vitamin C wird in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0, 1 bis 3 Gew.-%, bezogen auf das gesamte Mittel eingesetzt. Die Verwendung in Form des Palmitinsäureesters, der Glucoside oder Phosphate kann bevorzugt sein. Die Verwendung in Kombination mit Tocopherolen kann ebenfalls bevorzugt sein. Vitamin C (ascorbic acid). Vitamin C is used in the inventive compositions preferably in amounts of 0, 1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.
Vitamin E (Tocopherole, insbesondere α-Tocopherol). Tocopherol und seine Derivate, worunter insbesondere die Ester wie das Acetat, das Nicotinat, das Phosphat und das Succinat fallen, sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05-1 Gew.-%, bezogen auf das gesamte Mittel, enthalten.  Vitamin E (tocopherols, especially α-tocopherol). Tocopherol and its derivatives, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.
Vitamin F. Unter dem Begriff "Vitamin F" werden üblicherweise essentielle Fettsäuren, insbesondere Linolsäure, Linolensäure und Arachidonsäure, verstanden.  Vitamin F. The term "vitamin F" is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
Vitamin H. Als Vitamin H wird die Verbindung (3aS,4S, 6aR)-2-Oxohexahydrothienol[3,4-cf]- imidazol-4-valeriansäure bezeichnet, für die sich aber inzwischen der Trivialname Biotin durchgesetzt hat. Biotin ist in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,0001 bis 1 ,0 Gew.-%, insbesondere in Mengen von 0,001 bis 0,01 Gew.-% enthalten.  Vitamin H. Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-cf] - imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed. Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
Zusammenfassend sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die - bezogen auf ihr Gewicht - 0,1 bis 5 Gew.-%, vorzugsweise 0,2 bis 4 Gew.-%, besonders bevorzugt 0,25 bis 3,5 Gew.-%, weiter bevorzugt 0,5 bis 3 Gew.-% und insbesondere 0,5 bis 2,5 Gew.-% Vitamine und/oder Pro-Vitamine und/oder Vitaminvorstufen enthalten, die vorzugsweise den Gruppen A, B, C, E, F und H zugeordnet werden, wobei bevorzugte Mittel -2,4-Dihydroxy-A/-(3-hydroxypropyl)- 3,3-dimethyl-butyramid, Provitamin B5) und/oder Pantothensäure (Vitamin B3, Vitamin B5) und/oder Niacin, Niacinamid bzw. Nicotinamid (Vitamin B3) und/oder L-Ascorb insäure (Vitamin C) und/oder Thiamin (Vitamin B-ι) und/oder Riboflavin (Vitamin B2, Vitamin G) und/oder Biotin (Vitamin B7, Vitamin H) und/oder Folsäure (Vitamin B9, Vitamin Bc oder Vitamin M) und/oder Vitamin B6 und/oder Vitamin B12 enthalten. Es hat sich gezeigt, daß bestimmte Chinone eine besondere Eignung als Pflegestoff besitzen. Als weiteren Pflegestoff können die erfindungsgemäßen Mittel daher 0,0001 bis 5 Gew.-% mindestens eines Biochinons der Formel (Ubi) In summary, hair-treatment compositions according to the invention are preferred which, based on their weight, are 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.25 to 3.5% by weight, more preferably Contain 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors, preferably the groups A, B, C, E, F and H. 2,4,4-dihydroxy-A / - (3-hydroxypropyl) -3,3-dimethylbutyramide, provitamin B 5 ) and / or pantothenic acid (vitamin B 3 , vitamin B 5 ) and / or Niacin, niacinamide or nicotinamide (vitamin B 3 ) and / or L-ascorbic acid (vitamin C) and / or thiamine (vitamin B) and / or riboflavin (vitamin B 2 , vitamin G) and / or biotin (vitamin B 7 , vitamin H) and / or folic acid (vitamin B 9 , vitamin B c or vitamin M) and / or vitamin B 6 and / or vitamin B 12 . It has been shown that certain quinones have a special suitability as a care substance. As a further care substance, the compositions according to the invention can therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)
Figure imgf000018_0001
Figure imgf000018_0001
enthalten in der contained in the
X, Y, Z stehen unabhängig voneinander für -O- oder -NH- oder NR4- oder eine chemische Bindung X, Y, Z are independently -O- or -NH- or NR 4 - or a chemical bond
R , R2, R3 stehen unabhängig voneinander für ein Wasserstoffatom oder eine gegebenenfalls substituierte Arylgruppe oder eine gegebenenfalls substituierte (Ci-Ce)-Alkylgruppe oder eine Hydroxyalkylgruppe oder eine Polyhydroxyalkylgruppe oder eine gegebenenfalls substituierte (d-Ce)- Alkylengruppe, oder einen (Ci-Ce)-Acylrest, wobei bevorzugte Reste unabhängig voneinander ausgewählt sind aus -H, CH3, -CH2CH3, -(CH2)2CH2, -CH(CH3)2, -(CH2)3CH3, -CH(CH3)CH2CH3, - CH2CH(CH3)2, -C(CH3)3 R, R 2 , R 3 independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C 1 -C 6) -alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (d-Ce) -alkylene group, or a ( C 1 -C 6) -acyl radical, preferred radicals being selected independently of one another from -H, CH 3, -CH 2 CH 3, - (CH 2) 2 CH 2, -CH (CH 3) 2, - (CH 2) 3 CH 3, -CH (CH 3) CH 2 CH 3, CH 2 CH (CH 3 ) 2 , -C (CH 3 ) 3
R4 steht für -CH3, -CH2CH3, -(CH2)2CH2, -CH(CH3)2, R 4 is -CH 3 , -CH 2 CH 3 , - (CH 2 ) 2 CH 2 , -CH (CH 3 ) 2 ,
(CH2)3CH3, -CH(CH3)CH2CH3, -CH2CH(CH3)2, -C(CH3)3 (CH 2 ) 3 CH 3 , -CH (CH 3 ) CH 2 CH 3 , -CH 2 CH (CH 3 ) 2 , -C (CH 3 ) 3
n steht für Werte von 1 bis 20, vorzugsweise von 2 bis 15 und insbesondere für 5, 6, 7, 8, 9, 10.  n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.
Besonders bevorzugte erfindungsgemäße Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie als Pflegestoff - bezogen auf ihr Gewicht - 0,0001 bis 1 Gew.-%, bevorzugt 0,001 bis 0,5 Gew.-% und besonders bevorzugt 0,005 bis 0, 1 Gew.-% mindestens eines Ubichinons und/oder mindestens eines Ubichinols und/oder mindestens eines Derivates dieser Substanzen enthalten, wobei bevorzugte Mittel ein Ubichinon der Formel (Ubi) enthalten  Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0, 1 wt .-% containing at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, preferred agents containing a ubiquinone of the formula (Ubi)
Figure imgf000018_0002
Figure imgf000018_0002
(Ubi),  (Ubi)
in der n für die Werte = 6, 7, 8, 9 oder 10, besonders bevorzugt für 10 (Coenzym Q10) steht. Alternativ zu den besonders bevorzugten Ubichinonen oder zusätzlich zu ihnen können die erfindungsgemäßen Mittel auch Plastochinone enthalten. Hier sind bevorzugte erfindungsgemäße Mittel dadurch gekennzeichnet, daß sie 0,0002 bis 4 Gew.-%, vorzugsweise 0,0005 bis 3 Gew.-%, besonders bevorzugt 0,001 bis 2 Gew.-%, weiter bevorzugt 0,0015 bis 1 und insbesondere 0,002 bis 0,5 Gew.-% mindestens eines Plastochinons der Formel (Ubi-b) enthalten in which n stands for the values = 6, 7, 8, 9 or 10, particularly preferably 10 (coenzyme Q10). As an alternative to the particularly preferred ubiquinones or in addition to them, the agents according to the invention may also contain plastoquinones. Here, preferred agents according to the invention are characterized in that they are 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-b)
Figure imgf000019_0001
Figure imgf000019_0001
in der n für Werte von 1 bis 20, vorzugsweise von 2 bis 15 und insbesondere für 5, 6, 7, 8, 9, 10 steht, wobei besonders bevorzugt Mittel Plastochinon PQ-9 der Formel in which n stands for values of 1 to 20, preferably of 2 to 15 and in particular for 5, 6, 7, 8, 9, 10, whereby particularly preferred means Plastochinon PQ-9 of the formula
Figure imgf000019_0002
Figure imgf000019_0002
enthalten. contain.
Als weiteren Pflege-Enhacer können die erfindungsgemäßen Mittel Ectoin enthalten. Erfindungsgemäß bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie - bezogen auf ihr Gewicht - 0,001 bis 10 Gew.-%, vorzugsweise 0,01 bis 5 Gew.-%, besonders bevorzugt 0,05 bis 2,5 Gew.-% und insbesondere 0,1 bis 1 Gew.-% (S)-2-Methyl-1 , 4,5,6- tetrahydro-4-pyrimidincarbonsäure (Ectoin) sowie die physiologisch verträglichen Salze dieser Verbindung und/oder (S,S)-5-Hydroxy-2-methyl-1 ,4,5,6-tetrahydro-4-pyrimidincarbonsäure (Hydro- xyectoin) sowie die physiologisch verträglichen Salze dieser Verbindung, enthalten.  As a further care enhancer, the agents according to the invention may contain ectoin. Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0 , 1 to 1% by weight of (S) -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (ectoine) and the physiologically tolerated salts of this compound and / or (S, S) -5- Hydroxy-2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (hydroxyectoine) and the physiologically acceptable salts of this compound.
Zur Verbesserung der Elastizität und Festigung der inneren Struktur der mit erfindungsgemäßen Mitteln behandelter Haare können die erfindungsgemäßen Mittel Purin und/oder Purinderivate als Pflegestoff enthalten. Insbesondere die Kombination von Purin und/oder Purinderivaten mit Ubichinonen und/oder Plastochinonen als Pflegestoff führt dazu, daß die mit entsprechenden Mitteln behandelten Haare unter anderem höhere Meßwerte bei der Differenzthermoanalyse und verbesserte Naß- und Trockenkämmbarkeiten zeigen. To improve the elasticity and strengthen the internal structure of the hair treated with the agents according to the invention, the compositions according to the invention may contain purine and / or purine derivatives as a care substance. In particular, the combination of purine and / or purine derivatives with ubiquinones and / or plastoquinones as a care substance means that the hairs treated with appropriate agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.
Purin (7H-lmidazo[4,5-d]pyrimidin) kommt frei in der Natur nicht vor, bildet jedoch den Grundkörper der Purine. Purine ihrerseits sind eine Gruppe wichtiger, in der Natur weit verbreiteter und an menschlichen, tierischen, pflanzlichen und mikrobiellen Stoffwechselvorgängen beteiligter Verbindungen, die sich vom Grundkörper durch Substitution mit OH, NH2, SH in 2-, 6- und 8- Stellung und/oder mit CH3 in 1-, 3-, 7-Stellung ableiten. Purin kann beispielsweise aus Aminoacetonitril und Formamid hergestellt werden. Purine und Purinderivate werden oft aus Naturstoffen isoliert, sind aber auch auf vielen Wegen synthetisch zugänglich. Purine (7H-imidazo [4,5-d] pyrimidine) does not occur freely in nature, but forms the main body of the purines. Purines, in turn, are a group of important compounds of widespread nature involved in human, animal, plant and microbial metabolic processes, which differ from the parent by substitution with OH, NH 2 , SH in the 2-, 6-, and 8-positions and / or with CH 3 in 1-, 3-, 7-position derived. For example, purine can be made out Aminoacetonitrile and formamide are produced. Purines and purine derivatives are often isolated from natural products, but are also synthetically accessible in many ways.
Bevorzugte erfindungsgemäße Mittel enthalten Purin und/oder Purinderivate in engeren Mengenbereichen. Hier sind erfindungsgemäß bevorzugte kosmetische Mittel dadurch gekennzeichnet, daß sie - bezogen auf ihr Gewicht - 0,001 bis 2,5 Gew.-%, vorzugsweise 0,0025 bis 1 Gew.-%, besonders bevorzugt 0,005 bis 0,5 Gew.-% und insbesondere 0,01 bis 0, 1 Gew.-% Purin(e) und/oder Purinderivat(e) enthalten. Preferred agents according to the invention contain purine and / or purine derivatives in narrower quantitative ranges. Here are inventively preferred cosmetic agents characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% purine (s) and / or purine derivative (s).
Unter Purin, den Purinen und den Purinderivaten sind erfindungsgemäß einige Vertreter besonders bevorzugt. Erfindungsgemäß bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie als Pflegestoff - bezogen auf ihr Gewicht - 0,001 bis 2,5 Gew.-%, vorzugsweise 0,0025 bis 1 Gew.-%, besonders bevorzugt 0,005 bis 0,5 Gew.-% und insbesondere 0,01 bis 0,1 Gew.-% Purin(e) und/oder Purinderivat(e) enthält, wobei bevorzugte Mittel Purin und/oder Purinderivat(e) der Formel (Pur-I) enthalten  Among purine, the purines and the purine derivatives, some representatives are particularly preferred according to the invention. Hair treatment compositions which are preferred according to the invention are characterized in that they contain as care substance - based on their weight - from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s), preferred agents containing purine and / or purine derivative (s) of formula (Pur-I)
Figure imgf000020_0001
Figure imgf000020_0001
in der die Reste R , R2 und R3 unabhängig voneinander ausgewählt sind aus -H, - OH, NH2, -SH und die Reste R4, R5 und R6 unabhängig voneinander ausgewählt sind aus -H, -CH3 und -CH2- CH3, wobei folgende Verbindungen bevorzugt sind: in which the radicals R, R 2 and R 3 are independently selected from -H, - OH, NH 2 , -SH and the radicals R 4 , R 5 and R 6 are independently selected from -H, -CH 3 and -CH 2 - CH 3 , the following compounds being preferred:
- Purin (R = R2 = R3 = R4 = R5 = R6 = H) Purine (R = R 2 = R 3 = R 4 = R 5 = R 6 = H)
- Adenin (R = NH2, R2 = R3 = R4 = R5 = R6 = H) Adenine (R = NH 2 , R 2 = R 3 = R 4 = R 5 = R 6 = H)
- Guanin (R = OH, R2 = NH2, R3 = R4 = R5 = R6 = H) Guanine (R = OH, R 2 = NH 2 , R 3 = R 4 = R 5 = R 6 = H)
- Harnsäure (R = R2 = R3 = OH, R4 = R5 = R6 = H) Uric acid (R = R 2 = R 3 = OH, R 4 = R 5 = R 6 = H)
- Hypoxanthin (R = OH, R2 = R3 = R4 = R5 = R6 = H) Hypoxanthine (R = OH, R 2 = R 3 = R 4 = R 5 = R 6 = H)
- 6-Purinthiol (R = SH, R2 = R3 = R4 = R5 = R6 = H) 6-purethiol (R = SH, R 2 = R 3 = R 4 = R 5 = R 6 = H)
- 6-Thioguanin (R = SH, R2 = NH2, R3 = R4 = R5 = R6 = H) 6-thioguanine (R = SH, R 2 = NH 2 , R 3 = R 4 = R 5 = R 6 = H)
- Xanthin (R = R2 = OH, R3 = R4 = R5 = R6 = H) Xanthine (R = R 2 = OH, R 3 = R 4 = R 5 = R 6 = H)
- Coffein (R = R2 = OH, R3 = H, R4 = R5 = R6 = CH3) Caffeine (R = R 2 = OH, R 3 = H, R 4 = R 5 = R 6 = CH 3 )
- Theobromin (R = R2 = OH, R3 = R4 = H, R5 = R6 = CH3) - Theobromine (R = R 2 = OH, R 3 = R 4 = H, R 5 = R 6 = CH 3 )
- Theophyllin (R = R2 = OH, R3 = H, R4 = CH3, R5 = CH3, R6 = H). Theophylline (R = R 2 = OH, R 3 = H, R 4 = CH 3 , R 5 = CH 3 , R 6 = H).
Es ist weiterhin vorteilhaft, Purin bzw. Purinderivate und Biochinone in einem bestimmten Verhältnis zueinander einzusetzen. Hier sind erfindungsgemäße Mittel bevorzugt, bei denen das Gewichtsverhältnis von Purin(derivat(en)) und Biochinon(en) 10: 1 bis 1 : 100, vorzugsweise 5: 1 bis 1 :50, besonders bevorzugt 2:1 bis 1 :20 und insbesondere 1 : 1 bis 1 : 10 beträgt. Wie bereits erwähnt, ist Coffein ein besonders bevorzugtes Purinderivat, und das Coenzym Q10 ist ein besonders bevorzugtes Biochinon. Besonders bevorzugte erfindungsgemäße Mittel sind daher dadurch gekennzeichnet, daß sie - bezogen auf ihr Gewicht - 0,001 bis 2,5 Gew.-%, vorzugsweise 0,0025 bis 1 Gew.-%, besonders bevorzugt 0,005 bis 0,5 Gew.-% und insbesondere 0,01 bis 0,1 Gew.-% Coffein und 0,0002 bis 4 Gew.-%, vorzugsweise 0,0005 bis 3 Gew.-%, besonders bevorzugt 0,001 bis 2 Gew.-%, weiter bevorzugt 0,0015 bis 1 und insbesondere 0,002 bis 0,5 Gew.-% Coenzym Q10 enthalten. It is also advantageous to use purine or purine derivatives and biochinones in a certain ratio to each other. Here, agents according to the invention are preferred in which the weight ratio of purine (derivative (s)) and biochinone (s) is 10: 1 to 1: 100, preferably 5: 1 to 1:50, particularly preferably 2: 1 to 1:20 and in particular 1: 1 to 1:10. As already mentioned, caffeine is a particularly preferred purine derivative, and coenzyme Q10 is a particularly preferred biochinone. Particularly preferred agents according to the invention are therefore characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular 0.01 to 0.1 wt .-% caffeine and 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% coenzyme Q10 included.
Als Pflegestoff können die erfindungsgemäßen Mittel auch Flavonoide enthalten. Die Flavonoide sind eine Gruppe von wasserlöslichen Pflanzenfarbstoffen und spielen eine wichtige Rolle im Stoffwechsel vieler Pflanzen. Sie gehören zusammen mit den Phenolsäuren zu den Polyphenolen. Es sind weit über 6500 unterschiedliche Flavonoide bekannt, die sich in Flavonole, Flavone, Flavanone, Isoflavonoide und Anthocyane einteilen lassen.  As a conditioner, the compositions of the invention may also contain flavonoids. The flavonoids are a group of water-soluble plant dyes and play an important role in the metabolism of many plants. They belong together with the phenolic acids to the polyphenols. There are well over 6500 different flavonoids known, which can be divided into flavonols, flavones, flavanones, isoflavonoids and anthocyanins.
Erfindungsgemäß können Flavonoide aus allen sechs Gruppen eingesetzt werden, wobei bestimmte Vertreter aus den einzelnen Gruppen als Pflegestoff wegen ihrer besonders intensiven Wirkung bevorzugt sind. Bevorzugte Flavonole sind Quercetin, Rutin, Kaempferol, Myricetin, Isorhamnetin, bevorzugte Flavanole sind Catechin, Gallocatechin, Epicatechin, Epigallocatechingallat , Theaflavin, Thearubigin, bevorzugte Flavone sind Luteolin, Apigenin, Morin, bevorzugte Flavanone sind Hesperetin, Naringenin, Eriodictyol, bevorzugte Isoflavonoide sind Genistein, Daidzein, und bevorzugte Anthocyanidine (Anthocyane) sind Cyanidin, Delphinidin, Malvidin, Pelargonidin, Peonidin, Petunidin.  According to the invention flavonoids from all six groups can be used, with certain representatives from the individual groups are preferred as a care substance because of their particularly intense action. Preferred flavonols are quercetin, rutin, kaempferol, myricetin, isorhamnetin, preferred flavanols are catechin, gallocatechin, epicatechin, epigallocatechin gallate, theaflavin, thearubigin, preferred flavones are luteolin, apigenin, morin, preferred flavanones are hesperetin, naringenin, eriodictyol, preferred isoflavonoids are genistein , Daidzein, and preferred anthocyanidins (anthocyanins) are cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin.
Erfindungsgemäß besonders bevorzugte Haarbehandlungsmittel sind dadurch gekennzeichnet, daß sie - bezogen auf ihr Gewicht - 0,001 bis 2,5 Gew.-%, vorzugsweise 0,0025 bis 1 Gew.-%, besonders bevorzugt 0,005 bis 0,5 Gew.-% und insbesondere 0,01 bis 0, 1 Gew.-% Flavonoide, insbesondere Flavonole, besonders bevorzugt 3,3',4',5,7-Pentahydroxyflavon (Quercetin) und/oder 3,3',4',5,7-Pentahydroxyflavon-3-0-rutinosid (Rutin), enthalten.  According to the invention particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% flavonoids, especially flavonols, more preferably 3,3 ', 4', 5,7-Pentahydroxyflavon (quercetin) and / or 3,3 ', 4', 5,7-Pentahydroxyflavon -3-0-rutinoside (rutin), included.
Bevorzugt ist auch der Einsatz von Bisabolol und/oder Bisabololoxiden als Pflegestoff in den erfindungsgemäßen Mitteln. Hier sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die zusätzlich 0,001 bis 5 Gew.-%, vorzugsweise 0,01 bis 4 Gew.-%, besonders bevorzugt 0,02 bis 2,5 Gew.-% und insbesondere 0,1 bis 1 ,5 Gew.-% Bisabolol und/oder Oxide von Bisabolol, vorzugsweise (-)-alpha-Bisabolol enthalten.  Preference is also the use of bisabolol and / or bisabololoxides as a care substance in the inventive compositions. Here, hair treatment compositions according to the invention are preferred which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1, 5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol.
Auch Creatin eignet sich erfindungsgemäß als Pflegestoff. Creatin (3-Methylguanidinoessigsäure) ist eine organische Säure, die in Wirbeltieren u. a. zur Versorgung der Muskeln mit Energie beiträgt. Kreatin wird in der Niere, der Leber und in der Bauchspeicheldrüse synthetisiert. Sie leitet sich formal von den Aminosäuren Glycin und Arginin ab und ist zu 95 % im Skelettmuskel vorhanden. Besonders bevorzugte erfindungsgemäße Haarbehandlungsmittel enthalten - bezogen auf ihr Gewicht - 0,01 bis 15 Gew.-%, vorzugsweise 0,025 bis 12,5 Gew.-%, besonders bevorzugt 0,05 bis 10 Gew.-%, weiter bevorzugt 0, 1 bis 7,5 Gew.-% und insbesondere 0,5 bis 5 Gew.-% /V-Methyl- guanidino-essigsäure (Creatin). Die erfindungsgemäßen Mittel können zusätzlich zu den vorstehend genannten Inhaltsstoffen und optionalen weiteren Inhaltsstoffen weitere Stoffe enthalten, die Haarausfall verhindern, lindern oder heilen. Insbesondere ist ein Gehalt an haarwurzelstabilisierenden Wirkstoffen vorteilhaft. Diese Stoffe werden nachstehend beschrieben: Creatine is also suitable as a care substance according to the invention. Creatine (3-methylguanidinoacetic acid) is an organic acid that helps to supply muscles with energy in vertebrates. Creatine is synthesized in the kidney, liver and pancreas. It is formally derived from the amino acids glycine and arginine and is 95% present in skeletal muscle. Particularly preferred hair treatment compositions according to the invention contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 bis 7.5 wt .-% and in particular 0.5 to 5 wt .-% / V-methyl guanidino-acetic acid (creatine). The compositions according to the invention may contain, in addition to the ingredients mentioned above and optional further ingredients, other substances which prevent, alleviate or cure hair loss. In particular, a content of hair root stabilizing agents is advantageous. These substances are described below:
Propecia (Finasterid) ist das zur Zeit einzige Präparat, das weltweit zugelassen ist und für das in zahlreichen Studien eine Wirksamkeit und Verträglichkeit nachgewiesen wurde. Propecia bewirkt, daß sich weniger DHT aus Testosteron bilden kann. Propecia (Finasteride) is currently the only preparation that is approved worldwide and has been proven in many studies to be effective and tolerable. Propecia causes less DHT to form from testosterone.
Minoxidil ist mit oder ohne ergänzende Zusatzstoffe das wohl älteste nachweislich wirkende Haarwuchsmittel. Zur Behandlung von Haarausfall darf es nur zur äußeren Anwendung verwendet werden. Es gibt Haarwasser, die 2%-5% Minoxidil enthalten, außerdem Gels mit bis zu 15% Minoxidil. Die Wirksamkeit nimmt mit der Dosierung zu, in Haarwassern ist Minoxidil jedoch nur bis zu 5% Anteil löslich. In vielen Ländern sind Haarwasser mit bis zu 2% Minoxidilgehalt verschreibungsfrei erhältlich. Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. For the treatment of hair loss, it may only be used for external application. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil. The effectiveness increases with the dosage, in hair waters Minoxidil is only up to 5% share soluble. In many countries, hair tonic with up to 2% minoxidil content is available without prescription.
Zur Bekämpfung der hormonellen Einflüße auf die Haarfollikel kann zur äußeren Anwendung Spironolactone in Form von Haarwasser und in Kombination mit Minoxidil angewandt werden. Spironolactone wirkt als Androgen-Rezeptor-Blocker, dh. die Bindung von DHT an die Haarfollikel wird verhindert. To combat the hormonal influences on the hair follicles spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application. Spironolactone acts as an androgen receptor blocker, ie. the binding of DHT to the hair follicles is prevented.
Zusammenfassend sind erfindungsgemäße Haarbehandlungsmittel bevorzugt, die zusätzlich - bezogen auf sein Gewicht - 0,001 bis 5 Gew.-% Haarwurzel-stabilisierende Stoffe, insbesondere Minoxidil und/oder Finasterid und/oder Ketoconazol enthalten. In summary, hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.
Zusätzlich zu den Pflegestoffen können di erfindungsgemäßen Mittel weitere Pflegestoffe enthalten. Deren Anwesenheit ist für die Erzielung der erfindungsgemäßen Effekte nicht zwingend erforderlich, doch können weitergehende Effekte, wie ein angenehmer Griff oder eine angenehme Applikationshaptik aus dem Einsatz dieser Pflegestoffe resultieren.  In addition to the care agents, the agents according to the invention may contain further care substances. Their presence is not absolutely necessary for achieving the effects according to the invention, but further effects, such as a pleasant touch or a pleasant application feel, can result from the use of these care substances.
Als weiteren Inhaltsstoff können die erfindungsgemäßen Mittel mit besonderem Vorzug eine oder mehrere Aminosäuren enthalten. Erfindungsgemäß besonders bevorzugt einsetzbare Aminosäuren stammen aus der Gruppe Glycin, Alanin, Valin, Leucin, Isoleucin, Phenylalanin, Tyrosin, Tryptophan, Prolin, Asparaginsäure, Glutaminsäure, Asparagin, Glutamin, Serin, Threonin, Cystein, Methionin, Lysin, Arginin, Histidin, ß-Alanin, 4-Aminobuttersäure (GABA), Betain, L-Cystin (L-Cyss), L-Carnitin, L-Citrullin, L-Theanin, 3 ',4 '-Dihydroxy-L-phenylalanin (L-Dopa), 5 '-Hydroxy- L-tryptophan, L-Homocystein, S-Methyl-L-methionin, S-Allyl-L-cystein-sulfoxid (L-Alliin), L-trans-4- Hydroxyprolin, L-5-Oxoprolin (L-Pyroglutaminsäure), L-Phosphoserin, Kreatin, 3-Methyl-L-histidin, L-Ornithin, wobei sowohl die einzelnen Aminosäuren als auch Mischungen eingesetzt werden können.  As a further ingredient, the agents according to the invention may with particular preference contain one or more amino acids. Particularly preferred amino acids which can be used according to the invention are from the group of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-sulfoxide (L-alliin), L-trans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.
Bevorzugte erfindungsgemäße Mittel enthalten eine oder mehrere Aminosäuren in engeren Mengenbereichen. Hier sind erfindungsgemäß bevorzugte Haarbehandlungsmittel dadurch gekennzeichnet, daß sie als Pflegestoff - bezogen auf ihr Gewicht - 0,01 bis 5 Gew.-%, vorzugsweise 0,02 bis 2,5 Gew.-%, besonders bevorzugt 0,05 bis 1 ,5 Gew.-%, weiter bevorzugt 0,075 bis 1 Gew.-% und insbesondere 0,1 bis 0,25 Gew.-% Aminosäure(n), vorzugsweise aus der Gruppe Glycin und/oder Alanain und/oder Valin und/oder Lysin und/oder Leucin und/oder Threonin enthalten. Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here are preferred according to the invention hair treatment agent characterized in that it as a care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1, 5 wt .-%, further preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or Threonine included.
Als weiteren Bestandteil können die erfindungsgemäßen Mittel mindestens ein Kohlenhydrat aus der Gruppe der Monosaccharide, Disaccharide und/oder Oligosaccharide enthalten. Hier sind erfindungsgemäß bevorzugte Haarbehandlungsmittel dadurch gekennzeichnet, daß sie als Pflegestoff - bezogen auf ihr Gewicht - 0,01 bis 5 Gew.-%, vorzugsweise 0,05 bis 4,5 Gew.-%, besonders bevorzugt 0,1 bis 4 Gew.-%, weiter bevorzugt 0,5 bis 3,5 Gew.-% und insbesondere 0,75 bis 2,5 Gew.-% Kohlenhydrat(e), ausgewählt aus Monosacchariden, Disacchariden und/oder Oligosacchariden enthalten, wobei bevorzugte Kohlenhydrate ausgewählt sind aus  As a further component, the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides. Here are preferred hair treatment compositions according to the invention characterized in that they are used as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt. -%, more preferably 0.5 to 3.5 wt .-% and in particular 0.75 to 2.5 wt .-% carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides containing preferred carbohydrates are selected out
Monosachhariden, insbesondere D-Ribose und/oder D-Xylose und/oder L-Arabinose und/oder D-Glucose und/oder D-Mannose und/oder D-Galactose und/oder D-Fructose und/oder Sorbose und/oder L-Fucose und/oder L-Rhamnose  Monosaccharides, in particular D-ribose and / or D-xylose and / or L-arabinose and / or D-glucose and / or D-mannose and / or D-galactose and / or D-fructose and / or sorbose and / or L. Fucose and / or L-rhamnose
Disacchariden, insbesondere Saccharose und/oder Maltose und/oder Lactose und/oder Trehalose und/oder Cellobiose und/oder Gentiobiose und/oder Isomaltose.  Disaccharides, in particular sucrose and / or maltose and / or lactose and / or trehalose and / or cellobiose and / or gentiobiose and / or isomaltose.
Besonders bevorzugte erfindungsgemäße Mittel enthalten bezogen auf ihr Gewicht Particularly preferred agents according to the invention contain based on their weight
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Glucosemonohydrat, 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate,
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Saccharose,0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose,
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Fructose. 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose.
Wie bereits erwähnt, enthalten bevorzugte erfindungsgemäße Mittel (eine) Aminosäure(n).  As already mentioned, preferred agents according to the invention contain (a) amino acid (s).
Erfindungsgemäß besonders bevorzugt einsetzbare Aminosäuren stammen aus der Gruppe Glycin, Alanin, Valin, Leucin, Isoleucin, Phenylalanin, Tyrosin, Tryptophan, Prolin, Asparaginsäure, Glutaminsäure, Asparagin, Glutamin, Serin, Threonin, Cystein, Methionin, Lysin, Arginin, Histidin, ß-Alanin, 4-Aminobuttersäure (GABA), Betain, L-Cystin (L-Cyss), L-Carnitin, L-Citrullin, L-Theanin, 3 ',4 '-Dihydroxy-L-phenylalanin (L-Dopa), 5 '-Hydroxy-L-tryptophan, L-Homocystein, S-Methyl-L- methionin, S-Allyl-L-cystein-sulfoxid (L-Alliin), L-frans-4-Hydroxyprolin, L-5-Oxoprolin (L- Pyroglutaminsäure), L-Phosphoserin, Kreatin, 3-Methyl-L-histidin, L-Ornithin, wobei sowohl die einzelnen Aminosäuren als auch Mischungen eingesetzt werden können. Particularly preferred amino acids which can be used according to the invention are from the group glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-sulfoxide (L-alliin), L-frans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.
Bevorzugte erfindungsgemäße Mittel enthalten eine oder mehrere Aminosäuren in engeren Mengenbereichen. Hier sind erfindungsgemäß bevorzugte kosmetische Mittel dadurch gekennzeichnet, daß sie zusätzlich - 0,05 bis 5 Gew.-%, vorzugsweise 0,1 bis 2,5 Gew.-%, besonders bevorzugt 0, 15 bis 1 Gew.-% und insbesondere 0,2 bis 0,5 Gew.-% Aminosäure(n), vorzugsweise (eine) Aminosäure(n) aus der Gruppe Glycin und/oder Alanain und/oder Valin und/oder Lysin und/oder Leucin und/oder Threonin enthalten.  Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here, preferred cosmetic compositions according to the invention are characterized in that they additionally contain from 0.05 to 5% by weight, preferably from 0.1 to 2.5% by weight, more preferably from 0 to 15% by weight and in particular from 0 to 15% by weight , 2 to 0.5 wt .-% amino acid (s), preferably (one) amino acid (s) from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.
Besonders bevorzugte erfindungsgemäße Mittel enthalten bezogen auf ihr Gewicht Particularly preferred agents according to the invention contain based on their weight
0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Glucosemonohydrat und 0.005 to 0.015 wt .-% caffeine and 0.75 to 1, 5 wt .-% glucose monohydrate and
0,1 bis 0,25 Gew.-% Glycin, - 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Saccharose und 0,1 bis 0,25 Gew.-% Glycin, 0.1 to 0.25% by weight of glycine, 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of glycine,
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Fructose und 0,1 bis 0,25 Gew.-% Glycin,  0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of glycine,
0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Glucosemonohydrat und 0,1 bis 0,25 Gew.-% Alanin,  0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of alanine,
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Saccharose und 0,1 bis 0,25 Gew.-% Alanin,  0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of alanine,
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Fructose und 0,1 bis 0,25 Gew.-% Alanin,  0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of alanine,
0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Glucosemonohydrat und 0,1 bis 0,25 Gew.-% Valin,  0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of valine,
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Saccharose und 0,1 bis 0,25 Gew.-% Valin,  0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of valine,
- 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1 ,5 Gew.-% Fructose und 0,1 bis 0,25 Gew.-% Valin.  0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of valine.
Eine besonders bevorzugte Gruppe von Inhaltsstoffen stellen die Silikone dar.  A particularly preferred group of ingredients are the silicones.
Erfindungsgemäße bevorzugte Mittel sind dadurch gekennzeichnet, daß sie mindestens ein Silicon enthalten.  Preferred agents according to the invention are characterized in that they contain at least one silicone.
Erfindungsgemäß besonders bevorzugte Mittel enthalten das bzw. die Silikon(e) vorzugsweise in Mengen von 0,1 bis 10 Gew.-%, vorzugsweise von 0,25 bis 7 Gew.-% und insbesondere von 0,5 bis 5 Gew.-%, jeweils bezogen auf das gesamte Mittel.  Particularly preferred compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.
Bevorzugte Silikone werden nachstehend beschrieben. Preferred silicones are described below.
Besonders bevorzugte erfindungsgemäße Mittel sind dadurch gekennzeichnet, daß sie mindestens ein Silikon der Formel Si-I  Particularly preferred agents according to the invention are characterized in that they contain at least one silicone of the formula Si-I
(CH3)3Si-[0-Si(CH3)2]x-0-Si(CH3)3 (Si-I), (CH 3 ) 3 Si - [0-Si (CH 3 ) 2] x -O-Si (CH 3 ) 3 (Si-I),
enthalten, in der x für eine Zahl von 0 bis 100, vorzugsweise von 0 bis 50, weiter bevorzugt von 0 bis 20 und insbesondere 0 bis 10, steht. in which x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.
Diese Silikone werden nach der INCI-Nomenklatur als DIMETHICONE bezeichnet. Es werden im Rahmen der vorliegenden Erfindung als Silicon der Formel Si-I vorzugsweise die Verbindungen: (CH3)3Si-0-Si(CH3)3, (CH3)3Si-0-(CH3)2Si-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]2-0-Si(CH3)3, (CH3)3Si- [0-(CH3)2Si]3-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]4-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]5-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]6-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]7-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]8-0- Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]9-0-Si(CH3)3, (CH3)3Si-[O-(CH3)2Si]10-O-Si(CH3)3, (CH3)3Si-[0- (CH3)2Si]i i-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]12-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]13-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]14-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]15-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]16-0- Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]17-0-Si(CH3)3, (CH3)3Si-[0-(CH3)2Si]18-0-Si(CH3)3, (CH3)3Si-[0- (CH3)2Si]19-0-Si(CH3)3, (CH3)3Si-[O-(CH3)2Si]20-O-Si(CH3)3 eingesetzt, wobei (CH3)3Si-0-Si(CH3)3, (CH3)3Si-0-(CH3)2Si-0-Si(CH3)3 und/oder (CH3)3Si-[0-(CH3)2Si]2-0-Si(CH3)3 besonders bevorzugt sind. These silicones are called DIMETHICONE according to the INCI nomenclature. In the context of the present invention, the following compounds are preferably those compounds of the formula Si-I: (CH 3 ) 3 Si-O-Si (CH 3 ) 3, (CH 3 ) 3 Si-O- (CH 3 ) 2 Si 0-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 2 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 3 -0-Si (CH 3 ) 3 , (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 4 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 5 -O-Si (CH 3 ) 3 , (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 6 -O-Si (CH 3 ) 3, ( CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 7 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 8 -O-Si ( CH 3 ) 3, (CH 3 ) 3 Si [O- (CH 3 ) 2 Si] 9 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [O- (CH 3 ) 2 Si] 10 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] i i-0-Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 12 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 13 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 14 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 15 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 16 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 17 -O -Si (CH 3 ) 3, (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 18 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si - [0- (CH 3 ) 2 Si] 19 -O-Si (CH 3 ) 3, (CH 3 ) 3 Si [O- (CH 3 ) 2 Si] 20 -O-Si (CH 3 ) 3 , where (CH 3 ) 3 Si-O-Si (CH 3 ) 3 , (CH 3 ) 3 Si-O- (CH 3 ) 2 Si-O-Si (CH 3 ) 3 and / or (CH 3 ) 3 Si [0- (CH 3 ) 2 Si] 2 -O-Si (CH 3 ) 3 are particularly preferred.
Selbstverständlich können auch Mischungen der o.g. Silikone in den erfindungsgemäßen Mitteln enthalten sein.  Of course, mixtures of o.g. Silicones may be included in the compositions of the invention.
Bevorzugte erfindungsgemäß einsetzbare Silikone weisen bei 20°C Viskositäten von 0,2 bis 2 mm2s"1 auf, wobei Silikone mit Viskositäten von 0,5 bis 1 mm2s"1 besonders bevorzugt sind. Preferred silicones which can be used according to the invention have viscosities of 0.2 to 2 mm 2 s -1 at 20 ° C., silicones having viscosities of 0.5 to 1 mm 2 s -1 being particularly preferred.
Besonders bevorzugte erfindungsgemäße Mittel enthalten ein oder mehrere aminofunktionelle Silicone. Solche Silicone können z.B. durch die Formel Particularly preferred agents according to the invention contain one or more amino-functional silicones. Such silicones may e.g. through the formula
M(RaQbSiO(4 -a-b)/2)x(RcSiO(4-c)/2)yM M (R a Q b SiO ( 4- a - b ) / 2 ) x (R c SiO (4- c ) / 2 ) y M
beschrieben werden, wobei in der obigen Formel R ein Kohlenwasserstoff oder ein Kohlenwasserstoffrest mit 1 bis etwa 6 Kohlenstoffatomen ist, Q ein polarer Rest der allgemeinen Formel -R HZ ist, worin R eine zweiwertige, verbindende Gruppe ist, die an Wasserstoff und den Rest Z gebunden ist, zusammengesetzt aus Kohlenstoff- und Wasserstoffatomen, Kohlenstoff-, Wasserstoff- und Sauerstoffatomen oder Kohlenstoff-, Wasserstoff- und Stickstoffatomen, und Z ein organischer, aminofunktioneller Rest ist, der mindestens eine aminofunktionelle Gruppe enthält; "a" Werte im Bereich von etwa 0 bis etwa 2 annimmt, "b" Werte im Bereich von etwa 1 bis etwa 3 annimmt, "a" + "b" kleiner als oder gleich 3 ist, und "c" eine Zahl im Bereich von etwa 1 bis etwa 3 ist, und x eine Zahl im Bereich von 1 bis etwa 2.000, vorzugsweise von etwa 3 bis etwa 50 und am bevorzugtesten von etwa 3 bis etwa 25 ist, und y eine Zahl im Bereich von etwa 20 bis etwa 10.000, vorzugsweise von etwa 125 bis etwa 10.000 und am bevorzugtesten von etwa 150 bis etwa 1.000 ist, und M eine geeignete Silicon-Endgruppe ist, wie sie im Stande der Technik bekannt ist, vorzugsweise Trimethylsiloxy. Nicht einschränkende Beispiele der durch R repräsentierten Reste schließen Alkylreste, wie Methyl, Ethyl, Propyl, Isopropyl, Isopropyl, Butyl, Isobutyl, Amyl, Isoamyl, Hexyl, Isohexyl und ähnliche; Alkenylreste, wie Vinyl, Halogenvinyl, Alkylvinyl, Allyl, Halogenallyl, Alkylallyl; Cycloalkylreste, wie Cyclobutyl, Cyclopentyl, Cyclohexyl und ähnliche; Phenylreste, Benzylreste, Halogenkohlenwasserstoffreste, wie 3- Chlorpropyl, 4-Brombutyl, 3,3,3-Trifluorpropyl, Chlorcyclohexyl, Bromphenyl, Chlorphenyl und ähnliche sowie schwefelhaltige Reste, wie Mercaptoethyl, Mercaptopropyl, Mercaptohexyl, Mercaptophenyl und ähnliche ein; vorzugsweise ist R ein Alkylrest, der 1 bis etwa 6 Kohlenstoffatomen enthält, und am bevorzugtesten ist R Methyl. Beispiele von R schließen Methylen, Ethylen, Propylen, Hexamethylen, Decamethylen, - CH2CH(CH3)CH2-, Phenylen, Naphthylen, -CH2CH2SCH2CH 2-, -CH2CH2OCH2-, -OCH2CH2-, - OCH2 CH2CH2-, -CH2CH(CH3)C(0)OCH2-, -(CH2)3 CC(0)OCH2CH2-, -C6H 4C6H4-, -C6H 4CH2C6H4-; und -(CH 2)3C(0)SCH2CH2- ein. wherein R in the above formula is a hydrocarbon or a hydrocarbon radical having 1 to about 6 carbon atoms, Q is a polar radical of the general formula -R HZ, wherein R is a divalent linking group attached to hydrogen and the radical Z. Z is an organic, amino-functional radical containing at least one amino-functional group; "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 1 to about 3, "a" + "b" is less than or equal to 3, and "c" is a number in the range from about 1 to about 3, and x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25, and y is a number ranging from about 20 to about 10,000 , preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000, and M is a suitable silicone end group as known in the art, preferably trimethylsiloxy. Non-limiting examples of the groups represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals such as cyclobutyl, cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, 4-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur containing radicals such as mercaptoethyl, mercaptopropyl, mercaptohexyl, mercaptophenyl and the like; preferably R is an alkyl radical containing from 1 to about 6 carbon atoms, and most preferably R is methyl. Examples of R include methylene, ethylene, propylene, hexamethylene, decamethylene, - CH 2 CH (CH 3 ) CH 2 -, phenylene, naphthylene, -CH 2 CH 2 SCH 2 CH 2 -, -CH 2 CH 2 OCH 2 -, -OCH 2 CH 2 -, - OCH 2 CH 2 CH 2 -, -CH 2 CH (CH 3 ) C (O) 2 -, - (CH 2 ) 3 CC (O) 2 CH 2 -, -C 6 H 4 C 6 H 4 -, -C 6 H 4 CH 2 C 6 H 4 -; and - (CH 2 ) 3 C (O) SCH 2 CH 2 -.
Z ist ein organischer, aminofunktioneller Rest, enthaltend mindestens eine funktionelle Aminogruppe. Eine mögliche Formel für Z ist NH(CH2 )ZNH2, worin z 1 oder mehr ist. Eine andere mögliche Formel für Z ist -NH(CH2)Z(CH 2)ZZNH, worin sowohl z als auch zz unabhängig 1 oder mehr sind, wobei diese Struktur Diamino-Ringstrukturen umfaßt, wie Piperazinyl. Z ist am bevorzugtesten ein -NHCH2CH 2NH2-Rest. Eine andere mögliche Formel für Z ist - N(CH2)z(CH2)zzNX2 oder -NX2, worin jedes X von X2 unabhängig ausgewählt ist aus der Gruppe bestehend aus Wasserstoff und Alkylgruppen mit 1 bis 12 Kohlenstoffatomen, und zz 0 ist. Z is an organic, amino-functional radical containing at least one functional amino group. A possible formula for Z is NH (CH 2 ) Z NH 2 , wherein z is 1 or more. Another possible formula for Z is -NH (CH 2 ) Z (CH 2 ) ZZ NH, wherein both z and zz are independently 1 or more, which structure includes diamino ring structures, such as piperazinyl. Z is most preferably a -NHCH 2 CH 2 NH 2 radical. Another possible formula for Z is - N (CH 2 ) z (CH 2 ) zzNX 2 or -NX 2 , wherein each X of X 2 is independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0.
Q ist am bevorzugtesten ein polarer, aminfunktioneller Rest der Formel -CH2CH2CH2NHCH2CH2NH 2. In den Formeln nimmt "a" Werte im Bereich von etwa 0 bis etwa 2 an, "b" nimmt Werte im Bereich von etwa 2 bis etwa 3 an, "a" + "b" ist kleiner als oder gleich 3, und "c" ist eine Zahl im Bereich von etwa 1 bis etwa 3. Das molare Verhältnis der RaQb SiO(4.a-b)/2-Einheiten zu den RcSiO (4-c)/2-Einheiten liegt im Bereich von etwa 1 : 2 bis 1 : 65, vorzugsweise von etwa 1 : 5 bis etwa 1 : 65 und am bevorzugtesten von etwa 1 : 15 bis etwa 1 : 20. Werden ein oder mehrere Silicone der obigen Formel eingesetzt, dann können die verschiedenen variablen Substituenten in der obigen Formel bei den verschiedenen Siliconkomponenten, die in der Siliconmischung vorhanden sind, verschieden sein. Q is most preferably a polar, amine functional group of the formula -CH 2 CH 2 CH 2 NHCH 2 CH 2 NH 2 . In the formulas, "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 2 to about 3, "a" + "b" is less than or equal to 3, and "c "is a number in the range of about 1 to about 3. The molar ratio of the R a Q b SiO ( 4. a - b ) / 2 units to the R c SiO ( 4 -c) / 2 units is in the range from about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1:15 to about 1:20. When one or more silicones of the above formula are used, then the various variables can be used Substituents in the above formula may be different for the various silicone components present in the silicone blend.
Bevorzugte erfindungsgemäße Mittel sind dadurch gekennzeichnet, daß sie ein aminofunktionelles Silikon der Formel (Si-Il)  Preferred agents according to the invention are characterized in that they contain an amino-functional silicone of the formula (Si-II)
R'aG3-a-Si(OSiG 2)n-(OSiG bR'2- b)m-0-SiG3-a-R'a (Si-Il), R 'a G 3-a -Si (OSiG 2) n (OSiG b R'2- b) m -0-SiG3-a-R'a (Si-II),
enthalten, worin bedeutet:  contain, in which means:
- G ist-H, eine Phenylgruppe, -OH, -0-CH3, -CH3, -0-CH2CH3, -CH2CH3, -O-G is -H, a phenyl group, -OH, -O-CH 3 , -CH 3 , -O-CH 2 CH 3 , -CH 2 CH 3 , -O-
CH2CH2CH3,-CH2CH2CH3, -0-CH(CH3)2, -CH(CH3)2, -O-CH2CH2CH2CH3, CH2CH2CH2CH3, -0-CH2CH(CH3)2, -CH2CH(CH3)2, -0-CH(CH3)CH2CH3, - CH(CH3)CH2CH3, -0-C(CH3)3, -C(CH3)3 ; CH 2 CH 2 CH 3 , CH 2 CH 2 CH 3 , -O-CH (CH 3 ) 2 , -CH (CH 3 ) 2 , -O-CH 2 CH 2 CH 2 CH 3 , CH 2 CH 2 CH 2 CH 3 , -O-CH 2 CH (CH 3 ) 2 , -CH 2 CH (CH 3 ) 2 , -0-CH (CH 3) CH 2 CH 3, - CH (CH 3) CH 2 CH 3, -0-C (CH 3) 3, -C (CH 3) 3;
- a steht für eine Zahl zwischen 0 und 3, insbesondere 0;  a is a number between 0 and 3, in particular 0;
- b steht für eine Zahl zwischen 0 und 1 , insbesondere 1 ,  b is a number between 0 and 1, in particular 1,
- m und n sind Zahlen, deren Summe (m + n) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei n vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt,  m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n is preferably values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10,
- R' ist ein monovalenter Rest ausgewählt aus - R ' is a monovalent radical selected from
o -Q-N(R")-CH2-CH2-N(R")2 o -QN (R ") - CH 2 -CH 2 -N (R") 2
o -Q-N(R")2 o -QN (R ") 2
o -Q-N+(R")3A" o -QN + (R ") 3 A "
o -Q-N+H(R")2 A" o -QN + H (R ") 2 A "
o -Q-N+H2(R")A" o -QN + H 2 (R ") A "
o -Q-N(R")-CH2-CH2-N+R"H2A" , o -QN (R ") - CH 2 -CH 2 -N + R" H 2 A " ,
wobei jedes Q für eine chemische Bindung, -CH2-, -CH2-CH2-, -CH2CH2CH2- , -C(CH3)2-, -CH2CH2CH2CH2-, -CH2C(CH3)2-, -CH(CH3)CH2CH2- steht, each Q is a chemical bond, -CH 2 -, -CH 2 -CH 2 -, -CH2CH2CH2-, -C (CH 3) 2 -, -CH2CH2CH2CH2-, -CH 2 C (CH 3) 2 -, - CH (CH 3 ) CH 2 CH 2 -,
R" für gleiche oder verschiedene Reste aus der Gruppe -H, -Phenyl, -Benzyl, -CH2- CH(CH3)Ph, der Ci.20-Alkylreste, vorzugsweise -CH3, -CH2CH3, -CH2CH2CI-I3, - CH(CH3)2, -CH2CH2CH2H3, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -C(CH3)3, steht und A ein Anion repräsentiert, welches vorzugsweise ausgewählt ist aus Chlorid, Bromid, lodid oder Methosulfat. Besonders bevorzugte erfindungsgemäße Mittel sind dadurch gekennzeichnet, daß sie mindestens ein aminofunktionelles Silikon der Formel (Si-Ila) R "is identical or different radicals from the group -H, -phenyl, -benzyl, -CH 2 - CH (CH 3 ) Ph, the Ci. 20 -alkyl radicals, preferably -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 Cl-I 3 , - CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 H 3 , -CH 2 CH (CH 3 ) 2 , -CH (CH 3 ) CH 2 CH 3 , -C ( CH 3 ) 3 , and A represents an anion, which is preferably selected from chloride, bromide, iodide or methosulfate. Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)
(CH3)3Si-[0-Si(CH3)2]n[OSi(CH3)]m-OSi(CH3)3 (Si-Ila), (CH 3 ) 3 Si [0-Si (CH 3 ) 2 ] n [OSi (CH 3 )] m -OSi (CH 3 ) 3 (Si-Ila),
I I
CH2CH(CH3)CH2NH(CH2)2NH2 CH 2 CH (CH 3) CH 2 NH (CH 2 ) 2 NH 2
enthalten, worin m und n Zahlen sind, deren Summe (m + n) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei n vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt. in which m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.
Diese Silicone werden nach der INCI-Deklaration als Trimethylsilylamodimethicone bezeichnet. Besonders bevorzugt sind auch erfindungsgemäße Mittel, die ein aminofunktionelles Silikon der Formel (Si-Ilb)  These silicones are referred to as trimethylsilylamodimethicones according to the INCI declaration. Particular preference is also given to compositions according to the invention which are an amino-functional silicone of the formula (Si-IIb)
R-[Si(CH3)2-0]n1 [Si(R)-0]m-[Si(CH3)2]n2-R (Si-Ilb), R- [Si (CH 3 ) 2 -O] n 1 [Si (R) -O] m - [Si (CH 3 ) 2 ] n 2 -R (Si-Ilb),
I I
Figure imgf000027_0001
Figure imgf000027_0001
enthalten, worin R für -OH, -0-CH3 oder eine -CH3-Gruppe steht und m, n1 und n2 Zahlen sind, deren Summe (m + n1 + n2) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei die Summe (n1 + n2) vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt. in which R is -OH, -O-CH 3 or a -CH 3 group and m, n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.
Diese Silicone werden nach der INCI-Deklaration als Amodimethicone bezeichnet. These silicones are referred to as amodimethicones according to the INCI declaration.
Unabhängig davon, welche aminofunktionellen Silicone eingesetzt werden, sind erfindungsgemäße Mittel bevorzugt, die ein aminofunktionelles Silikon enthalten dessen Aminzahl oberhalb von 0,25 meq/g, vorzugsweise oberhalb von 0,3 meq/g und insbesondere oberhalb von 0,4 meq/g liegt. Die Aminzahl steht dabei für die Milli-Äquivalente Amin pro Gramm des aminofunktionellen Silicons. Sie kann durch Titration ermittelt und auch in der Einheit mg KOH/g angegeben werden. Regardless of which amino-functional silicones are used, agents according to the invention which contain an amino-functional silicone whose amine number is above 0.25 meq / g, preferably above 0.3 meq / g and in particular above 0.4 meq / g, are preferred , The amine number stands for the milliequivalents of amine per gram of the amino-functional silicone. It can be determined by titration and also expressed in mg KOH / g.
Erfindungsgemäß bevorzugte Mittel sind dadurch gekennzeichnet, dass sie, bezogen auf ihr Gewicht, 0,01 bis 10 Gew.%, vorzugsweise 0,1 bis 8 Gew.%, besonders bevorzugt 0,25 bis 7,5 Gew.% und insbesondere 0,5 bis 5 Gew.% aminofunktionelle(s) Silikon(e) enthalten.  Agents preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.1 to 8% by weight, particularly preferably 0.25 to 7.5% by weight and in particular 0, 5 to 5 wt.% Amino-functional silicone (s) included.
Auch die nach INCI als CYCLOMETHICONE bezeichneten cyclischen Dimethicone sind erfindungsgemäß mit Vorzug einsetzbar. Hier sind erfindungsgemäße Mittel bevorzugt, die mindestens ein Silikon der Formel Si-Ill The INCI CYCLOMETHICONE designated cyclic dimethicones are inventively used with preference. Here, agents according to the invention are preferred which contain at least one silicone of the formula Si-III
iO-SiiCH^2L- (Si-III) enthalten, in der x für eine Zahl von 3 bis 200, vorzugsweise von 3 bis 10, weiter bevorzugt von30 bis 7 und insbesondere 3, 4, 5 oder 6, steht. iO-SiiCH ^ 2 L- (Si-III) in which x is a number from 3 to 200, preferably from 3 to 10, more preferably from 30 to 7 and especially 3, 4, 5 or 6, stands.
Die vorstehend beschriebenen Silicone weisen ein Rückgrat auf, welches aus -Si-O-Si-Einheiten aufgebaut ist. Selbstverständlich können diese Si-O-Si-Einheiten auch durch Kohlenstoffketten unterbrochen sein. Entsprechende Moleküle sind durch Kettenverlängerungsreaktionen zugänglich und kommen vorzugsweise in Form von Silikon-in-Wasser-Emulsionen zum Einsatz. Erfindungsgemäß ebenfalls bevorzugte Mittel sind dadurch gekennzeichnet, daß sie mindestens ein Silikon der Formel Si-IV The silicones described above have a backbone composed of -Si-O-Si units. Of course, these Si-O-Si units may also be interrupted by carbon chains. Appropriate molecules are accessible by chain extension reactions and are preferably used in the form of silicone-in-water emulsions. Agents which are likewise preferred according to the invention are characterized in that they contain at least one silicone of the formula Si-IV
R3Si-[0-SiR2]x-(CH2)n-[0-SiR2]y-0-SiR3 (Si-IV), R 3 Si [0-SiR 2 ] x - (CH 2 ) n - [0-SiR 2 ] y -O-SiR 3 (Si-IV),
enthalten, in der R für gleiche oder verschiedene Reste aus der Gruppe -H, - Phenyl, -Benzyl, -CH2-CH(CH3)Ph, der Ci_20-Alkylreste, vorzugsweise -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2H3, -CH2CH(CH3)2, -CH(CH3)CH2CH3, -C(CH3)3, steht, x bzw. y für eine Zahl von 0 bis 200, vorzugsweise von 0 bis 10, weiter bevorzugt von 0 bis 7 und insbesondere 0, 1 , 2, 3, 4, 5 oder 6, stehen, und n für eine Zahl von 0 bis 10, bevorzugt von 1 bis 8 und insbesondere für 2, 3, 4, 5, 6 steht. included, in which R stands for identical or different radicals from the group -H, - phenyl, -benzyl, -CH 2 -CH (CH 3) Ph, the CI_ 20 -alkyl, preferably -CH 3, -CH 2 CH 3, -CH 2 CH 2 CH 3 , -CH (CH 3 ) 2 , -CH 2 CH 2 CH 2 H 3 , -CH 2 CH (CH 3 ) 2 , -CH (CH 3 ) CH 2 CH 3 , -C ( CH 3 ) 3 , x and y are a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and in particular 0, 1, 2, 3, 4, 5 or 6, and n is a number from 0 to 10, preferably from 1 to 8 and in particular from 2, 3, 4, 5, 6.
Mit Vorzug sind die Silikone wasserlöslich. Erfindungsgemäß bevorzugte Mittel sind dadurch gekennzeichnet, daß sie mindestens ein wasserlösliches Silikon enthalten.  The silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone.
Aus ästhetischen Gründen werden „klare" Produkte von Verbrauchern oft bevorzugt. Erfindungsgemäß bevorzugte Haarbehandlungsmittel sind daher dadurch gekennzeichnet, daß sie transparent bzw. transluzent sind.  For aesthetic reasons, "clear" products are often preferred by consumers, hair treatment agents which are preferred according to the invention are therefore characterized by being transparent or translucent.
Unter transparent oder transluzent wird im Rahmen der vorliegenden Erfindung eine Zusammensetzung verstanden, die einen NTU-Wert von unter 100 aufweist. Der NTU-Wert (Nephelometrie Turbidity Unit, Nephelometrischer Trübungswert; NTU) ist eine in der Wasseraufbereitung verwendete Einheit für Trübungsmessungen in Flüssigkeiten. Sie ist die Einheit einer mit einem kalibriertem Nephelometer gemessenen Trübung einer Flüssigkeit.  In the context of the present invention, transparent or translucent is understood as meaning a composition which has an NTU value of less than 100. The NTU value (Nephelometrie Turbidity Unit, NTU) is a unit used in water treatment for turbidity measurements in liquids. It is the unit of turbidity measured with a calibrated nephelometer.
Weiterhin kann in einer bevorzugten Ausführungsform der Erfindung ein erfindungsgemäßes Mittel auch UV - Filter (I) enthalten. Die erfindungsgemäß zu verwendenden UV-Filter unterliegen hinsichtlich ihrer Struktur und ihrer physikalischen Eigenschaften keinen generellen Einschränkungen. Vielmehr eignen sich alle im Kosmetikbereich einsetzbaren UV-Filter, deren Absorptionsmaximum im UVA(315-400 nm)-, im UVB(280-315nm)- oder im UVC(<280 nm)-Bereich liegt. UV-Filter mit einem Absorptionsmaximum im UVB-Bereich, insbesondere im Bereich von etwa 280 bis etwa 300 nm, sind besonders bevorzugt. Furthermore, in a preferred embodiment of the invention, an agent according to the invention may also contain UV filters (I). The UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC (<280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.
Die UV-Filter (I) sind in den erfindungsgemäßen Mitteln üblicherweise in Mengen 0,1 -5 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,4-2,5 Gew.-% sind bevorzugt.  The UV filters (I) are contained in the compositions according to the invention usually in amounts of 0.1-5 wt .-%, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.
Die erfindungsgemäßen Mittel können weiterhin eine 2-Pyrrolidinon-5-carbonsäure und deren Derivate (J) enthalten. Bevorzugt sind die Natrium-, Kalium-, Calcium-, Magnesium- oder Ammoniumsalze, bei denen das Ammoniumion neben Wasserstoff eine bis drei d- bis C4- Alkylgruppen trägt. Das Natriumsalz ist ganz besonders bevorzugt. Die eingesetzten Mengen in den erfindungsgemäßen Mitteln betragen vorzugsweise 0,05 bis 10 Gew.%, bezogen auf das gesamte Mittel, besonders bevorzugt 0, 1 bis 5, und insbesondere 0, 1 bis 3 Gew.%. The compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J). Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C 1 to C 4 alkyl groups. The sodium salt is most preferred. The amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total agent, more preferably 0, 1 to 5, and in particular 0, 1 to 3 wt.%.
Zusätzlich kann es sich als vorteilhaft erweisen, wenn in den erfindungsgemäßen Mitteln Penetrationshilfsstoffe und/ oder Quellmittel (M) enthalten sind. Hierzu sind beispielsweise zu zählen Harnstoff und Harnstoffderivate, Guanidin und dessen Derivate, Arginin und dessen Derivate, Wasserglas, Imidazol und dessen Derivate, Histidin und dessen Derivate, Benzylalkohol, Glycerin, Glykol und Glykolether, Propylenglykol und Propylenglykolether, beispielsweise Propylenglykolmonoethylether, Carbonate, Hydrogencarbonate, Diole und Triole, und insbesondere 1 ,2-Diole und 1 ,3-Diole wie beispielsweise 1 ,2-Propandiol, 1 ,2-Pentandiol, 1 ,2- Hexandiol, 1 ,2-Dodecandiol, 1 ,3-Propandiol, 1 ,6-Hexandiol, 1 ,5-Pentandiol, 1 ,4-Butandiol. In addition, it may prove advantageous if the compositions according to the invention contain penetration aids and / or swelling agents (M). These include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol, for example Propylene glycol monoethyl ether, carbonates, bicarbonates, diols and triols, and in particular 1, 2-diols and 1, 3-diols such as 1, 2-propanediol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-dodecanediol, 1 , 3-propanediol, 1, 6-hexanediol, 1, 5-pentanediol, 1, 4-butanediol.
Vorteilhaft im Sinne der Erfindung können zusätzlich kurzkettige Carbonsäuren (N) den Wirkstoffkomplex (A) unterstützen. Unter kurzkettigen Carbonsäuren und deren Derivaten im Sinne der Erfindung werden Carbonsäuren verstanden, welche gesättigt oder ungesättigt und/oder geradkettig oder verzweigt oder cyclisch und/oder aromatisch und/oder heterocyclisch sein können und ein Molekulargewicht kleiner 750 aufweisen. Bevorzugt im Sinne der Erfindung können gesättigte oder ungesättigte geradkettige oder verzweigte Carbonsäuren mit einer Kettenlänge von 1 bis zu 16 C-Atomen in der Kette sein, ganz besonders bevorzugt sind solche mit einer Kettenlänge von 1 bis zu 12 C - Atomen in der Kette. Advantageously in the context of the invention, short-chain carboxylic acids (N) may additionally support the active substance complex (A). Short-chain carboxylic acids and their derivatives in the context of the invention are understood to mean carboxylic acids which may be saturated or unsaturated and / or straight-chain or branched or cyclic and / or aromatic and / or heterocyclic and have a molecular weight of less than 750. For the purposes of the invention, preference may be given to saturated or unsaturated straight-chain or branched carboxylic acids having a chain length of from 1 to 16 C atoms in the chain, very particular preference being given to those having a chain length of from 1 to 12 C atoms in the chain.
Die kurzkettigen Carbonsäuren im Sinne der Erfindung können ein, zwei, drei oder mehr Carboxygruppen aufweisen. Bevorzugt im Sinne der Erfindung sind Carbonsäuren mit mehreren Carboxygruppen, insbesondere Di- und Tricarbonsäuren. Die Carboxygruppen können ganz oder teilweise als Ester, Säureanhydrid, Lacton, Amid, Imidsäure, Lactam, Lactim, Dicarboximid, Carbohydrazid, Hydrazon, Hydroxam, Hydroxim, Amidin, Amidoxim, Nitril, Phosphon- oder Phosphatester vorliegen. Die erfindungsgemäß verwendeten Carbonsäuren können selbstverständlich entlang der Kohlenstoffkette oder des Ringgerüstes substituiert sein. Zu den Substituenten der erfindungsgemäß verwendeten Carbonsäuren sind beispielsweise zu zählen C1- C8-Alkyl-, C2-C8-Alkenyl-, Aryl-, Aralkyl- und Aralkenyl-, Hydroxymethyl-, C2-C8-Hydroxyalkyl-,C2- C8-Hydroxyalkenyl-, Aminomethyl-, C2-C8-Aminoalkyl-, Cyano-, Formyl-, Oxo-, Thioxo-, Hydroxy-, Mercapto-, Amino-, Carboxy- oder Iminogruppen. Bevorzugte Substituenten sind C1-C8-Alkyl-, Hydroxymethyl-, Hydroxy-, Amino- und Carboxygruppen. Besonders bevorzugt sind Substituenten in - Stellung. Ganz besonders bevorzugte Substituenten sind Hydroxy-, Alkoxy- und Amino- gruppen, wobei die Aminofunktion gegebenenfalls durch Alkyl-, Aryl-, Aralkyl- und/oder Alkenylreste weiter substituiert sein kann. Weiterhin sind ebenfalls bevorzugte Carbonsäurederivate die Phosphon- und Phosphatester.  The short-chain carboxylic acids according to the invention may have one, two, three or more carboxy groups. Preferred within the meaning of the invention are carboxylic acids having a plurality of carboxy groups, in particular di- and tricarboxylic acids. The carboxy groups may be wholly or partly present as esters, acid anhydride, lactone, amide, imidic acid, lactam, lactim, dicarboximide, carbohydrazide, hydrazone, hydroxam, hydroxime, amidine, amidoxime, nitrile, phosphonic or phosphate ester. The carboxylic acids used according to the invention may of course be substituted along the carbon chain or the ring skeleton. The substituents of the carboxylic acids used according to the invention include, for example, C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, aryl, aralkyl and aralkenyl, hydroxymethyl, C 2 -C 8 -hydroxyalkyl, C 2 -C 8 -hydroxyalkenyl , Aminomethyl, C 2 -C 8 -aminoalkyl, cyano, formyl, oxo, thioxo, hydroxy, mercapto, amino, carboxy or imino groups. Preferred substituents are C 1 -C 8 alkyl, hydroxymethyl, hydroxy, amino and carboxy groups. Particularly preferred are substituents in position. Very particularly preferred substituents are hydroxyl, alkoxy and amino groups, where the amino function may optionally be further substituted by alkyl, aryl, aralkyl and / or alkenyl radicals. Furthermore, preferred carboxylic acid derivatives are the phosphonic and phosphate esters.
In einer weiteren bevorzugten Ausführungsform können die erfindungsgemäßen Mittel Emulgatoren (F) enthalten. Emulgatoren bewirken an der Phasengrenzfläche die Ausbildung von wasser- bzw. ölstabilen Adsorptionsschichten, welche die dispergierten Tröpfchen gegen Koaleszenz schützen und damit die Emulsion stabilisieren. Emulgatoren sind daher wie Tenside aus einem hydrophoben und einem hydrophilen Molekülteil aufgebaut. Hydrophile Emulgatoren bilden bevorzugt O/W - Emulsionen und hydrophobe Emulgatoren bilden bevorzugt W/O - Emulsionen. Unter einer Emulsion ist eine tröpfchenförmige Verteilung (Dispersion) einer Flüssigkeit in einer anderen Flüssigkeit unter Aufwand von Energie zur Schaffung von stabilisierenden Phasengrenzflächen mittels Tensiden zu verstehen. Die Auswahl dieser emulgierenden Tenside oder Emulgatoren richtet sich dabei nach den zu dispergierenden Stoffen und der jeweiligen äußeren Phase sowie der Feinteiligkeit der Emulsion. Erfindungsgemäß verwendbare Emulgatoren sind beispielsweise Anlagerungsprodukte von 4 bis 30 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare Fettalkohole mit 8 bis 22 C-Atomen, an Fettsäuren mit 12 bis 22 C-Atomen und an Alkylphenole mit 8 bis 15 C-Atomen in der Alkylgruppe, In a further preferred embodiment, the agents according to the invention may contain emulsifiers (F). Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion. Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions. An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants. The selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion. Emulsifiers which can be used according to the invention are, for example Addition products of 4 to 30 moles of ethylene oxide and / or 0 to 5 moles of propylene oxide to linear fatty alcohols having 8 to 22 carbon atoms, to fatty acids having 12 to 22 carbon atoms and to alkylphenols having 8 to 15 carbon atoms in the alkyl group,
C12-C22-Fettsäuremono- und -diester von Anlagerungsprodukten von 1 bis 30 Mol Ethylenoxid an Polyole mit 3 bis 6 Kohlenstoffatomen, insbesondere an Glycerin, C 12 -C 2 fatty acid mono- and diesters of addition products of from 1 to 30 moles of ethylene oxide onto polyols having from 3 to 6 carbon atoms, in particular to glycerol,
Ethylenoxid- und Polyglycerin-Anlagerungsprodukte an Methylglucosid-Fettsäureester, Fettsäurealkanolamide und Fettsäureglucamide,  Ethylene oxide and polyglycerol addition products to methyl glucoside fatty acid esters, fatty acid alkanolamides and fatty acid glucamides,
C8-C22-Alkylmono- und -oligoglycoside und deren ethoxylierte Analoga, wobei Oli- gomerisierungsgrade von 1 , 1 bis 5, insbesondere 1 ,2 bis 2,0, und Glucose als Zuckerkomponente bevorzugt sind, C 8 -C 2 2-alkylmono- and -oligoglycosides and their ethoxylated analogues, with degrees of oligomerization of from 1, 1 to 5, in particular 1, 2 to 2.0, and glucose as sugar component being preferred,
Gemische aus Alkyl-(oligo)-glucosiden und Fettalkoholen zum Beispiel das im Handel erhältliche Produkt Montanov®68, Glucosides mixtures of alkyl (oligo) and fatty alcohols, for example, the commercially available product ® Montanov 68,
Anlagerungsprodukte von 5 bis 60 Mol Ethylenoxid an Rizinusöl und gehärtetes Rizinusöl, Partialester von Polyolen mit 3-6 Kohlenstoffatomen mit gesättigten Fettsäuren mit 8 bis 22 C- Atomen,  Addition products of from 5 to 60 mol of ethylene oxide onto castor oil and hydrogenated castor oil, partial esters of polyols having 3-6 carbon atoms with saturated fatty acids having 8 to 22 carbon atoms,
Sterine. Als Sterine wird eine Gruppe von Steroiden verstanden, die am C-Atom 3 des Steroid- Gerüstes eine Hydroxylgruppe tragen und sowohl aus tierischem Gewebe (Zoosterine) wie auch aus pflanzlichen Fetten (Phytosterine) isoliert werden. Beispiele für Zoosterine sind das Cholesterin und das Lanosterin. Beispiele geeigneter Phytosterine sind Ergosterin, Stigmasterin und Sitosterin. Auch aus Pilzen und Hefen werden Sterine, die sogenannten Mykosterine, isoliert.  Sterols. Sterols are understood to mean a group of steroids which carry a hydroxyl group on C-atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterines) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are ergosterol, stigmasterol and sitosterol. Mushrooms and yeasts are also used to isolate sterols, the so-called mycosterols.
Phospholipide. Hierunter werden vor allem die Glucose-Phospolipide, die z.B. als Lecithine bzw. Phospahtidylcholine aus z.B. Eidotter oder Pflanzensamen (z.B. Sojabohnen) gewonnen werden, verstanden.  Phospholipids. Of these, especially the glucose phospholipids, e.g. as lecithins or phosphatidylcholines from e.g. Egg yolk or plant seeds (e.g., soybeans) are understood.
Fettsäureester von Zuckern und Zuckeralkoholen, wie Sorbit,  Fatty acid esters of sugars and sugar alcohols, such as sorbitol,
Polyglycerine und Polyglycerinderivate wie beispielsweise Polyglycerinpoly-12-hydroxystearat (Handelsprodukt Dehymuls® PGPH), Polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate (commercial product Dehymuls ® PGPH),
Lineare und verzweigte Fettsäuren mit 8 bis 30 C - Atomen und deren Na-, K-, Ammonium-, Ca-, Mg- und Zn - Salze.  Linear and branched fatty acids with 8 to 30 C atoms and their Na, K, ammonium, Ca, Mg and Zn salts.
Die erfindungsgemäßen Mittel enthalten die Emulgatoren bevorzugt in Mengen von 0,1 - 25 Gew.- %, insbesondere 0,5 - 15 Gew.-%, bezogen auf das gesamte Mittel.  The agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.
Bevorzugt können die erfindungsgemäßen Zusammensetzungen mindestens einen nichtionogenen Emulgator mit einem HLB-Wert von 8 bis 18 enthalten. Nichtionogene Emulgatoren mit einem HLB-Wert von 10 - 15 können erfindungsgemäß besonders bevorzugt sein.  The compositions according to the invention may preferably contain at least one nonionic emulsifier having an HLB value of 8 to 18. Nonionic emulsifiers having an HLB value of 10 to 15 may be particularly preferred according to the invention.
Als weiterhin vorteilhaft hat es sich gezeigt, wenn zusätzlich zu dem bzw. den Polymer(en) aus der Gruppe der kationischen und/oder amphoteren Polymere weitere Polymere (G) in den erfindungsgemäßen Mitteln enthalten sind. In einer bevorzugten Ausführungsform werden den erfindungsgemäßen Mitteln daher weitere Polymere zugesetzt, wobei sich sowohl anionische als auch nichtionische Polymere als wirksam erwiesen haben. It has furthermore proven to be advantageous if, in addition to the polymer (s) from the group of cationic and / or amphoteric polymers, further polymers (G) are contained in the agents according to the invention. In a preferred embodiment, the inventive agents therefore added more polymers, both anionic and nonionic polymers have been found to be effective.
Bei den anionischen Polymeren (G2) handelt es sich um anionische Polymere, welche Carboxylat- und/oder Sulfonatgruppen aufweisen. Beispiele für anionische Monomere, aus denen derartige Polymere bestehen können, sind Acrylsäure, Methacrylsäure, Crotonsäure, Maleinsäureanhydrid und 2-Acrylamido-2-methylpropansulfonsäure. Dabei können die sauren Gruppen ganz oder teilweise als Natrium-, Kalium-, Ammonium-, Mono- oder Triethanolammonium-Salz vorliegen. Bevorzugte Monomere sind 2-Acrylamido-2-methylpropansulfonsäure und Acrylsäure.  The anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups. Examples of anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid. The acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt. Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
Als ganz besonders wirkungsvoll haben sich anionische Polymere erwiesen, die als alleiniges oder Co-Monomer 2-Acrylamido-2-methylpropansulfonsäure enthalten, wobei die Sulfonsäuregruppe ganz oder teilweise als Natrium-, Kalium-, Ammonium-, Mono- oder Triethanolammonium-Salz vorliegen kann. Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for all or some of the sulfonic acid group to be present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,
Besonders bevorzugt ist das Homopolymer der 2-Acrylamido-2-methylpropansulfonsäure, das beispielsweise unter der Bezeichnung Rheothik®1 1-80 im Handel erhältlich ist. More preferably, the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid, which is commercially available, for example under the name Rheothik ® 1 1-80 is.
Innerhalb dieser Ausführungsform kann es bevorzugt sein, Copolymere aus mindestens einem anionischen Monomer und mindestens einem nichtionogenen Monomer einzusetzen. Bezüglich der anionischen Monomere wird auf die oben aufgeführten Substanzen verwiesen. Bevorzugte nichtionogene Monomere sind Acrylamid, Methacrylamid, Acrylsäureester, Methacrylsäureester, Vinylpyrrolidon, Vinylether und Vinylester. Within this embodiment, it may be preferable to use copolymers of at least one anionic monomer and at least one nonionic monomer. With regard to the anionic monomers, reference is made to the substances listed above. Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
Bevorzugte anionische Copolymere sind Acrylsäure-Acrylamid-Copolymere sowie insbesondere Polyacrylamidcopolymere mit Sulfonsäuregruppen-haltigen Monomeren. Ein besonders bevorzugtes anionisches Copolymer besteht aus 70 bis 55 Mol-% Acrylamid und 30 bis 45 Mol-% 2-Acrylamido-2-methylpropansulfonsäure, wobei die Sulfonsäuregruppe ganz oder teilweise als Natrium-, Kalium-, Ammonium-, Mono- oder Triethanolammonium-Salz vorliegt. Dieses Copolymer kann auch vernetzt vorliegen, wobei als Vernetzungsagentien bevorzugt polyolefinisch ungesättigte Verbindungen wie Tetraallyloxyethan, Allylsucrose, Allylpentaerythrit und Methylen-bisacrylamid zum Einsatz kommen. Ein solches Polymer ist in dem Handelsprodukt Sepigel®305 der Firma SEPPIC enthalten. Die Verwendung dieses Compounds, das neben der Polymerkomponente eine Kohlenwasserstoffmischung (Ci3-Ci4-lsoparaffin) und einen nichtionogenen Emulgator (Laureth-7) enthält, hat sich im Rahmen der erfindungsgemäßen Lehre als besonders vorteilhaft erwiesen. Auch die unter der Bezeichnung Simulgel®600 als Compound mit Isohexadecan und Polysorbat-80 vertriebenen Natriumacryloyldimethyltaurat-Copolymere haben sich als erfindungsgemäß besonders wirksam erwiesen. Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. A particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group is wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt is present. This copolymer may also be crosslinked, with crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used. Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC. The use of this compound, which in addition to the polymer component contains a hydrocarbon mixture (Ci 3 -Ci 4 -lsoparaffin) and a nonionic emulsifier (laureth-7), has proved to be particularly advantageous in the context of the teaching of the invention. Also sold under the name Simulgel ® 600 as a compound with isohexadecane and polysorbate-80 Natriumacryloyldimethyltaurat copolymers have proved to be particularly effective according to the invention.
Ebenfalls bevorzugte anionische Homopolymere sind unvernetzte und vernetzte Polyacrylsäuren. Dabei können Allylether von Pentaerythrit, von Sucrose und von Propylen bevorzugte Vernetzungsagentien sein. Solche Verbindungen sind beispielsweise unter dem Warenzeichen Carbopol® im Handel erhältlich. Copolymere aus Maleinsäureanhydrid und Methylvinylether, insbesondere solche mit Vernetzungen, sind ebenfalls farberhaltende Polymere. Ein mit 1 ,9-Decadiene vernetztes Maleinsäure- Methylvinylether-Copolymer ist unter der Bezeichnung Stabileze® QM im Handel erhältlich. Likewise preferred anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ® commercially. Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers. A 1, 9-decadiene crosslinked maleic acid methyl vinyl ether copolymer is available under the name ® Stabileze QM.
Die erfindungsgemäßen Mittel können in einer weiteren Ausführungsform nichtionogene Polymere (G4) enthalten. In another embodiment, the agents according to the invention may contain nonionic polymers (G4).
Geeignete nichtionogene Polymere sind beispielsweise:  Suitable nonionic polymers are, for example:
Vinylpyrrolidon/Vinylester-Copolymere, wie sie beispielsweise unter dem Warenzeichen Luviskol® (BASF) vertrieben werden. Luviskol® VA 64 und Luviskol® VA 73, jeweils Vinylpyrrolidon/Vinylacetat-Copolymere, sind ebenfalls bevorzugte nichtionische Polymere. Celluloseether, wie Hydroxypropylcellulose, Hydroxyethylcellulose und Methylhy- droxypropylcellulose, wie sie beispielsweise unter den Warenzeichen Culminal® und Benecel® (AQUALON) und Natrosol®-Typen (Hercules) vertrieben werden. Vinylpyrrolidone / vinyl ester copolymers, as sold, for example, under the trademark Luviskol ® (BASF). Luviskol ® VA 64 and Luviskol ® VA 73, each vinylpyrrolidone / vinyl acetate copolymers, are also preferred nonionic polymers. Cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropylcellulose Methylhy-, as sold for example under the trademark Culminal® ® and Benecel ® (AQUALON) and Natrosol ® grades (Hercules).
Stärke und deren Derivate, insbesondere Stärkeether, beispielsweise Structure® XL (National Starch), eine multifunktionelle, salztolerante Stärke; Starch and its derivatives, in particular starch, such as Structure XL ® (National Starch), a multifunctional, salt-tolerant starch;
Schellack  shellac
Polyvinylpyrrolidone, wie sie beispielsweise unter der Bezeichnung Luviskol® (BASF) vertrieben werden. Polyvinylpyrrolidones, as sold for example under the name Luviskol ® (BASF).
Siloxane. Diese Siloxane können sowohl wasserlöslich als auch wasserunlöslich sein. Geeignet sind sowohl flüchtige als auch nichtflüchtige Siloxane, wobei als nichtflüchtige Siloxane solche Verbindungen verstanden werden, deren Siedepunkt bei Normaldruck oberhalb von 200 °C liegt. Bevorzugte Siloxane sind Polydialkylsiloxane, wie beispielsweise Polydimethylsiloxan, Polyalkylarylsiloxane, wie beispielsweise Polyphenylmethylsiloxan, ethoxylierte Polydialkylsiloxane sowie Polydialkylsiloxane, die Amin- und/oder Hydroxy- Gruppen enthalten.  Siloxanes. These siloxanes can be both water-soluble and water-insoluble. Both volatile and nonvolatile siloxanes are suitable, nonvolatile siloxanes being understood as meaning those compounds whose boiling point is above 200 ° C. under normal pressure. Preferred siloxanes are polydialkylsiloxanes, such as, for example, polydimethylsiloxane, polyalkylarylsiloxanes, such as, for example, polyphenylmethylsiloxane, ethoxylated polydialkylsiloxanes and polydialkylsiloxanes which contain amine and / or hydroxyl groups.
Glycosidisch substituierte Silicone.  Glycosidically substituted silicones.
Es ist erfindungsgemäß auch möglich, daß die Zubereitungen mehrere, insbesondere zwei verschiedene Polymere gleicher Ladung und/oder jeweils ein ionisches und ein amphoteres und/oder nicht ionisches Polymer enthalten. It is also possible according to the invention that the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.
Die weiteren Polymere (G) sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05 bis 10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0, 1 bis 5, insbesondere von 0,1 bis 3 Gew.-%, sind besonders bevorzugt.  The other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0, 1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.
Ein weiterer Gegenstand der vorliegenden Erfindung ist ein Verfahren zur Behandlung von keratinischen Fasern, insbesondere menschlichen Haaren, bei dem ein erfindungsgemäßes Haarbehandlungsmittel auf keratinische Fasern aufgebracht und dort entweder bis zur nächsten Haarwäsche belassen (sogenanntes ,,leave-on"-Produkt) oder nach einer Einwirkzeit von 30 bis 300 Sekunden ausgespült (sogenanntes„rinse-off -Produkt) wird.  Another object of the present invention is a method for the treatment of keratinic fibers, in particular human hair, in which a hair treatment agent according to the invention applied to keratinic fibers and leave there either until the next hair wash (so-called "leave-on" product) or after Exposure time of 30 to 300 seconds rinsed out (so-called rinse-off product) is.
Dieses nicht-therapeutische kosmetische Verfahren führt zu einer Verringerung der Schuppenbildung. In anderen Worten ist ein Verfahren zur Bekämpfung von Kopfhautschuppen, bei dem ein Haarbehandlungsmittel enthaltend - bezogen auf sein Gewicht - a) 0,0001 bis 5 Gew.-% E silon-Poly-L-Lysin der allgemeinen Formel (I) This non-therapeutic cosmetic procedure leads to a reduction of dandruff. In other words, a method of combating dandruff, in which a hair treatment agent containing - based on its weight - a) 0.0001 to 5% by weight of E silone-poly-L-lysine of the general formula (I)
Figure imgf000033_0001
Figure imgf000033_0001
in der n für ganze Zahlen zwischen 5 und 100 steht,  where n stands for integers between 5 and 100,
b) 0,01 bis 10 Gew.-% Climbazol  b) from 0.01 to 10% by weight of climbazole
auf das Haar und die Kopfhaut aufgebracht und entweder applied to the hair and scalp and either
nach einer Einwirkzeit von 5 Sekunden bis 5 Minuten wieder ausgespült oder dort bis zur nächsten Haarwäsche belassen  rinsed out after a contact time of 5 seconds to 5 minutes or left there until the next hair wash
wird, ein weiterer Gegenstand der vorliegenden Erfindung. becomes, a further object of the present invention.
Bezüglich bevorzugter Ausführungsformen der erfindungsgemäßen Verfahren gilt mutatis mutandis das zu den erfindungsgemäßen Mitteln Gesagte.  With respect to preferred embodiments of the method according to the invention mutatis mutandis applies to the means of the invention.
Der Einsatz von Epsilon-Poly-L-Lysinen verstärkt und beschleunigt die Antschuppenwirkung von Climbazol. Ein weiterer Gegenstand der vorliegenden Erfindung ist die Verwendung von Epsilon- Poly-L-Lysin der all emeinen Formel (I)  The use of epsilon-poly-L-lysines enhances and accelerates the antidandruff effect of climbazole. A further subject of the present invention is the use of epsilon-poly-L-lysine of the general formula (I)
Figure imgf000033_0002
Figure imgf000033_0002
in der n für ganze Zahlen zwischen 5 und 100 steht,  where n stands for integers between 5 and 100,
zur Steigerung der Wirkung von Climbazol. to increase the effect of climbazole.
Ein weiterer Gegenstand der vorliegenden Erfindung ist die Verwendung von Mischungen  Another object of the present invention is the use of mixtures
a) Pol -L-Lysin der allgemeinen Formel (I)  a) Pol-L-lysine of the general formula (I)
Figure imgf000033_0003
Figure imgf000033_0003
in der n für ganze Zahlen zwischen 5 und 100 steht, und  where n stands for integers between 5 and 100, and
b) Climbazol  b) climbazole
zur Behandlung von Kopfhautschuppen. for the treatment of dandruff.
Auch bezüglich bevorzugter Ausführungsformen der erfindungsgemäßen Verwendungen gilt mutatis mutandis das zu den erfindungsgemäßen Mitteln Gesagte. Beispiele: Also with regard to preferred embodiments of the uses according to the invention mutatis mutandis applies to the means of the invention. Examples:
1. Haartonic:  1. hair tonic:
INCI-Bezeichnung % INCI name%
Benzophenone-4 0,05Benzophenone-4 0.05
Carbomer 0,20Carbomer 0.20
Alcohol denat. 40,0Alcohol denate. 40.0
Tetrahydroxypropylethylenediamine 0,20Tetrahydroxypropylethylenediamine 0.20
Menthol 0,03Menthol 0.03
Polylysine 0,02Polylysine 0.02
Climbazole 0,3Climbazole 0.3
Pantolactone 0,3Pantolactone 0.3
Parfüm q.s.Perfume q.s.
Aqua ad 100 Aqua ad 100
2. Haarspülung 2. Hair conditioner
INCI-Bezeichnung % INCI name%
Cetearyl Alcohol 6,25Cetearyl Alcohol 6.25
Quaternium-87 0,75Quaternium-87 0.75
Glycol Distearate 1 ,00Glycol Distearate 1, 00
Shea Butter 1 ,50Shea Butter 1, 50
Nephelium Lappaceum Oil 0,50Nephelium Lappaceum Oil 0.50
Behenoyl PG-Trimonium Chloride 1 ,50Behenoyl PG-Trimonium Chloride 1, 50
Distearoylethylhydroxyethylmonium 0,75 Methosulfate Distearoylethylhydroxyethylmonium 0.75 Methosulfate
Polylysine 1 ,0 Polylysine 1, 0
Climbazole 0,5Climbazole 0.5
Lactic Acid 2,5Lactic Acid 2.5
Panthenol 0,5Panthenol 0.5
Polyquaternium-37, Propylene Glycol 0,40 Dicaprylate/Dicaprate, PPG-1 Trideceth-6 Polyquaternium-37, propylene glycol 0.40 dicaprylate / dicaprate, PPG-1 trideceth-6
Glycerin 0,10 Glycerol 0.10
Dimethicone 1 ,00Dimethicone 1, 00
Parfüm q.s.Perfume q.s.
Water ad 100 3. Haarshampoo Water ad 100 3. Hair shampoo
INCI-Bezeichnung % INCI name%
Sodium Laureth Sulfate 15,0Sodium Laureth Sulfate 15.0
Cocamidopropyl Betaine 10,0Cocamidopropyl betaine 10.0
Coco-Glucoside 4,0Coco glucosides 4.0
Climbazole 0,5Climbazole 0.5
Niacinamide 0,3Niacinamide 0.3
Polyquaternium-10 0,3Polyquaternium-10 0.3
Citric Acid 0,5Citric acid 0.5
Laureth-2 1 ,2Laureth-2 1, 2
Sodium Chloride 1 ,3Sodium Chloride 1, 3
Allantoin 3,0Allantoin 3.0
Polylysine 0,7Polylysine 0.7
Parfüm q.s.Perfume q.s.
Water ad 100 Water ad 100
4. Haarshampoo 4. Hair shampoo
INCI-Bezeichnung % INCI name%
Disodium Cocoamphodiacetate 8,0Disodium Cocoamphodiacetate 8.0
Cocamidopropyl Betaine 5,0Cocamidopropyl Betaine 5.0
Coco-Glucoside 4,0Coco glucosides 4.0
Climbazole 0,3Climbazole 0.3
Niacinamide 0,3Niacinamide 0.3
Citric Acid 0,5Citric acid 0.5
Sodium Chloride 1 ,3Sodium Chloride 1, 3
Pantolactone 1 ,0Pantolactone 1, 0
Epsilon-Polylysine 0,1Epsilon-polylysine 0.1
Sodiumbenzoate 0,5Sodium benzoate 0.5
Salicylsäure 0,5Salicylic acid 0.5
Water ad 100 Water ad 100

Claims

Patentansprüche claims
1. Haarbehandlungsmittel, enthaltend - bezogen auf sein Gewicht - a) 0,0001 bis 5 Gew.-% Epsilon-Pol -L-Lysin der allgemeinen Formel (I)  1. hair treatment composition containing - based on its weight - a) 0.0001 to 5 wt .-% epsilon-pol-L-lysine of the general formula (I)
Figure imgf000036_0001
Figure imgf000036_0001
in der n für ganze Zahlen zwischen 5 und 100 steht,  where n stands for integers between 5 and 100,
b) 0,01 bis 10 Gew.-% Climbazol.  b) from 0.01 to 10% by weight of climbazole.
Haarbehandlungsmittel nach Anspruch 1 , dadurch gekennzeichnet, daß es 0,0005 bis 4, vorzugsweise 0,001 bis 3, weiter bevorzugt 0,005 bis 2 und insbesondere 0,01 bis 1 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) enthält.  Hair treatment composition according to Claim 1, characterized in that it contains from 0.0005 to 4, preferably from 0.001 to 3, more preferably from 0.005 to 2 and in particular from 0.01 to 1% by weight of epsilon-poly-L-lysine of the general formula (I) contains.
Haarbehandlungsmittel nach einem der Ansprüche 1 oder 2, dadurch gekennzeichnet, daß es Epsilon-Poly-L-Lysin der allgemeinen Formel (I) enthält, in der n für ganze Zahlen von 10 bis 70, vorzugsweise von 15 bis 60, weiter bevorzugt von 20 bis 50 und insbesondere für die Zahlen 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35 steht.  Hair treatment composition according to one of claims 1 or 2, characterized in that it contains epsilon-poly-L-lysine of the general formula (I), in which n stands for integers from 10 to 70, preferably from 15 to 60, more preferably from 20 to 50 and in particular to the numbers 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35.
Haarbehandlungsmittel nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß es 0,02 bis 7,5, vorzugsweise 0,03 bis 5, weiter bevorzugt 0,04 bis 2,5 und insbesondere 0,05 bis 0,5 Gew.-% Climbazol enthält.  Hair treatment composition according to one of Claims 1 to 3, characterized in that it contains 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5,% by weight. Contains% climbazole.
Haarbehandlungsmittel nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß es eine Gesamtmenge von Epsilon-Poly-L-Lysin der allgemeinen Formel (I) (Inhaltsstoff a)) und Climbazol (Inhaltsstoff b)) von 0,01 bis 2 Gew.-%, vorzugsweise von 0, 1 bis 1 ,75 Gew.-%, weiter bevorzugt von 0,25 bis 1 ,5 Gew.-% und insbesondere von 0,5 bis 1 ,25 Gew.-% enthält. Haarbehandlungsmittel nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß es mindestens einen feuchtigkeitspendenden Aktivstoff aus der Gruppe Pantolacton, Glycerin, Allantoin, Panthenol, Isopentyldiol enthält.  Hair treatment composition according to one of claims 1 to 4, characterized in that it contains a total amount of epsilon-poly-L-lysine of the general formula (I) (ingredient a)) and climbazole (ingredient b)) of 0.01 to 2 wt. -%, preferably from 0, 1 to 1, 75 wt .-%, more preferably from 0.25 to 1, 5 wt .-% and in particular from 0.5 to 1, 25 wt .-%. Hair treatment composition according to one of claims 1 to 5, characterized in that it contains at least one moisturizing active substance from the group of pantolactone, glycerol, allantoin, panthenol, isopentyldiol.
Haarbehandlungsmittel nach Anspruch 6, dadurch gekennzeichnet, daß es den bzw. die feuchtigkeitspendenden Aktivstoff(e) in Mengen von 0, 1 bis 10 Gew.-%, vorzugsweise von 0, 15 bis 7,5 Gew.-%, weiter bevorzugt von 0,2 bis 5 Gew.-% und insbesondere von 0,25 bis 4 Gew.-% enthält.  Hair treatment composition according to Claim 6, characterized in that it contains the moisturizing active substance (s) in amounts of 0.1 to 10% by weight, preferably 0.15 to 7.5% by weight, more preferably 0 , 2 to 5 wt .-% and in particular from 0.25 to 4 wt .-%.
Verfahren zur Bekämpfung von Kopfhautschuppen, dadurch gekennzeichnet, daß ein Haarbehandlungsmittel enthaltend - bezogen auf sein Gewicht - a) 0,0001 bis 5 Gew.-% Epsilon-Poly-L-Lysin der allgemeinen Formel (I) A method for combating dandruff, characterized in that a hair treatment composition containing - based on its weight - a) 0.0001 to 5 wt .-% epsilon-poly-L-lysine of the general formula (I)
Figure imgf000037_0001
Figure imgf000037_0001
in der n für ganze Zahlen zwischen 5 und 100 steht,  where n stands for integers between 5 and 100,
b) 0,01 bis 10 Gew.-% Climbazol  b) from 0.01 to 10% by weight of climbazole
auf das Haar und die Kopfhaut aufgebracht und entweder applied to the hair and scalp and either
nach einer Einwirkzeit von 5 Sekunden bis 5 Minuten wieder ausgespült oder dort bis zur nächsten Haarwäsche belassen  rinsed out after a contact time of 5 seconds to 5 minutes or left there until the next hair wash
wird. becomes.
Verwendun von Epsilon-Poly-L-Lysin der allgemeinen Formel (I)  Use of epsilon-poly-L-lysine of the general formula (I)
Figure imgf000037_0002
Figure imgf000037_0002
in der n für ganze Zahlen zwischen 5 und 100 steht, where n stands for integers between 5 and 100,
zur Steigerung der Wirkung von Climbazol. to increase the effect of climbazole.
Verwendung von Mischungen aus Use of mixtures from
a) Pol -L-Lysin der allgemeinen Formel (I)  a) Pol-L-lysine of the general formula (I)
Figure imgf000037_0003
Figure imgf000037_0003
in der n für ganze Zahlen zwischen 5 und 100 steht, und  where n stands for integers between 5 and 100, and
b) Climbazol  b) climbazole
zur Behandlung von Kopfhautschuppen. for the treatment of dandruff.
PCT/EP2011/059039 2010-10-28 2011-06-01 Active ingredient combination and anti-dandruff hair treatment products iii WO2012055587A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11722461.8A EP2632422A1 (en) 2010-10-28 2011-06-01 Active ingredient combination and anti-dandruff hair treatment products iii

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201010043074 DE102010043074A1 (en) 2010-10-28 2010-10-28 Active substance combination and hair treatment agent for dandruff III
DE102010043074.9 2010-10-28

Publications (1)

Publication Number Publication Date
WO2012055587A1 true WO2012055587A1 (en) 2012-05-03

Family

ID=44119410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/059039 WO2012055587A1 (en) 2010-10-28 2011-06-01 Active ingredient combination and anti-dandruff hair treatment products iii

Country Status (3)

Country Link
EP (1) EP2632422A1 (en)
DE (1) DE102010043074A1 (en)
WO (1) WO2012055587A1 (en)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010708A3 (en) * 2011-07-21 2013-09-26 Henkel Ag & Co. Kgaa Surfactant hair treatment agent comprising poly-l-lysine ii
WO2012167935A3 (en) * 2011-06-07 2013-09-26 Beiersdorf Ag ACTIVE INGREDIENT COMBINATIONS CONSISTING OF ε-POLYLYSINE (EPSILON-POLYLYSINE) AND ONE OR MORE AROMATIC ESTERS, ALDEHYDES AND/OR ALCOHOLS
WO2013010706A3 (en) * 2011-07-21 2013-10-03 Henkel Ag & Co. Kgaa High-performance active agent combination and hair treatment agent against dandruff ii
WO2013010707A3 (en) * 2011-07-21 2013-10-03 Henkel Ag & Co. Kgaa High-performance active agent combination and hair treatment agent against dandruff i
WO2013010710A3 (en) * 2011-07-21 2013-10-03 Henkel Ag & Co. Kgaa Surfactant hair treatment agent comprising poly-l-lysine i
WO2012168360A3 (en) * 2011-06-07 2013-10-03 Beiersdorf Ag Active substance preparations made from εpsilon-polylysine (epsilon-polylsine) and piroctone olamine and/or climbazole
WO2013010709A3 (en) * 2011-07-21 2013-11-07 Henkel Ag & Co. Kgaa Alcoholic hair treatment agent comprising poly-l-lysine
WO2012167936A3 (en) * 2011-06-07 2013-11-21 Beiersdorf Ag ACTIVE INGREDIENT COMBINATIONS OF ε-POLYLYSIN (EPSILON-POLYLYSINE) AND ONE OR MORE TERPENES
WO2016172409A1 (en) * 2015-04-23 2016-10-27 The Procter & Gamble Company Delivery of surfactant soluble anti-dandruff agent
US9949914B2 (en) 2015-04-23 2018-04-24 The Procter & Gamble Company Low viscosity hair care composition
US9949901B2 (en) 2015-04-23 2018-04-24 The Procter & Gamble Company Low viscosity hair care composition
US10311575B2 (en) 2016-03-23 2019-06-04 The Procter And Gamble Company Imaging method for determining stray fibers
US10426713B2 (en) 2017-10-10 2019-10-01 The Procter And Gamble Company Method of treating hair or skin with a personal care composition in a foam form
US10441519B2 (en) 2016-10-21 2019-10-15 The Procter And Gamble Company Low viscosity hair care composition comprising a branched anionic/linear anionic surfactant mixture
US10653590B2 (en) 2016-10-21 2020-05-19 The Procter And Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits comprising an anionic/zwitterionic surfactant mixture
US10799434B2 (en) 2016-10-21 2020-10-13 The Procter & Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
US10842720B2 (en) 2016-10-21 2020-11-24 The Procter And Gamble Company Dosage of foam comprising an anionic/zwitterionic surfactant mixture
US10888505B2 (en) 2016-10-21 2021-01-12 The Procter And Gamble Company Dosage of foam for delivering consumer desired dosage volume, surfactant amount, and scalp health agent amount in an optimal formulation space
US10912732B2 (en) 2017-12-20 2021-02-09 The Procter And Gamble Company Clear shampoo composition containing silicone polymers
US11116704B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition
US11116703B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
US11116705B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
US11129783B2 (en) 2016-10-21 2021-09-28 The Procter And Gamble Plaza Stable compact shampoo products with low viscosity and viscosity reducing agent
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
US11141361B2 (en) 2016-10-21 2021-10-12 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair volume benefits
US11154467B2 (en) 2016-10-21 2021-10-26 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair conditioning benefits
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
US11318073B2 (en) 2018-06-29 2022-05-03 The Procter And Gamble Company Low surfactant aerosol antidandruff composition
US11446217B2 (en) 2016-03-03 2022-09-20 The Procter & Gamble Company Aerosol antidandruff composition
US11679065B2 (en) 2020-02-27 2023-06-20 The Procter & Gamble Company Compositions with sulfur having enhanced efficacy and aesthetics
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US11819474B2 (en) 2020-12-04 2023-11-21 The Procter & Gamble Company Hair care compositions comprising malodor reduction materials
US11980679B2 (en) 2019-12-06 2024-05-14 The Procter & Gamble Company Sulfate free composition with enhanced deposition of scalp active
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045285A1 (en) 2011-08-15 2013-02-21 Qing Stella Methods of Enhancing Skin Hydration and Improving Non-Diseased Skin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61243010A (en) * 1985-04-20 1986-10-29 Nonogawa Shoji:Kk Cosmetic containing epsilon-polylysine and hydrochloride thereof as preservative and germicide incorporated therein
DE3725030A1 (en) 1987-07-29 1989-02-09 Henkel Kgaa SURFACE ACTIVE HYDROXYSULFONATE
EP0348015A1 (en) 1987-06-18 1989-12-27 Kao Corporation Hair preparation
EP1238645A2 (en) * 2001-03-09 2002-09-11 Wella Aktiengesellschaft Antidandruff composition
EP1970045A2 (en) * 2007-03-15 2008-09-17 Henkel AG & Co. KGaA Anti-dandruff hair treatment agent
FR2922446A1 (en) * 2007-10-19 2009-04-24 Oreal Composition, useful for oxidation coloring, lightening direct dyeing, and bleaching of the keratin fibers, comprises polylysines, and additional alkaline agents comprising e.g. ammonium salts and alkali metal or alkaline earth carbonates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136093A (en) 1991-02-06 1992-08-04 Smith Ronald J Quaternized panthenol compounds and their use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61243010A (en) * 1985-04-20 1986-10-29 Nonogawa Shoji:Kk Cosmetic containing epsilon-polylysine and hydrochloride thereof as preservative and germicide incorporated therein
EP0348015A1 (en) 1987-06-18 1989-12-27 Kao Corporation Hair preparation
DE3725030A1 (en) 1987-07-29 1989-02-09 Henkel Kgaa SURFACE ACTIVE HYDROXYSULFONATE
EP1238645A2 (en) * 2001-03-09 2002-09-11 Wella Aktiengesellschaft Antidandruff composition
EP1238645B1 (en) 2001-03-09 2005-01-12 Wella Aktiengesellschaft Antidandruff composition
EP1970045A2 (en) * 2007-03-15 2008-09-17 Henkel AG & Co. KGaA Anti-dandruff hair treatment agent
FR2922446A1 (en) * 2007-10-19 2009-04-24 Oreal Composition, useful for oxidation coloring, lightening direct dyeing, and bleaching of the keratin fibers, comprises polylysines, and additional alkaline agents comprising e.g. ammonium salts and alkali metal or alkaline earth carbonates

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167935A3 (en) * 2011-06-07 2013-09-26 Beiersdorf Ag ACTIVE INGREDIENT COMBINATIONS CONSISTING OF ε-POLYLYSINE (EPSILON-POLYLYSINE) AND ONE OR MORE AROMATIC ESTERS, ALDEHYDES AND/OR ALCOHOLS
WO2012168360A3 (en) * 2011-06-07 2013-10-03 Beiersdorf Ag Active substance preparations made from εpsilon-polylysine (epsilon-polylsine) and piroctone olamine and/or climbazole
WO2012167936A3 (en) * 2011-06-07 2013-11-21 Beiersdorf Ag ACTIVE INGREDIENT COMBINATIONS OF ε-POLYLYSIN (EPSILON-POLYLYSINE) AND ONE OR MORE TERPENES
WO2013010708A3 (en) * 2011-07-21 2013-09-26 Henkel Ag & Co. Kgaa Surfactant hair treatment agent comprising poly-l-lysine ii
WO2013010706A3 (en) * 2011-07-21 2013-10-03 Henkel Ag & Co. Kgaa High-performance active agent combination and hair treatment agent against dandruff ii
WO2013010707A3 (en) * 2011-07-21 2013-10-03 Henkel Ag & Co. Kgaa High-performance active agent combination and hair treatment agent against dandruff i
WO2013010710A3 (en) * 2011-07-21 2013-10-03 Henkel Ag & Co. Kgaa Surfactant hair treatment agent comprising poly-l-lysine i
WO2013010709A3 (en) * 2011-07-21 2013-11-07 Henkel Ag & Co. Kgaa Alcoholic hair treatment agent comprising poly-l-lysine
US11291616B2 (en) 2015-04-23 2022-04-05 The Procter And Gamble Company Delivery of surfactant soluble anti-dandruff agent
US9949914B2 (en) 2015-04-23 2018-04-24 The Procter & Gamble Company Low viscosity hair care composition
US9949901B2 (en) 2015-04-23 2018-04-24 The Procter & Gamble Company Low viscosity hair care composition
JP2018511638A (en) * 2015-04-23 2018-04-26 ザ プロクター アンド ギャンブル カンパニー Delivery of surfactant soluble anti-dandruff agents
WO2016172409A1 (en) * 2015-04-23 2016-10-27 The Procter & Gamble Company Delivery of surfactant soluble anti-dandruff agent
US11446217B2 (en) 2016-03-03 2022-09-20 The Procter & Gamble Company Aerosol antidandruff composition
US10311575B2 (en) 2016-03-23 2019-06-04 The Procter And Gamble Company Imaging method for determining stray fibers
US10653590B2 (en) 2016-10-21 2020-05-19 The Procter And Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits comprising an anionic/zwitterionic surfactant mixture
US10799434B2 (en) 2016-10-21 2020-10-13 The Procter & Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
US10842720B2 (en) 2016-10-21 2020-11-24 The Procter And Gamble Company Dosage of foam comprising an anionic/zwitterionic surfactant mixture
US10888505B2 (en) 2016-10-21 2021-01-12 The Procter And Gamble Company Dosage of foam for delivering consumer desired dosage volume, surfactant amount, and scalp health agent amount in an optimal formulation space
US10441519B2 (en) 2016-10-21 2019-10-15 The Procter And Gamble Company Low viscosity hair care composition comprising a branched anionic/linear anionic surfactant mixture
US11202740B2 (en) 2016-10-21 2021-12-21 The Procter And Gamble Company Concentrated shampoo dosage of foam for providing hair care benefits
US11154467B2 (en) 2016-10-21 2021-10-26 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair conditioning benefits
US11141361B2 (en) 2016-10-21 2021-10-12 The Procter And Gamble Plaza Concentrated shampoo dosage of foam designating hair volume benefits
US11129783B2 (en) 2016-10-21 2021-09-28 The Procter And Gamble Plaza Stable compact shampoo products with low viscosity and viscosity reducing agent
US11141370B2 (en) 2017-06-06 2021-10-12 The Procter And Gamble Company Hair compositions comprising a cationic polymer mixture and providing improved in-use wet feel
US11224567B2 (en) 2017-06-06 2022-01-18 The Procter And Gamble Company Hair compositions comprising a cationic polymer/silicone mixture providing improved in-use wet feel
US11679073B2 (en) 2017-06-06 2023-06-20 The Procter & Gamble Company Hair compositions providing improved in-use wet feel
US11607373B2 (en) 2017-10-10 2023-03-21 The Procter & Gamble Company Sulfate free clear personal cleansing composition comprising low inorganic salt
US11904036B2 (en) 2017-10-10 2024-02-20 The Procter & Gamble Company Sulfate free clear personal cleansing composition comprising low inorganic salt
US11116703B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
US10426713B2 (en) 2017-10-10 2019-10-01 The Procter And Gamble Company Method of treating hair or skin with a personal care composition in a foam form
US11129775B2 (en) 2017-10-10 2021-09-28 The Procter And Gamble Company Method of treating hair or skin with a personal care composition in a foam form
US11116704B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition
US11116705B2 (en) 2017-10-10 2021-09-14 The Procter And Gamble Company Compact shampoo composition containing sulfate-free surfactants
US11992540B2 (en) 2017-10-10 2024-05-28 The Procter & Gamble Company Sulfate free personal cleansing composition comprising low inorganic salt
US10912732B2 (en) 2017-12-20 2021-02-09 The Procter And Gamble Company Clear shampoo composition containing silicone polymers
US11318073B2 (en) 2018-06-29 2022-05-03 The Procter And Gamble Company Low surfactant aerosol antidandruff composition
US11980679B2 (en) 2019-12-06 2024-05-14 The Procter & Gamble Company Sulfate free composition with enhanced deposition of scalp active
US11679065B2 (en) 2020-02-27 2023-06-20 The Procter & Gamble Company Compositions with sulfur having enhanced efficacy and aesthetics
US11819474B2 (en) 2020-12-04 2023-11-21 The Procter & Gamble Company Hair care compositions comprising malodor reduction materials
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants

Also Published As

Publication number Publication date
DE102010043074A1 (en) 2012-05-03
EP2632422A1 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
EP2734176B1 (en) High-performance active agent combination and hair treatment agent against dandruff ii
WO2012055587A1 (en) Active ingredient combination and anti-dandruff hair treatment products iii
WO2010020516A1 (en) Non-sulfate mild surfactant system for skin and hair cleaning
DE102009048299A1 (en) Hair treatment preparations containing surfactant (s) and proteolipid (s)
WO2012055585A1 (en) Active ingredient combination and anti-dandruff hair treatment products i
WO2012055586A1 (en) Active ingredient combination and anti-dandruff hair treatment products ii
WO2009024360A1 (en) Hair treatment compositions with surfactant(s) and melatonin/agomelatin
EP2632416A1 (en) Active ingredient combination and anti-dandruff hair treatment products iv
DE102011087343A1 (en) Hair treatment agent with 4-morpholinomethyl-substituted silicone (s)
WO2012076280A2 (en) Active ingredient combination and hair treatment composition
WO2009024361A1 (en) Hair treatment compositions with alcohol(s) and melatonin/agomelatine
EP2734177A2 (en) High-performance active agent combination and hair treatment agent against dandruff i
WO2012055584A2 (en) Hair treatment products containing 3-methyl-1,3-butanediol and alkyl polyglycoside(s)
WO2009071355A1 (en) Hair shampoo having a surfactant/thickening combination
DE102011079666A1 (en) Hair treating agent useful e.g. for reducing dirt of skin or keratinous fibers, and care and conditioning of skin or keratinous fibers, comprises oils from seeds of cape chestnut, polymeric quaternary ammonium compound and aqueous carrier
WO2012055582A2 (en) Hair treatment products containing 3-methyl-1,3-butanediol and amphoteric surfactant(s)
EP2779985B1 (en) Hair care compositions
DE102011079536A1 (en) Surfactant hair treatment agent with poly-L-lysine II
WO2009083283A1 (en) Hair cleaning products containing structurants
WO2012055583A2 (en) Hair treatment products containing 3-methyl-1,3-butanediol and anionic surfactant(s)
DE102011079537A1 (en) Surfactant hair treatment agent with poly-L-lysine I
WO2009083284A1 (en) Stabilization of hair cleaning products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11722461

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2011722461

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011722461

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE